UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 10-K

(Mark One)

☑ ANNUAL REPORT PURSUANT TO SEC	CTION 13 OR 15(d) OF TH	HE SECURITIES EXCHANGE ACT OF 1934
For the	fiscal year ended December	31, 2024
	or	
\square TRANSITION REPORT PURSUANT TO S	ECTION 13 OR 15(d) OF	THE SECURITIES EXCHANGE ACT OF 1934
For the transition	on period from	_ to
Con	nmission file number: 001-3	36616
	LogicMark, Inc	
(Exact nam	ne of registrant as specified i	n its charter)
Nevada	46-0678374	
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)
	2801 Diode Lane Louisville, KY 40299	
(Address o	of principal executive offices) (Zip Code)
	one number, including area of	· · · · ·
Tioglovium v coropin		(602) 112 ///12
Securities reg	istered pursuant to Section 1	2(b) of the Act:
Title of each class:	Trading symbol(s):	Name of each exchange on which registered:
Common Stock, par value \$0.0001 per share	LGMK	The Nasdaq Stock Market LLC
Securities reg	istered pursuant to Section 1	2(g) of the Act:
	None	
	(Title of class)	
Indicate by check mark if the registrant is a well-known seasoned		
Indicate by check mark if the registrant is not required to file repo	_	
		ion 13 or 15(d) of the Securities Exchange Act of 1934 during the s), and (2) has been subject to such filing requirements for the past
Indicate by check mark whether the registrant has submitted elec (§232.405 of this chapter) during the preceding 12 months (or for		ile required to be submitted pursuant to Rule 405 of Regulation S-T ant was required to submit such files). Yes \boxtimes No \square
		ccelerated filer, a smaller reporting company or an emerging growth "and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer	Accelerated f	<u> </u>
Non-accelerated filer	Smaller repor Emerging gro	ting company 🗵
If an emerging growth company, indicate by check mark if the r financial accounting standards provided pursuant to Section 13(a)		extended transition period for complying with any new or revised
Indicate by check mark whether the registrant has filed a report or reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.)		s assessment of the effectiveness of its internal control over financial ic accounting firm that prepared or issued its audit report. \Box
If securities are registered pursuant to Section 12(b) of the Act, in correction of an error to previously issued financial statements.		inancial statements of the registrant included in the filing reflect the
Indicate by check mark whether any of those error corrections are registrant's executive officers during the relevant recovery period		ery analysis of incentive-based compensation received by any of the
Indicate by check mark whether the registrant is a shell company	•	
approximately \$1,239,272 based on a closing price of \$15.25 per	share on the last trading day prioring Common Stock have been exclu	ne 30, 2024, the last business day of the second fiscal quarter, was to such date. Shares of Common Stock held by each director, each ded from this calculation in that such persons may be deemed to be
The registrant had 60 588 224 shares of its Common Stock outsta	nding as of March 27, 2025	

registrant nad 60,588,224 snares of its Common Stock outstanding as of March 27, 2025

TABLE OF CONTENTS

		Page
PART I		
Item 1.	Business	1
Item 1A.	Risk Factors.	7
Item 1B.	Unresolved Staff Comments	23
Item 1C.	Cybersecurity	23
Item 2.	Properties	24
Item 3.	Legal Proceedings	24
Item 4.	Mine Safety Disclosures	24
PART II		
Item 5.	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer	
	Purchases of Equity Securities	25
Item 6.	[Reserved]	25
Item 7.	Management's Discussion and Analysis if Financial Condition and Results of Operations	25
Item 7A.	Quantitative and Qualitative Disclosures about Market Risk	33
Item 8.	Financial Statements and Supplementary Data	33
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	33
Item 9A.	Controls and Procedures	33
Item 9B.	Other Information	34
Item 9C.	Disclosure Regarding Foreign Jurisdictions That Prevent Inspections	34
PART III		
Item 10.	Directors, Executive Officers and Corporate Governance	35
Item 11.	Executive Compensation	41
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	44
Item 13.	Certain Relationships and Related Transactions, and Director Independence	47
Item 14.	Principal Accountant Fees and Services	48
PART IV		
Item 15.	Exhibits and Financial Statement Schedules	50

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K (this "Report") contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as "anticipate," "believe," "estimate," "intend," "could," "should," "would," "may," "seek," "plan," "might," "will," "expect," "predict," "project," "forecast," "potential," "continue," negatives thereof or similar expressions. These forward-looking statements are found at various places throughout this Report and include information concerning possible or assumed future results of LogicMark, Inc.'s ("LogicMark", the "Company", "our", "us" or "we") operations; business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future operations, future cash needs, business plans and future financial results; and any other statements that are not historical facts.

From time to time, forward-looking statements also are included in our other periodic reports on Forms 10-Q and 8-K, in our press releases, in our presentations, on our website and in other materials released to the public. Any or all of the forward-looking statements included in this Report and in any other reports or public statements made by us are not guarantees of future performance and may turn out to be inaccurate. These forward-looking statements represent our intentions, plans, expectations, assumptions, and beliefs about future events and are subject to risks, uncertainties, and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral forward-looking statements concerning other matters addressed in this Report and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report.

Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances, or assumptions underlying such statements, or otherwise.

For discussion of factors that we believe could cause our actual results to differ materially from expected and historical results, see "Item 1A — Risk Factors" below. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.

Item 1. Business

LogicMark, Inc. (NASDAQ: LGMK) ("LogicMark", the "Company", "we", "us" or "our") provides personal emergency response systems ("PERS"), health communications devices, and Internet of Things ("IoT") technology that creates a connected care platform. The Company's devices provide people with the ability to receive care at home and age independently. The Company's PERS devices incorporate two-way voice communication technology directly in the medical alert pendant and provide life-saving technology at a customer-friendly price point aimed at everyday consumers. These PERS technologies, as well as other personal safety devices are sold direct-to-consumer through the Company's eCommerce website and Amazon.com, through dealers and resellers, as well as directly to the United States Veterans Health Administration ("VHA"). The Company was awarded a contract by the U.S. General Services Administration ("GSA") that enables the Company to distribute its products to federal, state, and local governments (the "GSA Agreement").

Overview

LogicMark builds technology to remotely check, manage and monitor a loved one's health and safety. The Company is focused on modernizing remote monitoring to help people stay safe and live independently longer. We believe there are five trends driving the demand for better remote monitoring systems:

- 1. The "Silver Tsunami". With 11,000 Baby Boomers turning 65 in the U.S. every day, there will be more older adults than children under 18 for the first time in the near future. With 72 million "Baby Boomers" in the United States, they are not only one of the largest generations, but the wealthiest. Unlike generations before them, Baby Boomers are reliant and comfortable with technology. Most of them expect to live independently at their home.
- 2. Shift to At-Home Care. As it stands, the current healthcare system is unprepared for the human resource strain and is shifting much of the care elderly patients used to receive at a hospital, medical or assisted living facility to the patient's home. The rise of digital communication to support remote care increased dramatically during the COVID-19 pandemic. The need for connected and remote monitoring devices is more necessary and in-demand than ever before.
- 3. Rise of Data and IoT. Doctors and clinicians are asking patients to track more and more vital signs. Whether it's how they're reacting to medication or tracking blood sugar, patients and their caregivers are participating in their healthcare in unprecedented ways. Consumers are using data collected from connected devices like never before. This data can be used to prevent health emergencies as technology companies use machine learning ("ML")/artificial intelligence ("AI") to learn patient patterns and alert the patient and their care team of potential emergencies, leading to a switch from reacting to problems after they occur to predicting potential problems before they occur.
- 4. Lack of Healthcare Workers. It's estimated that 20% of healthcare workers quit during the COVID-19 pandemic. Many healthcare workers who were working during the COVID-19 pandemic suffered from burnout, exhaustion and demoralization due to the COVID-19 pandemic. There were not enough healthcare workers to support our entire population throughout the pandemic, let alone enough to support our elderly population. The responsibility of taking care of elderly family members is increasingly falling on the family, and they need help.
- 5. Rise of the Care Economy. The term "Care Economy" refers to the money people contribute to care for people until the end of their lives; the Care Economy offsets the deficiencies within the healthcare system and the desire to age in place. There has been little innovation in the industry because the majority of PERS are operated by home security companies. It is not their main line of business, and they have little expertise in developing or launching machine-learning algorithms or artificial intelligence.

Together, we believe these trends have produced a large and growing market opportunity for LogicMark. The Company enjoys a strong base of business with the VHA and plans to expand to other government agencies after being awarded the five-year GSA Agreement in July 2021, which is renewable for up to 25 years.

The PERS Opportunity

PERS, also known as a medical alert or medical alarm system, is designed to detect a threat that requires attention and then immediately contacts a trusted caregiver and/or the emergency medical workforce. Unlike conventional alarm systems which consist of a transmitter and are activated in the case of an emergency, PERS transmits signals to an alarm monitoring medical team, which then departs for the location where the alarm was activated. These types of medical alarms are traditionally utilized by the disabled, elderly or those living alone.

The PERS market is generally divided into direct-to-consumer and healthcare customer channels. With the advent of new technologies, demographic changes, and our five previously stated trends in healthcare, an expanded opportunity exists for LogicMark to provide at-home and on-the-go health and safety solutions to both customer channels.

For LogicMark, growing the healthcare opportunity relies on partnering with organizations such as government, Medicaid, hospitals, insurance companies, managed care organizations, affiliates and dealers. Partners can provide leads at no cost for new and replacement customers, have significant buying power and can provide collaboration on product research and development.

Our longstanding partnership with the VHA is a good example. LogicMark has sold over 850,000 PERS devices since 2012, of which over 500,000 devices have been sold to the U.S. government. The signing of the GSA Agreement in 2021 further strengthened our partnership with the government and expanded our ability to capture new sales. We envision a continued focus on growing the healthcare channel during 2025.

In addition to the healthcare channel, LogicMark also expects to continue growth in sales volume through its direct-to-consumer channel. It is estimated that approximately 70% of PERS customers fall into the direct-to-consumer category. Family members regularly conduct research and purchase PERS devices or sign up for monthly subscription services for their loved ones through online websites or phone apps. The Company expects traditionally higher customer acquisition costs to be balanced by higher recurring revenue.

With the growth in IoT devices, data driven solutions using AI and ML are expected to help guide the growth of the PERS industry. In both the healthcare and direct-to-consumer channels, product offerings can include 24/7 emergency response, fall detection, location tracking and geo-fencing, activity monitoring, medication management, caregiver and patient portals, concierge services, telehealth, vitals monitoring, and customer dashboards. These product offerings are primarily delivered via mobile and home-base equipment. LogicMark will also continue to pursue research and development partnerships to grow our product offering.

Our PERS Products

LogicMark produces a range of products within the PERS market as a result of the Company's 2016 acquisition of LogicMark, LLC, the former wholly owned subsidiary of the Company and now a division of the Company. Historically, the Company has differentiated itself by offering "no monthly fee" products, which only require a one-time purchase expense, instead of a contract with recurring monthly charges.

The "no monthly fee" products contact family, friends or 911 directly, eliminating the recurring monthly fee from a monitoring center, making it one of the most cost-effective options on the market. LogicMark offers both traditional (i.e., landline), mPERS (i.e., cell-based), and Internet (i.e., Wi-Fi-based) solutions. Our no monthly fee products are sold primarily to the VHA.

PRODUCT

GUARDIAN ALERT 911 PLUS



FREEDOM ALERT



GUARDIAN ALERT 911



FEATURES

- · Two-way voice via pendant
- · 911 direct dial
- 4G cellular connection; no Wi-Fi or landline necessary
- Can be used on the go
- 6 − 12 month rechargeable battery life
- No monthly fee or service agreement
- Two-way voice via pendant
- · Dial friends, family, and caregivers
- 911 forwarding
- · Landline necessary
- 6 − 12 month battery standby
- No monthly fee or service arrangement
- Two-way voice via pendant
- 911 direct dial
- · Landline necessary
- 6-9 month battery standby
- No monthly fee or service arrangement

In the past, LogicMark has offered monitored products that were exclusively sold to consumers by monitored resellers. LogicMark sold its devices to resellers, who in turn offered the monitoring component to their consumers as part of their product and service offerings. The resellers would own the device and then lease the PERS product to the consumer. The resellers would charge the consumers a monthly monitoring fee for the lease of the PERS equipment and associated monitoring service. These products were monitored by a third-party central station. During 2023, the Company began selling the LifeSentry Monitored PERS products direct-to-consumers through the Company's website. In addition, the Company began selling the Freedom Alert Plus and Freedom Alert Mini in the last quarter of 2023 whereby the Company would lease the PERS equipment and charge the monthly monitoring fee for the monitoring services. In late 2024, the Company began selling the Freedom Alert Max, both a PERS unit and cellular phone, which detects falls and sudden movements, instantly triggering an alert for help.

FREEDOM ALERT MINI



- 4G LTE
- · Fall Detection
- GPS & Wi-Fi Location Services
- 24/7 US based emergency operators
- Mobile Device
- · Geofencing Notification
- 2-4-day Battery Life with Battery Save Mode and 30-day Battery Life with Battery Save Mode Off
- Two-Way Voice Communication
- IP-67 Water-Resistant
- · Small Form Factor
- Free Connected Care Mobile App for iOS & Android
- Emergency Notifications for Caregivers
- Device Battery Monitoring
- Device Set-Up and Bluetooth Pairing
- · Monthly monitoring fee
- 4G LTE cell phone
- Fall detection technology that automatically calls emergency services
- GPS-location services pinpoint the user's exact location for quicker response times
- Geofencing alerts notify caregivers when a device is outside of a safety boundary
- Emergency caregiver video
- Simple Care Coordination for family, friends, & caregivers
- · Non-emergency calling
- Unlimited minutes
- Emergency two-way calling and voice communication via Wi-Fi
- · On-the-go device
- Free LogicMark Care Village mobile app for iOS or Android.
- Crisis and Suicide Lifeline (988) pre-programmed into the device
- Caregivers receive emergency alerts and alerts for device battery and connection status

FREEDOM ALERT MAX



In early 2024, the Company released Aster, an on-the-go personal safety app that provides 24/7 monitoring along with a Bluetooth button in order to maximize ease of use and convenience.

PRODUCT

FEATURES





- Home-Screen Slider: Contacts Emergency Services immediately
- "Hold Until Safe" Button: Connects to Emergency Services upon release
- Countdown Timer: Scheduled Timer signaling followers to check-in
- Follow Me: Schedule events to request followers to check-in after
- Bluetooth Button: Clips to keys or purse to contact Emergency Services immediately

Bluetooth Button



- Pairs with Aster app: Press the button three times to connect to Emergency Services
- Clips to your keys for immediate access to Emergency Services
- Add to a purse, backpack, or briefcase for extra peace of mind
- 200-foot Bluetooth connection range
- 5-month battery life

Industry Competition

LogicMark is focused on expanding its market position through both the direct-to-consumer and healthcare channels. The Company enjoys a strong business relationship with the VHA, through which it serves veterans who suffer from chronic conditions that often require emergency assistance. We believe that this relationship, coupled with the GSA Agreement, gives LogicMark a solid foundation to grow its healthcare channel business.

As technology and innovation have improved, barriers to entry have been lowered in the PERS sector. This has resulted in a highly fragmented market with many competitors, mostly privately held, who are solely dedicated to providing PERS. Other competitors, many of which are divisions of large publicly traded companies, offer PERS solutions in an effort to leverage their call center operations in place for other parts of their business. Competition is also found from companies in the healthcare, telecommunications and home and commercial security sectors.

Competitors may have greater financial, technical, and personnel resources, broader distribution networks, a larger portfolio of intellectual property and customers. Success in acquiring new customers is dependent on a variety of factors, including brand and reputation, market visibility, service and product capabilities, quality, price, and the ability to identify and sell to prospective customers. Our approach is to grow our product capabilities as well as key partnerships. The Company has switched from a reactive holistic personal safety perspective approach to capturing data to anticipate potential problems. These steps are expected to help us benefit from the favorable trends and growing demand for PERS in the direct-to-consumer and healthcare channels. In particular, the growing demand from the aging baby boomer generation, of which 11,000 boomers turn 65 each day.

Our Care Economy and Business Strategy

The number of Americans 65 and older make up more than 23% of the US population (over 80 million people) and more than 90% of those over 50 would like to age at home. We believe that our existing PERS and medical alert systems provide this "silver tsunami" of seniors seeking to continue living independently, the ability to stay safe,

comfortable, and content in their own home. Our customers' increasingly mobile and active lifestyles have created new opportunities for us in the fast-growing market for self-monitored products and mobile technology. We plan to continue to grow our unmonitored PERS business, which for those who are on low or fixed income and/or require long charge devices, is a cost effective and potentially life-saving product. However, we continue to see strong opportunities to build and expand our business into monitored services. We plan to continue expanding our cell-based (mPERS) product line to provide a multi-layer safety support using CPaaS, LogicMark's Caring Platform as a Service, which allows us to integrate with various third-party connected and wearable devices so that we can better serve our customers whether they are at home or on-the-go. This will allow us to capture data required for predictive analysis in order to warn the caregiver of potential future problems.

We plan to continue to expand our business into the "aging with independence" market as well as expanding further into the Care Economy by providing enhanced products and services that make the caring for loved ones easier. One in four millennials as well as more than half of GenX are taking care of loved ones with very little, but much needed, assistance. Further, as the in-home professional care business continues to expand, we believe this is an opportunity for LogicMark to extend its products and services to meet the increasing needs of the growing Care Economy. We intend to do so by expanding the tools for caretakers to better manage both the care of their elderly living independent lives, and to provide mobile and personal safety to others in their care circle so they too can feel safe on the go. We want our products and services to be available for anyone with personal safety concerns, including children or students who are navigating new environments and social situations for the first time.

Our Intellectual Property

Our ability to compete effectively depends to a significant extent on our ability to protect our proprietary information. We currently rely and will continue to rely primarily on patents and trade secret laws and confidentiality procedures to protect our intellectual property rights. Since the Company's acquisition in 2016, we have filed fifty-five new patent applications, twenty-three of which have been awarded to date.

We enter into confidentiality agreements with all our employees and consultants and maintain control over access to and distribution of our technology, software, and other proprietary information.

Government Regulations

In order to sell any products to the U.S. government, companies are required to obtain approval from the GSA and must obtain a GSA authorization number. The Company obtained GSA approval to sell its products to the federal government when it was awarded the five-year GSA Agreement in July 2021. Our U.S. government contract is subject to a large number of federal regulations and oversight requirements. Compliance with the array of government regulations requires extensive record keeping and the maintenance of complex policies and procedures relating to all aspects of our business, as well as to work performed for us by any subcontractors. In addition, government contracts are subject to audits and oversight by government inspectors at various points in the contracting process.

In addition, our devices are required to meet Federal Communications Commission ("FCC") approval, specifically relating to FCC Part 15 requirements for Class B digital devices. FCC Part 15 covers the regulations under which a device emits radio frequency energy by radiation, and the technical specifications, administrative requirements, and other conditions relating to the marketing of FCC Part 15 devices. The FCC's definition of a Class B Digital Device is one which is marketed for use in a residential environment, and FCC Part 15 compliance means that our devices may not cause harmful interference, must accept interference from other devices, and all device changes must be approved by the manufacturer. All of our devices are FCC Part 15 compliant Class B digital devices. All of our devices are manufactured to never exceed FCC specific absorption rate (SAR) limitations for exposure to radio frequency emissions for body worn devices.

Corporate Information

History

We were incorporated in the State of Delaware on February 8, 2012. In July 2016, we acquired LogicMark, LLC, which operated as a wholly owned subsidiary of the Company until December 30, 2021, when it was merged into the Company (formerly known as Nxt-ID, Inc.) along with the Company's other subsidiary, 3D-ID, LLC. As a result of the merger, 3D-ID, LLC was liquidated. Effective February 28, 2022, the Company changed its name from Nxt-ID, Inc. to

LogicMark, Inc. The Company has realigned its business strategy with that of its former LogicMark, LLC operating division, managing contract manufacturing and distribution of non-monitored and monitored PERS sold through the VHA, direct-to-consumers, healthcare durable medical equipment dealers and resellers, and monitored security dealers and resellers.

On June 1, 2023, the Company was re-incorporated in the State of Nevada by merging its predecessor entity with and into its wholly-owned subsidiary, LogicMark, Inc., a Nevada corporation, pursuant to an agreement and plan of merger, dated as of June 1, 2023. Such Nevada entity survived and succeeded to the assets, continued the business and assumed the rights and obligations of LogicMark, Inc., the Delaware corporation that existed immediately prior to the effective date of such agreement.

Our principal executive office is located at 2801 Diode Lane, Louisville, KY 40299, and our telephone number is (502) 519-2419.

Our website address is www.logicmark.com. The information contained therein or connected thereto shall not be deemed to be a part of or incorporated into this Report.

Employees

As of March 27, 2025, we had a total of 31 full-time employees, one part-time employee and three long-term contractors. None of our employees are represented by a collective bargaining agreement, nor have we experienced any work stoppage. We consider our relations with our employees to be very good. Our future success depends on our continuing ability to attract and retain highly qualified personnel. In addition, we have fractional independent contractors whose services we are using on an as-needed basis to assist us in all areas.

Available Information

We are required to file annual, quarterly and current reports, proxy statements and other information with the U.S. Securities and Exchange Commission (the "SEC"). Our filings with the SEC are available to the public through the SEC's website at *www.sec.gov*.

You can find more information about us online at our investor relations website located at *investors.logicmark.com*. Our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K and any amendments to those reports are available free of charge on our website as soon as reasonably practicable after we electronically file such material with the SEC. The information posted on or accessible through our website is not incorporated into this Annual Report on Form 10-K.

Item 1A. Risk Factors

Our business, financial condition and operating results are subject to a number of risk factors, both those that are known to us and identified below and others that may arise from time to time. These risk factors could cause our actual results to differ materially from those suggested by forward-looking statements in this Report and elsewhere, and may adversely affect our business, financial condition, or operating results. If any of these risk factors should occur, moreover, the trading price of our securities could decline, and investors in our securities could lose all or part of their investment in our securities. These risk factors should be carefully considered in evaluating our prospects.

Risks Relating to our Business

We are uncertain of our ability to generate sufficient revenue and profitability in the future.

We continue to develop and refine our business model, but we can provide no assurance that we will be able to generate a sufficient amount of revenue from our business in order to achieve profitability. It is not possible for us to predict at this time the potential success of our business. The revenue and income potential of our proposed business and operations are currently unknown. If we cannot continue as a viable entity, you may lose some or all your investment in our Company.

The Company generated an operating loss of \$7.7 million and a net loss of \$9.0 million for the year ended December 31, 2024, compared to an operating loss of \$15.3 million and a net loss of \$14.6 million for the year ended December 31, 2023. As of December 31, 2024, the Company had cash and cash equivalents and stockholders' equity of \$3.8 million

and \$10.4 million, respectively, compared to cash and cash equivalents and stockholders' equity of \$6.4 million and \$13.1 million, respectively, as of December 31, 2023. As of December 31, 2024, the Company had working capital of \$3.3 million, compared to working capital on December 31, 2023, of \$6.0 million. In February 2025, the Company completed a public offering, which resulted in total gross proceeds of \$14.4 million. We cannot provide any assurance that we will be able to raise additional cash from equity financing, secure debt financing, and/or generate revenue from the sales of our products. If we are unable to secure additional capital, we may be required to curtail our research and development initiatives and take additional measures to reduce costs in order to conserve our cash in amounts sufficient to sustain operations and meet our obligations.

The loss or material reduction of significant customer contracts, including the termination of the GSA Agreement, would have a material adverse effect on our results of operations and cash flows.

Our historical operations depend on, and a significant portion of our revenue is derived from our contract with the GSA. While we believe that our business relationship with the GSA is strong, any change in that relationship, including without limitation, the termination of the GSA Agreement, would have a significant adverse impact on our revenue, operating cash flow and financial results; and we would likely be faced with a decision to initiate cost reduction actions that would largely include reductions for personnel and assets affected by the contract loss. The loss, without replacement, of our contract with the GSA could also have a material adverse effect on our ability to win new business and our future operating results.

Our inability to win or renew government contracts during regulated procurement processes or preferences granted to certain bidders for which we would not qualify could harm our operations and significantly reduce or eliminate our profits.

U.S. government contracts are awarded through a regulated procurement process. The U.S. government has increasingly relied upon multi-year contracts with pre-established terms and conditions, such as indefinite delivery, indefinite quantity ("IDIQ") contracts, which generally require those contractors who have previously been awarded contracts to engage in an additional competitive bidding process. The increased competition may require us to make sustained efforts to reduce costs to realize revenue and profits under government contracts. If we are not successful in reducing the amount of costs we incur, our profitability on government contracts will be negatively impacted.

The U.S. government has also increased its use of contracts in which the client qualifies multiple contractors for a specific program and then awards specific task orders or projects among the qualified contractors, which have the potential to create pricing pressure and to increase our costs by requiring us to submit multiple bids and proposals. The competitive bidding process entails substantial costs and managerial time to prepare bids and proposals for contracts that may not be awarded to us or may be split among competitors. Further, the U.S. government has announced specific statutory goals regarding awarding prime and subcontracts to small businesses, women-owned small businesses, service-disabled veteran-owned businesses and small disadvantaged businesses, which may obligate us to involve such businesses as subcontractors with respect to these contracts, resulting in lower margins than when we sell direct. While we are unaware of any reason why our status as a public company would negatively impact our ability to compete for and be awarded government contracts, our inability to win or renew government contracts during regulated procurement processes or as a result of the policies pursuant to which these processes are implemented could harm our operations and significantly reduce or eliminate our profits.

Further, our U.S. government contracts are subject to termination by the U.S. government either at its convenience or upon the default of the contractor. Termination for convenience provisions provide only for the recovery of costs incurred or committed, settlement expenses, and profit on work completed prior to termination. Termination for default clauses impose liability on the contractor for excess costs incurred by the U.S. government in re-procuring undelivered items from another source. Any decisions by the U.S. government to not exercise contract options or to terminate, cancel, delay, modify or curtail our major programs or contracts would adversely affect our revenues, revenue growth and profitability.

A failure by us to continue to generate task orders or fulfill our obligations under an IDIQ contract with the GSA, or our inability to secure an IDIQ contract with the GSA, would have a material adverse effect on our financial condition and results of operation.

Our contract with the GSA provides for the issuance by the government of orders for our PERS and contains a multi-year term with unfunded ceiling amounts, which allows but does not commit the GSA to purchase from us. Additionally, we currently do not have an IDIQ contract with the GSA, and we may not be able to secure an IDIQ contract with the GSA in the future. A failure to be awarded task orders under any contracts with the government would have a material adverse effect on our results of operations and financial conditions. Additionally, any failure by us to fulfill our contractual obligations under these government contracts, or to secure an IDIQ contract with the GSA, would result in substantially reduced revenue and profits and would have a material adverse effect on our financial condition and results of operation. Our ability to fulfill our contractual obligations may be limited by our ability to devote sufficient resources and limited by availability of material supplies. If we do not fulfill our contractual obligations in a timely manner, we may experience delays in product delivery which would postpone receipt of revenue from those delayed deliveries. Additionally, if we are consistently unable to fulfill the orders and other related obligations, this may be a disincentive to customers to award large contracts to us in the future until they are comfortable that we can effectively manage the orders, or even result a termination of an existing contract.

Significant disruptions of information technology systems or security breaches could materially adversely affect our business.

We are increasingly dependent upon information technology systems, infrastructure, and data to operate our business. In the ordinary course of business, we collect, store, and transmit large amounts of confidential information (including, among other things, trade secrets or other intellectual property, proprietary business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We also have outsourced elements of our operations to third parties, and as a result, we manage a number of third-party vendors who may or could have access to our confidential information. Attacks on information technology systems are increasing in their frequency, levels of persistence, sophistication, and intensity, and they are being conducted by increasingly sophisticated and organized groups and individuals with a wide range of motives and expertise. The size and complexity of our information technology systems, and those of third-party vendors with whom we contract, and the large amounts of confidential information stored on those systems, make such systems vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors, and/or business partners, or from cyber-attacks by malicious third parties. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering, and other means to affect service reliability and threaten the confidentiality, integrity and availability of information.

Significant disruptions of our information technology systems, or those of our third-party vendors, or security breaches could materially adversely affect our business operations and/or result in the loss, misappropriation and/or unauthorized access, use or disclosure of, or the prevention of access to, confidential information, including, among other things, trade secrets or other intellectual property, proprietary business information and personal information, and could result in financial, legal, business and reputational harm to us. The Company continually assesses these threats and makes investments to increase internal protection, detection, and response capabilities, as well as ensure the Company's third-party providers have required capabilities and controls, to address this risk.

Any failure or perceived failure by us or any third-party collaborators, service providers, contractors or consultants to comply with our privacy, confidentiality, data security or similar obligations to third parties, or any data security incidents or other security breaches that result in the unauthorized access, release or transfer of sensitive information, including personally identifiable information, may result in governmental investigations, enforcement actions, regulatory fines, litigation or public statements against us, could cause third parties to lose trust in us or could result in claims by third parties asserting that we have breached our privacy, confidentiality, data security or similar obligations, any of which could have a material adverse effect on our reputation, business, financial condition or results of operations. Moreover, data security incidents and other security breaches can be difficult to detect, and any delay in identifying them may lead to increased harm. To date, the Company has not experienced any material impact to the business or operations resulting from information or cybersecurity attacks; however, because of the frequently changing attack techniques, along with the increased volume and sophistication of the attacks, there is the potential for the Company to be adversely impacted. While we have implemented data security measures intended

to protect our information technology systems and infrastructure, there can be no assurance that such measures will successfully prevent service interruptions or data security incidents. The Company maintains cybersecurity insurance in the event of an information security or cyber incident; however, the coverage may not be sufficient to cover all financial losses.

We are exposed to risks related to cybersecurity.

Although we maintain systems and processes that are designed to protect the security of our computer systems, software, networks and other technology, there is no assurance that all of our security measures will provide absolute security. Any material incidents could cause us to experience financial losses that are either not insured against or not fully covered through any insurance maintained by us and increased expenses related to addressing or mitigating the risks associated with any such material incidents. Cyber threats are rapidly evolving and are becoming increasingly sophisticated. Despite our efforts to ensure the integrity of our systems, as cyber threats evolve and become more difficult to detect and successfully defend against, one or more cyber threats might defeat the measures that we or our vendors take to anticipate, detect, avoid or mitigate such threats. Certain techniques used to obtain unauthorized access, introduce malicious software, disable or degrade service, or sabotage systems may be designed to remain dormant until a triggering event and we may be unable to anticipate these techniques or implement adequate preventative measures since techniques change frequently or are not recognized until discovered, and because cyberattacks can originate from a wide variety of sources. If our information security systems or data are compromised in a material way, our ability to conduct our business may be impaired, we may incur financial losses and we may incur costs to remediate possible harm and/or to pay fines or take other action which could have a material adverse impact on our business.

The Company employs a multi-layered approach to security and recovery in the event of a cybersecurity attack. There exists the possibility that our third-party data backup and recovery service provider may also be impaired during a targeted cybersecurity attack, which would prevent us from rapidly recovering access to the data required to process orders and continue regular operations. A localized attack affecting the physical data centers used by the Company's cloud computing platform would affect our ability to continue operations until data can be shifted to a parallel data center. There also exists the remote possibility that our data backup and recovery provider would be affected by the same localized event, further impairing our ability to rapidly restore operations.

Defects or disruptions in our products or services could diminish demand for such products or services and subject us to substantial liability.

As our products and services are complex and incorporate a variety of product, proprietary software and third-party software, such products or services may have errors or defects that could result in unanticipated downtime for our subscribers and harm to our reputation and our business. Cloud services frequently contain undetected errors when first introduced or when new versions or enhancements are released. We have from time to time found defects in, and experienced disruptions to, our products and services and new defects or disruptions may occur in the future. Such defects could also create vulnerabilities that could inadvertently permit access to protected customer data. However, any defect or disruption in our products or services in the future could materially affect our business, reputation, or financial results.

Our supply chains in Taiwan subject us to risks and uncertainties relating to the regulations of Taiwan as well as potential geopolitical friction.

The move of our contract manufacturing from China and Hong Kong to Taiwan exposes us to certain risks with respect to regulations in Taiwan and the relationship between Tawain and China. Tensions between mainland China and Taiwan have increased significantly in recent years, presenting an elevated risk of hostilities. Significant or prolonged military or other geopolitical conflict involving China and Taiwan could severely limit or prevent us from receiving our products from Taiwan, which would have a material adverse impact on our business. The manufacturing of our products depends on our operations in Taiwan, and as such, any disruption impacting Taiwan could significantly and adversely impact our ability to supply our customers with products.

In recent years, international market conditions and the international regulatory environment have been increasingly affected by competition among countries and geopolitical frictions. In particular, the U.S. government has advocated for and taken steps towards restricting trade in certain goods. The United States may take further actions to eliminate perceived unfair competitive advantages created by alleged manipulating actions. Changes to national trade or

investment policies, treaties and tariffs, fluctuations in exchange rates, or the perception that these changes could occur, could adversely affect the financial and economic conditions in the jurisdictions in which we operate, as well as our international and cross-border operations, our financial condition and results of operations.

Changes in national trade laws and policies and barriers to trade by the United States or other countries where our business operates could negatively affect our business. Conflicting regulatory requirements could also increase our compliance costs and subject us to regulatory scrutiny. Any further escalation in geopolitical tensions or a trade war, or news and rumors of any escalation, could affect activity levels within our ecosystem and have a material and adverse effect on our business, results of operations, and/or the trading prices of our shares and/or other securities. Changes in national investment laws and policies and barriers to cross-border investment, such as any restrictions imposed by the United States or other countries on capital flows, may prevent potential investors from investing in us, and the trading prices and liquidity of our shares and/or other securities may suffer as a result.

If we fail to keep pace with changing industry technology and consumer preferences, we will be at a competitive disadvantage.

The industry segments in which we are operating evolve rapidly and are characterized by continuous change, including rapid product evolution and rapidly changing industry standards and end-user/consumer preferences. In order to continue to compete effectively in these markets, we need to respond quickly to technological changes and to understand their impact on our customers' preferences. It may take significant time and resources to respond to these technological changes. If we are unable to do so on a timely basis or within reasonable cost parameters, or if we are unable to appropriately and timely train our employees to operate any of these new systems, our business may suffer. Moreover, developments by others may render our technologies and intended products non-competitive or obsolete, or we may be unable to keep pace with technological developments or other market factors. If any of our competitors implement new technologies before we are able to implement them, those competitors may be able to provide more effective products than ours. Any delay or failure in the introduction of new or enhanced products could have a material adverse effect on our business, results of operations and financial condition. Furthermore, our inability to keep pace with changing industry technology and consumer preferences may cause our inventory to become obsolete at a rate faster than anticipated, which may result in our taking goodwill impairment charges in past or future acquisitions that negatively impact our results of operations. We also may not achieve the benefits that we anticipate from any new system or technology and failure to do so could result in higher than anticipated costs or could impair our operating results.

If we cannot obtain additional capital required to finance our research and development efforts and sales and marketing efforts, our business may suffer, and our security holders may lose the value of their investment in the Company.

We may require additional funds to further execute our business plan and expand our business. If we are unable to obtain additional capital when needed, we may have to restructure our business or delay or abandon our development and expansion plans. We will have ongoing capital needs as we expand our business. If we raise additional funds through the sale of equity or convertible securities, our securityholders' ownership percentage of our Common Stock will be reduced. In addition, these transactions may dilute the value of our Common Stock. We may have to issue securities that have rights, preferences, and privileges senior to our Common Stock. The terms of any additional indebtedness may include restrictive financial and operating covenants that would limit our ability to compete and expand. There can be no assurance that we will be able to obtain the additional financing we may need to fund our business, or that such financing will be available on terms acceptable to us.

We face intense competition in our market, especially from larger, well-established companies, and we may lack sufficient financial or other resources to maintain or improve our competitive position.

A number of other companies engage in the business of developing applications for PERS. The market for such products is intensely competitive, and we expect competition to increase in the future from established competitors and new market entrants. Our current competitors include both emerging and developmental stage companies as well as larger companies. Many of our existing competitors have, and some of our potential competitors could have, substantial competitive advantages such as:

- greater name recognition and longer operating histories;
- larger sales and marketing budgets and resources;

- broader distribution and established relationships with distribution partners and end-customers;
- greater customer support resources;
- greater resources to make acquisitions;
- larger and more mature intellectual property portfolios; and
- substantially greater financial, technical, and other resources.

In addition, some of our larger competitors have substantially broader product offerings and leverage their relationships based on other products or incorporate functionality into existing products to gain business in a manner that discourages users from purchasing our products, including through selling at zero or negative margins, product bundling, or closed technology platforms. Conditions in our market could change rapidly and significantly as a result of technological advancements, partnering by our competitors or continuing market consolidation. New start-up companies that innovate and large competitors that are making significant investments in research and development may invent similar or superior products and technologies that compete with our products and technology. Our current and potential competitors may also establish cooperative relationships among themselves or with third parties that may further enhance their resources.

Our markets are subject to technological change and our success depends on our ability to develop and introduce new products.

Each of the governmental and commercial markets for our products is characterized by:

- changing technologies;
- changing customer needs;
- frequent new product introductions and enhancements;
- increased integration with other functions; and
- product obsolescence.

Our success will be dependent in part on the design and development of new products. To develop new products and designs for our target markets, we must develop, gain access to, and use leading technologies in a cost-effective and timely manner and continue to expand our technical and design expertise. The product development process is time-consuming and costly, and there can be no assurance that product development will be successfully completed, that necessary regulatory clearances or approvals will be granted on a timely basis, or at all, or that the potential products will achieve market acceptance. Our failure to develop, obtain necessary regulatory clearances or approvals for, or successfully market, potential new products could have a material adverse effect on our business, financial condition, and results of operations.

Claims by others that we infringe on their intellectual property rights could increase our expenses and delay the development of our business. As a result, our business and financial condition could be materially harmed.

Our industries are characterized by the existence of a large number of patents as well as frequent claims and related litigation regarding patent and other intellectual property rights. We cannot be certain that our products do not and will not infringe on issued patents, patents that may be issued in the future, or other intellectual property rights of others.

We do not have the resources to conduct exhaustive patent searches to determine whether the technology used in our products infringe on patents held by third parties. In addition, product development is inherently uncertain in a rapidly evolving technological environment in which there may be numerous patent applications pending, many of which are confidential when filed.

We may face claims by third parties that our products or technology infringe on their patents or other intellectual property rights. Any claim of infringement could cause us to incur substantial costs defending against the claim, even if the claim is invalid, and could distract our management. If any of our products are found to violate third-party proprietary rights, we may be required to pay substantial damages. In addition, we may be required to re-engineer our products or obtain licenses from third parties to continue to offer our products. Any efforts to re-engineer our products

or obtain licenses on commercially reasonable terms may not be successful, which would prevent us from selling our products, and, in any case, could substantially increase our costs and have a material adverse effect on our business, financial condition and results of operations.

We may not be able to protect our intellectual property rights adequately.

Our ability to compete for government contracts is affected, in part, by our ability to protect our intellectual property rights. We rely on a combination of patents, trademarks, copyrights, trade secrets, confidentiality procedures and non-disclosure and licensing arrangements to protect our intellectual property rights. Despite these efforts, we cannot be certain that the steps we take to protect our proprietary information will be adequate to prevent misappropriation of our technology or protect that proprietary information. The validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain. Nor can we assure you that, if challenged, our patents will be found to be valid or enforceable, or that the patents of others will not have an adverse effect on our ability to do business. In addition, the enforcement of laws protecting intellectual property may be inadequate to protect our technology and proprietary information.

We may not have the resources to assert or protect our rights to our patents and other intellectual property. Any litigation or proceedings relating to our intellectual property, whether or not meritorious, will be costly and may divert the efforts and attention of our management and technical personnel.

We also rely on other unpatented proprietary technology, trade secrets and know-how and no assurance can be given that others will not independently develop substantially equivalent proprietary technology, techniques or processes, that such technology or know-how will not be disclosed or that we can meaningfully protect our rights to such unpatented proprietary technology, trade secrets, or know-how. We require members of the Company's board of directors (the "Board"), employees and contractors to sign non-disclosure agreements There can be no assurance that such non-disclosure agreements will provide adequate protection for our trade secrets or other proprietary know-how.

Our success will depend, in part, on our ability to obtain new patents.

Our success will depend, in part, on our ability to obtain patent and trade secret protection for proprietary technology that we currently possess or that we may develop in the future. No assurance can be given that any pending or future patent applications will be issued to us as patents, that the scope of any patent protection obtained will be sufficient to exclude competitors or provide competitive advantages to us, that any of our patents will be held valid if subsequently challenged or that others will not claim rights in or ownership of the patents and other proprietary rights held by us.

Furthermore, there can be no assurance that our competitors have not or will not independently develop technology, processes or products that are substantially similar or superior to ours, or that they will not duplicate any of our products or design around any patents issued or that may be issued in the future to us. In addition, whether or not patents are issued to us, others may hold or receive patents which contain claims having a scope that covers products or processes developed by us.

We may not have the resources to adequately defend any patent infringement litigation or proceedings. Any such litigation or proceedings, whether or not determined in our favor or settled by us, is costly and may divert the efforts and attention of our management and technical personnel. In addition, we may be required to obtain licenses to patents or proprietary rights from third parties. There can be no assurance that such licenses will be available on acceptable terms if at all. If we do not obtain required licenses, we could encounter delays in product development or find that the development, manufacture, or sale of products requiring such licenses could be foreclosed. Accordingly, challenges to our intellectual property, whether or not ultimately successful, could have a material adverse effect on our business and results of operations.

Our future success depends on the continued service of management, engineering, sales and marketing personnel and our ability to identify, hire and retain additional personnel.

Our success depends, to a significant extent, upon the efforts and abilities of members of senior management. We have not entered into employment agreements with most of our key employees, which we believe presents a greater risk of losing some of these key employees than if we had employment agreements with them. The loss of the services of one or more of our senior management or other key employees could adversely affect our business. There is intense competition for qualified employees in our industry, particularly for highly skilled design, applications, engineering,

and salespeople. We may not be able to continue to attract and retain developers, managers, or other qualified personnel necessary for the development of our business or to replace qualified individuals who may leave us at any time in the future. Our anticipated growth is expected to place increased demands on our resources and will likely require the addition of new management and engineering staff as well as the development of additional expertise by existing management employees. If we lose the services of or fail to recruit engineers or other technical and management personnel, our business could be materially harmed.

The requirements of being a public company may strain our resources and divert management's attention.

As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002 (the "Sarbanes-Oxley Act"), the Dodd-Frank Wall Street Reform and Consumer Protection Act and other applicable securities rules and regulations. The Exchange Act requires, among other things, that we file annual and current reports with the SEC with respect to our business and operating results. Compliance with these rules and regulations increases our legal and financial compliance costs, makes some activities more difficult, time-consuming, or costly, and increases demand on our systems and resources.

As a result of disclosure of information in this Report and in filings required of a public company, our business and financial condition is more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If such claims are successful, our business and operating results could be harmed, and even if the claims do not result in litigation or are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert resources of our management and harm our business and operating results.

Periods of rapid growth and expansion could place a significant strain on our resources, including our employee base, which could negatively impact our operating results.

We may experience periods of rapid growth and expansion, which may place a significant strain and demands on our management, our operational and financial resources, customer operations, research and development, sales and marketing, administrative, and other resources. To manage our possible future growth effectively, we will be required to continue to improve our management, operational and financial systems. Future growth would also require us to successfully hire, train, motivate and manage our employees. In addition, our continued growth and the evolution of our business plan will require significant additional management, technical and administrative resources. If we are unable to manage our growth successfully, we may not be able to effectively manage the growth and evolution of our current business and our operating results could suffer.

We depend on contract manufacturers, and our production and products could be harmed if they are unable to meet our volume and quality requirements and alternative sources are not available.

We rely on contract manufacturers to provide manufacturing services for our products. If such services by any contract manufacturer become unavailable, we would be required to identify and enter into an agreement with a new contract manufacturer or take such manufacturing in-house. The loss of any of our contract manufacturers could significantly disrupt production as well as increase the cost of production, thereby increasing the prices of our products. These changes could have a material adverse effect on our business and results of operations.

We are presently a small company with too limited resources and personnel to establish a comprehensive system of internal controls. If we fail to maintain an effective system of internal controls, we would not be able to accurately report our financial results on a timely basis or prevent fraud. As a result, current and potential stockholders could lose confidence in our financial reporting, which would harm our business and the trading price of our Common Stock.

Effective internal controls are necessary for us to provide reliable financial reports and effectively prevent fraud. If we cannot provide reliable financial reports or prevent fraud, our brand and operating results would be harmed. We may in the future discover areas of our internal controls that need improvement. For example, because of size and limited resources, our external auditors have determined that we lack the personnel and infrastructure necessary to properly carry out an independent audit function. Although we believe that we have adequate internal controls for a company with our size and resources, we are not certain that the measures that we have in place will ensure that we implement and maintain adequate controls over our financial processes and reporting in the future. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, would harm our operating

results, or cause us to fail to meet our reporting obligations. Inferior internal controls would also cause investors to lose confidence in our reported financial information, which would have a negative effect on our company and the trading price of our Common Stock.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis.

As of December 31, 2023, we remediated certain matters that constituted material weaknesses in our internal controls over financial reporting. However, if the measures taken to remediate these weaknesses prove to be insufficient, or if new deficiencies arise, we may experience inaccuracies in our financial reporting, delays in preparing our financial statements, or undetected fraud, all of which could adversely impact our business operations, investor confidence, and the trading price of our Common Stock.

Due to recent disruption in the financial markets and global economic conditions, our business, liquidity and financial results could be materially adversely affected.

Recent disruption in the financial markets, particularly the volatility of the stock market and the scarcity of capital available to smaller businesses, could adversely affect us, primarily through limiting our access to capital and disrupting our clients' businesses. In addition, continuation or worsening of general market conditions in economies important to our businesses may adversely affect our clients' level of spending and ability to obtain financing, leading to us being unable to generate the levels of funding and sales that we require. Current and continued disruption of global economic conditions, including to the financial markets, could have a material adverse effect on our business, financial condition, results of operations and future prospects.

We may seek or need to raise additional funds. Our ability to obtain financing for general corporate and commercial purposes or acquisitions depends on operating and financial performance and is also subject to prevailing economic conditions and to financial, business, and other factors beyond our control. We face the risk that we may not be able to access various capital sources, including investors, lenders, or suppliers. The global credit markets and the financial services industry continue to experience turmoil characterized by the bankruptcy, failure or sale of various businesses and institutions. As a result of such disruption, our ability to raise capital may be severely restricted and the cost of raising capital through such markets or privately may increase significantly at a time when we would like, or need, to do so. Failure to access the equity or credit markets from any of these sources could have a material adverse effect on our business, financial condition, results of operations, and prospects. Any of these events could have an impact on our flexibility to fund our business operations, make capital expenditures, pursue additional expansion, or acquisition opportunities, or make another discretionary use of cash and could adversely impact our financial results.

The uncertainty caused by inflation, conflict, loss of life and disaster connected to ongoing armed conflicts between Ukraine and Russia in Europe and Israel and Hamas in the Middle East, and the foreign and domestic government sanctions imposed on Russia as a result of its invasion of Ukraine, and global supply chain disruptions have also caused greater volatility in the financial markets. A change or disruption in the global financial markets for any reason, including adverse public health developments, may cause consumers, businesses, and governments to defer purchases in response to tighter credit, decreased cash availability and declining consumer confidence. Accordingly, demand for our products could decrease and differ materially from current expectations. Further, some of our customers may require substantial financing in order to fund their operations and make purchases from us. The inability of these customers to obtain sufficient credit to finance purchases of our products and meet their payment obligations to us or possible insolvencies of our customers could result in decreased customer demand, an impaired ability for us to collect on outstanding accounts receivable, significant delays in accounts receivable payments, and significant write-offs of accounts receivable, each of which could adversely impact our financial results.

Risks Related to Our Products

The steps that we have taken to protect our technology may be inadequate to prevent others from using what we regard as our technology to compete with us.

We do not generally conduct exhaustive patent searches to determine whether the technology used in our products infringes on the patents that are held by third parties. In addition, product development is inherently uncertain in a rapidly evolving technological environment in which there may be numerous patent applications pending, many of which are confidential when filed, with regard to similar technologies.

We may face claims by third parties that our products or technology infringe their patents or other intellectual property rights in the future. Any claim of infringement could cause us to incur substantial costs defending against the claim, even if the claim is invalid, and could distract the attention of our management. If any of our products are found to violate third-party proprietary rights, we may be required to pay damages. In addition, we may be required to re-engineer our products or seek to obtain licenses from third parties to continue to offer our products. Any efforts to re-engineer our products or obtain licenses on commercially reasonable terms may not be successful, which would prevent us from selling our products, and in any case, could substantially increase our costs and have a material adverse effect on our business, financial condition, and results of operations.

Our products and technologies may not be accepted by the intended commercial consumers of our products, which could harm our future financial performance.

There can be no assurance that our PERS will achieve wide acceptance by commercial consumers of such healthcare products, and/or market acceptance generally. The degree of market acceptance for products and services based on our technology will also depend upon a number of factors, including the receipt and timing of regulatory approvals, if any, and the establishment and demonstration of the ability of our proposed device to provide the level of confidence and independence in an efficient manner and at a reasonable cost. Our failure to develop a commercial product to compete successfully with existing medical technologies could delay, limit, or prevent market acceptance. Moreover, the market for new PERS is largely undeveloped, and we believe that the overall demand for such response systems technology will depend significantly upon public perception of the need for such a level of assistance. There can be no assurance that the public will believe that our products are necessary or that the medical industry will actively pursue our technology as a means to solve such issues. Long-term market acceptance of our products and services will depend, in part, on the capabilities, operating features and price of our products and technologies as compared to those of other available products and services. As a result, there can be no assurance that currently available products, or products under development for commercialization, will be able to achieve market penetration, revenue growth or profitability.

Our PERS devices may become obsolete if we do not effectively respond to rapid technological change on a timely

The medical and two-way voice communication industries are characterized by rapid technological change, frequent new product innovations, changes in customer requirements and expectations and evolving industry standards. If we are unable to keep pace with these changes, our business may be harmed. Products using new technologies, or emerging industry standards, could make our technologies less attractive. In addition, we may face unforeseen problems when developing our products, which could harm our business. Furthermore, our competitors may have access to technologies not available to us, which may enable them to produce products of greater interest to consumers or at a more competitive cost.

Our business model is evolving. Because of the evolving nature of healthcare technology, it is difficult to predict the size of this specialized market, the rate at which the market for our PERS will grow or be accepted, if at all, or whether other healthcare technologies will render our applications less competitive or obsolete. If the market for our healthcare products fails to develop or grows slower than anticipated, we would be significantly and materially adversely affected.

If our products and services do not achieve market acceptance, we may never have significant revenues or any profits.

If we are unable to operate our business as contemplated by our business model or if the assumptions underlying our business model prove to be unfounded, we could fail to achieve our revenue and earnings goals within the time we have projected, or at all, which would have a detrimental effect on our business. As a result, the value of any investment in our Company could be significantly reduced or completely lost.

We may fail to create new products, provide new services, and enter new markets, which would have an adverse effect on our operations, financial condition, and prospects.

Our future success depends in part on our ability to develop and market our technology other than those currently intended. If we fail in these goals, our business strategy and ability to generate revenues and cash flow would be significantly impaired. We intend to expend significant resources to develop new technology, but the successful development of new technology cannot be predicted, and we cannot guarantee we will succeed in these goals.

Our products may have defects, which could damage our reputation, decrease market acceptance of our products, cause us to lose customers and revenue and result in costly litigation or liability.

Our products may contain defects for many reasons, including defective design or manufacture, defective material, or software interoperability issues. Products as complex as those we offer, frequently develop, or contain undetected defects or errors. Despite testing defects or errors may arise in our existing or new products, which could result in loss of revenue, market share, failure to achieve market acceptance, diversion of development resources, injury to our reputation and increased service and maintenance cost. Defects or errors in our products and solutions might discourage customers from purchasing future products. Often, these defects are not detected until after the products have been shipped. If any of our products contain defects or perceived defects or have reliability, quality or compatibility problems or perceived problems, our reputation might be damaged significantly, we could lose or experience a delay in market acceptance of the affected product or products and we may be unable to retain existing customers or attract new customers. In addition, these defects could interrupt or delay sales. In the event of an actual or perceived defect or other problem, we may need to invest significant capital, technical, managerial, and other resources to investigate and correct the potential defect or problem and potentially divert these resources from other development efforts. If we are unable to provide a solution to the potential defect or problem that is acceptable to our customers, we may be required to incur substantial product recall, repair, and replacement and even litigation costs. These costs could have a material adverse effect on our business and operating results.

We provide warranties on certain product sales and allowances for estimated warranty costs are recorded during the period of sale. The determination of such allowances requires us to make estimates of product return rates and expected costs to repair or to replace the products under warranty. We will establish warranty reserves based on our best estimates of warranty costs for each product line combined with liability estimates based on the prior twelve months' sales activities. If actual return rates and/or repair and replacement costs differ significantly from our estimates, adjustments to recognize additional cost of sales may be required in future periods. In addition, because our customers rely on secure authentication and identification of cardholders to prevent unauthorized access to programs, PCs, networks, or facilities, a malfunction of or design defect in its products (or even a perceived defect) could result in legal or warranty claims against us for damages resulting from security breaches. If such claims are adversely decided against us, the potential liability could be substantial and have a material adverse effect on our business and operating results. Furthermore, the possible publicity associated with any such claim, whether or not decided against us, could adversely affect our reputation. In addition, a well-publicized security breach involving smart card-based or other security systems could adversely affect the market's perception of products like ours in general, or our products in particular, regardless of whether the breach is attributable to our products. Any of the foregoing events could cause demand for our products to decline, which would cause its business and operating results to suffer.

Risks Related to our Securities

The market price for our Common Stock is particularly volatile given our status as a relatively unknown company with a small and thinly traded public float, and lack of profits, which could lead to wide fluctuations in the price of our Common Stock.

The market for our Common Stock is characterized by significant price volatility when compared to the securities of larger, more established companies that have large public floats, and we expect that the price of our Common Stock will continue to be more volatile than the securities of such larger, more established companies for the indefinite future. The volatility in the price of our Common Stock is attributable to a number of factors. First, as noted above, our Common Stock is, compared to the securities of such larger, more established companies, sporadically and thinly traded. The price of our Common Stock could, for example, decline precipitously in the event that a large number of shares of our Common Stock is sold on the market without commensurate demand. Secondly, we are a speculative or "risky" investment due to our lack of profits to date. As a consequence of this enhanced risk, more risk-adverse investors may, under the fear of losing all or most of their investment in the event of negative news or lack of progress, be more inclined to sell their shares of Common Stock on the market more quickly and at greater discounts than would be the case with the securities of a larger, more established company that has a large public float. Many of these factors are beyond our control and may decrease the market price of our Common Stock regardless of our operating performance.

Because of volatility in the stock market in general, the market price of our Common Stock will also likely be volatile.

The stock market in general, and the market for stocks of healthcare technology companies in particular, has been highly volatile. As a result, the market price of our Common Stock is likely to be volatile, and investors in our Common Stock may experience a decrease, which could be substantial, in the value of their shares of Common Stock or the loss of their entire investment for a number of reasons, including reasons unrelated to our operating performance or prospects. The market price of our Common Stock could be subject to wide fluctuations in response to a broad and diverse range of factors, including those described elsewhere in this Report, including this "Risk Factors" section, and the following:

- recent price volatility and any known risks of investing in our Common Stock under these circumstances;
- the market price of our Common Stock prior to the recent price volatility;
- any recent change in financial condition or results of operations, such as in earnings, revenues or other
 measure of company value that is consistent with the recent change in the prices of our Common Stock;
 and
- risk factors addressing the recent extreme volatility in stock price, the effects of a potential "short squeeze" due to a sudden increase in demand for our Common Stock as a result of current investor exuberance associated with healthcare or technology-related stocks, to the extent that the Company expects to conduct additional offerings in the future to fund its operations or provide liquidity, the dilutive impact of those offerings on investors that receive shares of our Common Stock in connection with those offerings at a significantly higher price.

If and when a larger trading market for our Common Stock develops, the market price of our Common Stock is still likely to be highly volatile and subject to wide fluctuations, and you may be unable to resell your shares of Common Stock at or above the price at which you acquired them.

The market price of our Common Stock may be highly volatile and could be subject to wide fluctuations in response to a number of factors that are beyond our control, including, but not limited to:

- variations in our revenues and operating expenses;
- actual or anticipated changes in the estimates of our operating results or changes in stock market analyst recommendations regarding our Common Stock, other comparable companies, or our industry generally;
- market conditions in our industry, the industries of our customers and the economy as a whole;

- actual or expected changes in our growth rates or our competitors' growth rates;
- developments in the financial markets and worldwide or regional economies;
- announcements of innovations or new products or services by us or our competitors;
- announcements by the government relating to regulations that govern our industry;
- sales of our Common Stock or other securities by us or in the open market;
- changes in the market valuations of other comparable companies; and
- other events or factors, many of which are beyond our control, including those resulting from such events, or the prospect of such events, including war, terrorism and other international conflicts, public health issues including health epidemics or pandemics, and natural disasters such as fire, hurricanes, earthquakes, tornados or other adverse weather and climate conditions, whether occurring in the United States or elsewhere, could disrupt our operations, disrupt the operations of our suppliers or result in political or economic instability.

In addition, if the market for technology and/or healthcare stocks or the stock market in general experiences loss of investor confidence, the trading price of our Common Stock could decline for reasons unrelated to our business, financial condition, or operating results. The trading price of our Common Stock might also decline in reaction to events that affect other companies in our industry, even if these events do not directly affect us. Each of these factors, among others, could harm the value of your investment in our Common Stock. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial costs and diversion of management's attention and resources, which could materially and adversely affect our business, operating results, and financial condition.

We have been notified by The Nasdaq Stock Market LLC that we are not in compliance with Listing Rule 5550(a) (2) of The Nasdaq Stock Market LLC; if we are not able to regain compliance with such rule, maintain compliance with such rule, and/or maintain compliance with all other Nasdaq continued listing requirements or standards, our Common Stock will likely be delisted from the Nasdaq Capital Market ("Nasdaq").

Our Common Stock is currently listed on Nasdaq. In order to maintain that listing, we must satisfy several minimum financial and other continued listing requirements and standards, including those regarding director independence and independent committee requirements, minimum stockholders' equity, minimum share price, and certain corporate governance requirements.

On March 20, 2025, the Company received a written notification (the "Notice") from the Listing Qualifications Department (the "Staff") of Nasdaq indicating that the Company was not in compliance with its Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement") because the Company's closing bid price for its Common Stock had closed below \$1.00 per share for the prior thirty (30) consecutive business days. Pursuant to the Notice, normally a Nasdaq-listed company would be afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement. However, due to a recent rule change modifying the delisting process for certain listed stocks that fail to maintain compliance with the Minimum Bid Price Requirement, the Company is not eligible for such a compliance period under amended Listing Rule 5810(c)(3)(A) due to the fact that the Company has effected (i) a Common Stock Reverse Stock Split over the prior one-year period and (ii) one or more reverse stock splits of the Common Stock over the prior two-year period with a cumulative ratio of 250 shares or more to one. As a result, the Notice states that the Common Stock will be delisted from Nasdaq on March 31, 2025, unless the Company appeals the Staff's determination to a hearings panel (the "Panel") by March 27, 2025.

Upon receipt of the Notice, the Company promptly requested a hearing before the Panel to appeal the Notice and to address compliance with the Minimum Bid Price Requirement, which hearing date has been set as April 29, 2025. While the appeal process is pending, the suspension of trading of the Common Stock will be stayed and the Common Stock will continue to trade on Nasdaq until the hearing process concludes and the Panel issues a written decision. The Company has been diligently working on a plan to regain and maintain compliance with the Minimum Bid Price Requirement. However, there are no assurances that the Company will be able to regain or maintain compliance with

the Minimum Bid Price Requirement or any other listing standards of Nasdaq, that the Nasdaq Panel will grant the Company any extension of time to regain compliance with the Minimum Bid Price Requirement or any other of its listing requirements, or that any such appeal to the Panel will be successful, as applicable.

In the event that our Common Stock is delisted from Nasdaq due to a failure to regain compliance with the Minimum Bid Price Requirement or to comply with any other requirement for continued listing on Nasdaq, and our Common Stock is not eligible for listing on another exchange, trading in the shares of our Common Stock could be conducted in the over-the-counter market established for unlisted securities such as the Pink Open Market or the other markets operated by the OTC Markets Group Inc. In such event, it could become more difficult to trade or obtain accurate price quotations for our Common Stock. Also, it may be difficult for us to raise additional capital if we are not listed on a national exchange.

In the event that our Common Stock is delisted from Nasdaq, U.S. broker-dealers may be discouraged from effecting transactions in shares of our Common Stock because they may be considered penny stocks and thus be subject to the penny stock rules.

The SEC has adopted a number of rules to regulate "penny stock" that restricts transactions involving stock which is deemed to be penny stock. Such rules include Rules 3a51-1, 15g-1, 15g-2, 15g-3, 15g-4, 15g-5, 15g-6, 15g-7, and 15g-9 under the Exchange Act. These rules may have the effect of reducing the liquidity of penny stocks. "Penny stocks" generally are equity securities with a price of less than \$5.00 per share (other than securities registered on certain national securities exchanges or quoted on Nasdaq if current price and volume information with respect to transactions in such securities is provided by the exchange or system). Our shares of Common Stock have in the past constituted, and may again in the future constitute, "penny stock" within the meaning of the rules. The additional sales practice and disclosure requirements imposed upon U.S. broker-dealers may discourage such broker-dealers from effecting transactions in shares of our Common Stock, which could severely limit the market liquidity of such shares of Common Stock and impede their sale in the secondary market.

A U.S. broker-dealer selling a penny stock to anyone other than an established customer or "accredited investor" (generally, an individual with a net worth in excess of \$1,000,000 or an annual income exceeding \$200,000, or \$300,000 together with his or her spouse) must make a special suitability determination for the purchaser and must receive the purchaser's written consent to the transaction prior to sale, unless the broker-dealer or the transaction is otherwise exempt. In addition, the "penny stock" regulations require the U.S. broker-dealer to deliver, prior to any transaction involving a "penny stock", a disclosure schedule prepared in accordance with SEC standards relating to the "penny stock" market, unless the broker-dealer or the transaction is otherwise exempt. A U.S. broker-dealer is also required to disclose commissions payable to the U.S. broker-dealer and the registered representative and current quotations for the securities. Finally, a U.S. broker-dealer is required to submit monthly statements disclosing recent price information with respect to the "penny stock" held in a customer's account and information with respect to the limited market in "penny stocks".

Stockholders should be aware that, according to the SEC, the market for "penny stocks" has suffered in recent years from patterns of fraud and abuse. Such patterns include: (i) control of the market for the security by one or a few broker-dealers that are often related to the promoter or issuer; (ii) manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases; (iii) "boiler room" practices involving high-pressure sales tactics and unrealistic price projections by inexperienced salespersons; (iv) excessive and undisclosed bid-ask differentials and markups by selling broker-dealers; and (v) the wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, resulting in investor losses. Our management is aware of the abuses that have occurred historically in the penny stock market. Although we do not expect to be in a position to dictate the behavior of the market or of broker-dealers who participate in the market, management will strive within the confines of practical limitations to prevent the described patterns from being established with respect to our securities.

We may seek to raise additional funds, finance acquisitions, or develop strategic relationships by issuing securities that would dilute the ownership of the Common Stock. Depending on the terms available to us, if these activities result in significant dilution, it may negatively impact the trading price of our shares of Common Stock.

The issuance of material amounts of Common Stock by us would cause our existing stockholders to experience significant dilution in their investment in us. We have financed our operations, and we expect to continue to finance our operations, acquisitions, if any, and the development of strategic relationships by issuing equity and/or convertible

securities, which could significantly reduce the percentage ownership of our existing stockholders. Further, any additional financing that we secure may require the granting of rights, preferences, or privileges senior to, or pari passu with, those of our Common Stock. Additionally, we may acquire other technologies or finance strategic alliances by issuing our equity or equity-linked securities, which may result in additional dilution. Any issuances by us of equity securities may be at or below the prevailing market price of our Common Stock and in any event may have a dilutive impact on the ownership interest of existing stockholders, which could cause the market price of our Common Stock to decline. We may also raise additional funds through the incurrence of debt or the issuance or sale of other securities or instruments senior to our shares of Common Stock. The holders of any securities or instruments that we may issue may have rights superior to the rights of our existing stockholders. If we experience dilution from issuance of additional securities and we grant superior rights to new securities over such stockholders, it may negatively impact the trading price of our shares of Common Stock. In addition, if we obtain additional financing involving the issuance of equity securities or securities convertible into equity securities, our existing stockholders' investment would be further diluted. Such dilution could cause the market price of our Common Stock to decline, which could impair our ability to raise additional financing.

Substantial future issuances and sales of shares of our Common Stock, including as a result of certain provisions contained in the Series C Warrants and Series D Warrants (each as defined below), could cause the market price of our Common Stock to decline.

We expect that significant additional capital will be needed in the near future to continue our planned operations. Sales of a substantial number of shares of our Common Stock in the public, or the perception that such sales might occur, could depress the market price of our Common Stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that such sales may have on the prevailing market price of our Common Stock.

Additionally, at a special meeting of our stockholders held on March 27, 2025, we received stockholder approval (the "Stockholder Approval") for the issuance of all shares of Common Stock upon the exercise of our Series C common stock purchase warrants (the "Series C Warrants") and our Series D common stock purchase warrants (the "Series D Warrants" and collectively with the Series C Warrants, the "Warrants"), dated February 18, 2025, and we subsequently filed a certificate of amendment (the "Charter Amendment") with the Secretary of State of the State of Nevada to our articles of incorporation, as amended ("Articles of Incorporation"), in order to increase the number of authorized shares of capital stock from 110,000,000 shares to 880,000,000 shares immediately after the Special Meeting. Upon obtaining Stockholder Approval and the filing of the Charter Amendment, the Warrants became immediately exercisable. Certain anti-dilutive provisions in the Warrants provide that the exercise prices of the Warrants will be reduced upon the Company obtaining Stockholder Approval to the lowest VWAP (as defined in the Warrants) of the Common Stock within a set period before and after such Stockholder Approval, subject to a floor price of \$0.118 per share, with the number of shares of Common Stock issuable upon exercise of such Warrants to be increased proportionately such that the aggregate exercise price of such Warrants remains the same. The recent trading prices of the Common Stock during such measurement period have been below such floor price, and consequently upon exercise, the exercise prices of the Warrants will equal to such floor price, with the number of shares of Common Stock issuable increased proportionately as a result. Holders of the Warrants have commenced exercising and may continue to exercise the Warrants, including using the alternative cashless exercise provision contained in the Series D Warrants, which permits the exercising holder to obtain three (3) shares of Common Stock for each Series D Warrant they exercise, without any cash payment to us. Such issuance of shares of Common Stock will result in significant dilution to our stockholders. As of March 27, 2025, holders of Series D Warrants have exercised a portion of such warrants for an aggregate of 33,435,000 shares of Common Stock.

We do not anticipate paying dividends on our Common Stock in the foreseeable future; you should not invest in our shares of Common Stock if you expect dividends.

The payment of dividends on our Common Stock will depend on earnings, financial condition and other business and economic factors affecting us at such time as our Board may consider relevant. If we do not pay dividends, our shares of Common Stock may be less valuable because a return on your investment will only occur if our stock price appreciates.

Additionally, the holder of our shares of Series C non-convertible voting preferred stock, par value \$0.0001 per share (the "Series C Preferred Stock") is entitled to receive dividends pursuant to the certificate of designations, preferences and rights of the Series C Preferred Stock (the "Series C Certificate of Designations"). The Series C Certificate of Designations requires us to pay cash dividends on our Series C Preferred Stock on a quarterly and cumulative basis at a rate of five percent (5%) per annum commencing on the date of issuance of such shares, which rate increases to fifteen percent (15%) per annum in the event that the Company's market capitalization is \$50 million or greater for thirty consecutive days. We are currently obligated to declare and pay \$75,000 in quarterly dividends on our shares of Series C Preferred Stock. The certificate of designation of preferences, rights and limitations (the "Series F Certificate of Designation") of our Series F convertible preferred stock, par value \$0.0001 per share (the "Series F Preferred Stock") required us to pay dividends on our Series F Preferred Stock at a rate of ten percent (10%) per annum commencing on the date of issuance of such shares, which were payable until the earlier of the date on which such shares were converted or twelve months from such date of issuance, as applicable. As of the date of this Report, we are no longer obligated to declare and pay dividends on outstanding shares of Series F Preferred Stock, as such shares were issued over twelve months prior to such date, and an aggregate of approximately 1,512 shares of Common Stock were paid as dividends to the holder of our shares of Series F Preferred Stock.

Subject to the payment of dividends on our shares of Series C Preferred Stock, we currently intend to retain our future earnings to support operations and to finance expansion and, therefore, we do not anticipate paying any cash dividends on our capital stock in the foreseeable future.

We could issue "blank check" preferred stock without stockholder approval with the effect of diluting then current stockholder interests and impairing their voting rights; and provisions in our charter documents could discourage a takeover that stockholders may consider favorable.

Our Articles of Incorporation authorize the issuance of up to 80,000,000 shares of "blank check" preferred stock with designations, rights and preferences as may be determined from time to time by our Board. Our Board is empowered, without stockholder approval, to issue a series of preferred stock with dividend, liquidation, conversion, voting or other rights which could dilute the interest of, or impair the voting power of, our common stockholders. The issuance of a series of preferred stock could be used as a method of discouraging, delaying or preventing a change in control of the Company. For example, it would be possible for our Board to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of the Company.

The Series C Preferred Stock currently ranks senior to the Common Stock and our Series F Preferred Stock, and any class or series of capital stock created after the Series C Preferred Stock and has a special preference upon the liquidation of the Company. The Series F Preferred Stock currently ranks senior to the Common Stock and any class or series of capital stock created after the Series F Preferred Stock and has a special preference upon the liquidation of the Company. The Company is also party to a rights agreement, entered into on November 1, 2024, with Nevada Agency and Transfer Company (the "Rights Agreement"), pursuant to which, in the event that a person or entity, or group thereof, becomes the Beneficial Owner (as defined in the Rights Agreement) of at least fifteen percent (15%) of the outstanding shares of Common Stock (an "Acquiring Person"), each holder of Common Stock as of the close of business on November 1, 2024 will be entitled to receive on the Distribution Date (as defined in the Rights Agreement) a dividend of one right for each share of Common Stock owned by such holder (each, a "Right"), with each Right exercisable for one one-hundredth of a share of the Company's Series G Non-Convertible Voting Preferred Stock, \$0.0001 par value per share (the "Series G Preferred Stock"), at a price of \$1.25 per one-hundredth of a share (the "Series G Purchase Price"), and upon such issuance, the shares of Series G Preferred Stock will rank junior to all other series of preferred stock as to the payment of dividends and the distribution of assets, unless the terms of any series shall provide otherwise. For further information regarding our shares of (i) Series C Preferred Stock, please refer to the disclosure contained in our Current Report on Form 8-K filed with the SEC on May 30, 2017 and the Series C Certificate of Designations filed as an exhibit to our Current Report on Form 8-K filed with the SEC on June 2, 2023 and the Series C Certificate of Amendment to the Series C Certificate of Designations filed with the SEC on November 18, 2024; (ii) Series F Preferred Stock, please refer to the disclosure contained in our Current Report on Form 8-K filed with the SEC on August 17, 2021 and the Series F Certificate of Designation filed as an exhibit to our Current Report on Form 8-K filed with the SEC on June 2, 2023; and (iii) Series G Preferred Stock and the Rights Agreement, please refer to the disclosure contained in our Current Report on Form 8-K filed with the SEC on November 1, 2024, the Series G Certificate of Designations and the Rights Agreement filed as exhibits thereto.

If securities or industry analysts do not publish research or reports about our business, or publish negative reports about our business, our share price and trading volume could decline.

The trading market for our Common Stock may depend in part on the research and reports that securities or industry analysts may publish about us or our business, our market, and our competitors. We do not have any control over such analysts. If one or more such analysts downgrade or publish a negative opinion of our Common Stock, our share price would likely decline. If analysts do not cover our Company or do not regularly publish reports on us, we may not be able to attain visibility in the financial markets, which could have a negative impact on our share price or trading volume.

Financial Industry Regulatory Authority, Inc. ("FINRA") sales practice requirements may limit a stockholder's ability to buy and sell our shares of Common Stock.

FINRA has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer's financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for certain customers. FINRA requirements will likely make it more difficult for broker-dealers to recommend that their customers buy our shares of Common Stock, which may have the effect of reducing the level of trading activity in our Common Stock. As a result, fewer broker-dealers may be willing to make a market in our Common Stock, reducing a stockholder's ability to resell shares of our Common Stock.

Item 1B. Unresolved Staff Comments.

None.

Item 1C. Cybersecurity.

Risk Management and Strategy

We have developed and continue to enhance our cybersecurity governance program to help protect the security of our computer systems, software, networks, and other technology assets against material risks from cybersecurity threats, including unauthorized attempts to access confidential information or to disrupt or degrade our business operations. Our cybersecurity governance program is strategically integrated into our broader risk management framework and aims to (1) proactively manage cyber and information security risks at the Company, (2) implement the internal controls required by cybersecurity regulatory requirements as well as the Company's information security control objective documents and information security standards, and (3) improve the efficiency, maturity, and effectiveness of technology functions and processes.

To date, risks from cybersecurity threats have not materially affected us, and we currently do not expect that the risks from cybersecurity threats are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. Despite our efforts to ensure the integrity of our computer systems, software, networks, and other technology assets, we may not be able to anticipate, detect, or recognize threats to our systems and assets, or to implement effective preventative measures against all cyber threats, especially because the techniques used are increasingly sophisticated, change frequently, are complex, and are often not recognized until discovered.

Governance

Our Board of Directors is acutely aware of the critical nature of managing risks associated with cybersecurity threats and oversees risks associated with cybersecurity threats. The Board's Audit Committee is central to the Board's oversight of cybersecurity risks and has primary responsibility for this area. The Audit Committee is composed of independent directors with diverse expertise including, risk management, technology, and finance, equipping them to oversee cybersecurity risks effectively.

Our Chief Risk Officer ("CRO") with the assistance of IT support plays a pivotal role in informing the Audit Committee on cybersecurity risks. He provides comprehensive briefings directly to the Board of Directors, as needed. These briefings encompass a broad range of topics, including any emerging threats, the status of ongoing

cybersecurity initiatives, and incident reports and learnings from any cybersecurity events that may occur. The Audit Committee actively participates and offers guidance in strategic decisions related to cybersecurity. This involvement helps ensure that cybersecurity considerations are integrated into our broader strategic objectives.

Our CRO works closely with our IT support to assess, monitor, and manage our cybersecurity risks. Our IT support regularly provides updates and reports to our CRO of all aspects related to cybersecurity risks and incidents, which are then presented to the Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), as necessary. This helps ensure that the highest levels of management are kept abreast of the cybersecurity potential risks facing the Company. Furthermore, significant cybersecurity matters and strategic risk management decisions, if any, are escalated to our Board of Directors, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.

Item 2. Properties.

Our principal executive offices are located at 2801 Diode Lane, Louisville, Kentucky 40299. On June 15, 2020, we entered into a new five-year and two-month lease agreement for warehouse space at the Louisville, Kentucky facility. The current monthly rent for the space is \$6,800 and this lease agreement expires in August 2025.

Item 3. Legal Proceedings

From time to time, we may become subject to legal proceedings, claims, or litigation arising in the ordinary course of business. We are not presently a party to any action, suit, proceeding, inquiry or investigation before or by any court, public Board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of the Company, threatened against or affecting the Company, that in the opinion of our management, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition or cash flows.

Item 4. Mine Safety Disclosures

Not applicable.

PART II

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

On November 18, 2024, we effected a one-for-twenty-five reverse stock split (the "Common Stock Reverse Stock Split") of all of our outstanding shares of Common Stock. Unless the context expressly indicates otherwise, all references to share and per share amounts referred to hereafter, including in this Item 5, reflect the amounts after giving effect to the Common Stock Reverse Stock Split.

Market Information

Our Common Stock trades on Nasdaq under the symbol "LGMK."

As of March 27, 2025, there were approximately 94 holders of record of our Common Stock. This number does not include shares of Common Stock held by brokerage clearing houses, depositories, or others in unregistered form.

Dividends

We have never declared or paid dividends on our Common Stock, and our Board does not intend to declare or pay any dividends on our Common Stock in the foreseeable future. Our earnings are expected to be retained for use in expanding our business. The declaration and payment in the future of any cash or stock dividends on our Common Stock will be at the discretion of our Board and will depend upon a variety of factors, including our future earnings, capital requirements, financial condition and such other factors as our Board may consider to be relevant from time to time.

Securities Authorized for Issuance under Equity Compensation Plans

Reference is made to "Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters — Securities Authorized for Issuance under Equity Compensation Plans" for the information required by this item.

Recent Sales of Unregistered Securities

On April 3, 2024, the Company granted Chia-Lin Simmons, our CEO, 1,848 shares of restricted Common Stock under the Company's 2023 Stock Incentive Plan ("2023 Plan"), in accordance with the terms of her employment agreement with the Company. Such shares vest over four years commencing on April 3, 2024, with a quarter to vest on the anniversary of the grant, and thereafter in quarterly amounts until the entire award has vested, so long as Ms. Simmons remains in the service of the Company.

On October 1, 2024, the Company granted an aggregate of 10,044 fully vested options to purchase shares of Common Stock to the independent members of the Board under the 2023 Plan. On July 1, 2024, the Company granted an aggregate of 2,623 fully vested options to purchase shares of Common Stock to the independent members of the Board under the 2023 Plan. On April 3, 2024, the Company granted an aggregate of 1,600 fully vested options to purchase shares of Common Stock to the independent members of the Board under the 2023 Plan. On January 19, 2024 and January 2, 2024, the Company granted an aggregate of 2,083 fully vested options to purchase shares of Common Stock to the independent members of the Board under the 2023 Plan. Additionally, during the year ended December 31, 2024, the Company issued an aggregate of 20 stock options vesting over a period of four years to employees at an average exercise price of \$25.00 per share.

Item 6. [Reserved]

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Overview

LogicMark, Inc. provides PERS, health communications devices, and IoT technology that creates a connected care platform. The Company's devices provide people with the ability to receive care at home and age independently and to check, manage and monitor a loved one's health and safety remotely. The Company's PERS devices incorporate

two-way voice communication technology directly in the medical alert pendant and providing life-saving technology at a consumer-friendly price point aimed at everyday consumers. The Company is focused on modernizing remote monitoring to help people stay safe and live independently longer. The PERS technologies, as well as other personal safety devices, are sold direct to consumer through dealers and resellers, the Company's eCommerce website (logicmark.com) and Amazon.com, as well as directly to the VHA. The Company was awarded a contract by the GSA that enables the Company to distribute its products to federal, state, and local governments.

Recent Developments

February 2025 Public Offering

On February 18, 2025 (the "Closing Date"), the Company, in connection with a best efforts public offering (the "February Offering"), sold an aggregate of (x) 2,260,000 units of the Company (the "Units") at an offering price of \$0.59 per Unit, consisting of (i) 2,260,000 shares (the "Shares") of Common Stock, (ii) Series C Warrants to purchase up to 2,260,000 shares of Common Stock, and (iii) Series D Warrants to purchase up to 2,260,000 shares of Common Stock; and (y) 22,146,750 pre-funded units of the Company (the "Pre-Funded Units") at an offering price \$0.589 per Pre-Funded Unit, consisting of (i) pre-funded common stock purchase warrants exercisable for up to 22,146,750 shares of Common Stock at \$0.001 per share (the "Pre-Funded Warrants"), (ii) Series C Warrants exercisable for up to 22,146,750 shares of Common Stock and (iii) Series D Warrants exercisable for up to 22,146,750 shares of Common Stock, pursuant to the Company's registration statement on Form S-1, as amended (File No. 333-284135), filed by the Company with the SEC under the Securities Act, which the SEC declared effective on February 14, 2025, and (ii) the Registration Statement on Form S-1MEF (File No. 333-284997) filed by the Company with the SEC on February 14, 2025 pursuant to Rule 462(b) of the Securities Act and securities purchase agreements, each dated February 18, 2025, between the Company and each of the purchasers signatory thereto (the "February Purchasers"). On the Closing Date, the Company received gross proceeds of approximately \$14.4 million, before deducting placement agent commissions and estimated Offering expenses. The Company has begun to use the net proceeds from the Offering for continued new product development, working capital and other general corporate purposes.

As of March 27, 2025, the February Purchasers exercised all Pre-Funded Warrants for an aggregate of 22,146,750 shares of Common Stock.

Nasdaq Compliance

On March 20, 2025, the Company received a written notification from The Nasdaq Stock Market LLC indicating that the Company was not in compliance with the Minimum Bid Price Requirement because the Company's closing bid price for the Common Stock was below \$1.00 per share for the prior thirty (30) consecutive business days. The Company has requested a hearing before a Nasdaq hearings panel to appeal such determination and to address compliance with the Minimum Bid Price Requirement, which hearing date has been set as April 29, 2025. While the appeal process is pending, the suspension of trading of the Common Stock will be stayed and the Common Stock will continue to trade on the Nasdaq Capital Market until the hearing process concludes and the Nasdaq hearings panel issues a written decision. If the Company does not regain compliance within any compliance period granted or is not successful in its appeal, the Common Stock may be subject to delisting.

Stockholder Approval at Special Meeting and Amendment to Articles of Incorporation

On March 27, 2025, the Company held the Special Meeting, at which, among other actions, the Company's stockholders approved the issuance of all shares of Common Stock upon the exercise of the Warrants, as well as the filing of the Charter Amendment, whereupon the Company filed the Charter Amendment on the same day to increase the number of authorized shares of the Company's capital stock from 110,000,000 shares to 880,000,000 shares, of which 800,000,000 shares are classified as Common Stock and 80,000,000 shares are classified as "blank check" preferred stock, par value \$0.0001 per share. Upon the filing of the Charter Amendment, all of the Warrants became immediately exercisable, and as of March 27, 2025 holders of Series D Warrants have exercised a portion of such warrants for an aggregate of 33,435,000 shares of Common Stock. For more information, see the Current Report on Form 8-K filed by the Company with the SEC on March 27, 2025.

Fiscal Year 2024 Highlights

Nasdaq Compliance

On December 4, 2024, the Company received a letter from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC confirming that the Company had regained compliance with the Minimum Bid Price Requirement because the closing bid price of the Common Stock had been \$1.00 per share or greater for 10 consecutive business days prior to such letter. The Company had previously not been in compliance with the Minimum Bid Price Requirement since May 2024. For more information on the Company's regained compliance with the Minimum Bid Price Requirement, see the Current Reports on Form 8-K filed by the Company with the SEC on May 10, 2024, November 18, 2024 and December 6, 2024.

Reverse Stock Split

On November 18, 2024, the Company effected a 1-for-25 reverse stock split of the outstanding shares of the Common Stock and Series C Preferred Stock, whereby every 25 shares of Common Stock and Series C Preferred Stock was consolidated into 1 share of each such class following such split, with fractional shares rounded up to the nearest whole share. All applicable information in this Management's Discussion and Analysis of Financial Condition and Results of Operations section has been retroactively adjusted to reflect such reverse stock splits.

August 2024 Public Offering and Settlement Agreements

On August 5, 2024 (the "August Closing Date"), the Company sold to certain purchasers in connection with a best efforts public offering (the "August 2024 Offering") an aggregate of (x) 57,997 units of the Company (the "August Units") at an offering price of \$11.64 per August Unit, consisting of (i) 57,997 shares of Common Stock (ii) 57,997 of the Company's Series A warrants to purchase Common Stock, exercisable for up to 57,997 shares of Common Stock at an exercise price of \$11.64 per share (the "August Series A Warrants"), and (iii) 57,997 of the Company's Series B warrants to purchase Common Stock at an exercise price of \$11.64 per share, exercisable for up to 57,997 shares of Common Stock (the "August Series B Warrants"); and (y) 328,803 pre-funded units of the Company (the "August Pre-Funded Units") at an offering price \$11.61 per August Pre-Funded Unit, consisting of (i) 328,803 pre-funded common stock purchase warrants exercisable for up to 328,803 shares of Common Stock at \$0.001 per share, (the "August Pre-Funded Warrants"), (ii) 328,803 August Series A Warrants and (iii) 328,803 August Series B Warrants, pursuant to the Company's Form S-1 registration statement, as amended (File No. 333-279133), declared effective by the SEC on August 1, 2024 and securities purchase agreements, dated August 2, 2024, between the Company and each of the purchasers signatory thereto. The August Series B Warrants can be exercised on an alternate cashless basis which would result in holders receiving four (4) times the number of common stock if such election is made. On the August Closing Date, the Company received gross proceeds of approximately \$4.5 million, before deducting placement agent commissions and estimated August Offering expenses. The Company used the net proceeds from the August Offering for continued new product development, sales and marketing, working capital and other general corporate purposes.

On November 13, 2024, the Company entered into settlement and release agreements (the "Settlement Agreements") with the current and former holders (the "Series B Holders") of its August Series B Warrants issued in the August 2024 Offering. Pursuant to the Settlement Agreements, in consideration for the Series B Holders' agreement to exercise any outstanding August Series B Warrants on or before the date of the issuance of the New Preferred Stock (as defined below) and waive certain claims with respect to the August Series B Warrants, the Company issued to the Series B Holders (i) an aggregate of 1,000 shares of Series H Convertible Non-Voting Preferred Stock, \$0.0001 par value per share (the "Series H Preferred Stock"), convertible into shares of Common Stock at an initial conversion price of \$11.64 (subject to adjustment on the fifth trading day following the effective date of the Common Stock Reverse Stock Split to the greater of (x) the lowest volume weighted average price of the Common Stock during the five trading days immediately preceding such reset date and (y) the floor price of \$4.4625) and (ii) an aggregate of 1,000 of Series I Non-Convertible Voting Preferred Stock, \$0.0001 par value per share (the "Series I Preferred Stock"), and together with the Series H Preferred Stock, the "New Preferred Stock"), each share of which entitled the holder thereof to two (2) votes per share. The shares of Series H Preferred Stock had a stated value of \$1,000 and were initially convertible into approximately 85,947 shares of Common Stock in the aggregate, subject to beneficial ownership limitations.

The Series I Preferred Stock were automatically redeemable for no consideration upon the redemption, conversion or sale of shares of Series H Preferred Stock on a one for one basis. The Company completed a fair value assessment of the Series H Preferred Stock and Series I Preferred Stock, as of November 14, 2024, using an option pricing method ("OPM") to allocate the fair value of Series H Preferred Stock and Series I Preferred Stock based on the total equity value of the Company. Based on the fair value assessment, the Company determined that the Series H Preferred Stock had a fair value of \$1.5 million. As of December 31, 2024, the conversion price of the Series H Preferred Stock was subject to an adjustment due to the Common Stock Reverse Stock Split, which adjusted the conversion price of the shares of Series H Preferred Stock to \$1.75 per share. As of December 31, 2024, 690 shares of Series H Preferred Stock had been converted into 361,781 shares of Common Stock and 690 shares of Series I Preferred Stock were redeemed upon the conversion of such Series H Preferred Stock. As of the date of this Report all such shares of Series H Preferred Stock have been redeemed.

Results of Operations

Year ended December 31, 2024, compared with the year ended December 31, 2023.

Revenue, Cost of Goods Sold, and Gross Profit

	Twelve Mo Decem					
	2024		2023		\$ Change	% Change
Revenue	\$ 9,901,987	\$	9,929,629	\$	(27,642)	0%
Cost of Goods Sold	3,285,994		3,269,967		16,027	0%
Gross Profit	\$ 6,615,993	\$	6,659,662	\$	(43,669)	
Profit Margin	67%	ó ====	67%	ó ====		

We experienced a \$27.6 thousand decrease in revenue for the year ended December 31, 2024, as compared to the year ended December 31, 2023. The decrease in revenue was primarily related to a reduction in sales of our Guardian Alert Plus and Freedom Alert devices.

Gross profit margin for the year ended December 31, 2024, was 67%, flat compared to the year ended December 31, 2023.

Operating Expenses

	Twelve Months Ended December 31,					
Operating Expenses		2024		2023	\$ Change	% Change
Direct operating cost	\$	1,338,758	\$	1,142,596	\$ 196,162	17%
Advertising cost		557,783		270,709	287,074	106%
Selling and marketing		2,277,698		2,206,091	71,607	3%
Research and development		558,621		982,684	(424,063)	(43)%
General and administrative		7,626,124		8,478,947	(852,823)	(10)%
Other expense		317,313		147,506	169,807	119%
Goodwill impairment				7,815,000	(7,815,000)	(100)%
Depreciation and amortization		1,610,427		944,596	665,831	69%
Total Operating Expenses	\$	14,286,724	\$	21,988,129	\$ (7,701,405)	

Direct Operating Cost

The \$0.2 million increase in direct operating cost for the year ended December 31, 2024, compared to December 31, 2023, was primarily driven by an increase in salaries and related expenses, direct operating fees incurred from an increase in sales through Amazon.com, and an increase in consulting fees.

Advertising Costs

The \$0.3 million increase in advertising costs for the year ended December 31, 2024, compared to December 31, 2023, was driven by the continuation in 2024 of social media advertising and web-based advertising to support our eCommerce platform and Amazon.com business.

Selling and Marketing

The \$0.1 million increase in selling and marketing expense for the year ended December 31, 2024, compared to December 31, 2023, was driven by an increase in consultants' fees and their related expenses and a focus on recruitment expenses for additional personnel offset by a decrease in personnel and related expenses.

Research and Development

The \$0.4 million decrease in research and development for the year ended December 31, 2024, compared to December 31, 2023, was driven by a reduction in product development and engineering costs as new products have been released.

General and Administrative

General and administrative costs decreased \$0.9 million for the year ended December 31, 2024, compared to December 31, 2023. This was mostly driven by lower recruiting, accounting costs and legal fees.

Other Expense

Other expenses increased \$0.2 million for the year ended December 31, 2024, compared to December 31, 2023. The increase was mostly driven by the increased cost incurred due to severance paid to terminated employees.

Goodwill Impairment

As of December 31, 2024, the Company determined that there were no indicators present to suggest that it was more likely than not that the fair value of goodwill was less than the carrying amount.

The Company performed a quantitative assessment of goodwill and assessed trends of market capitalization for the year ended December 31, 2023, which showed declines throughout the year compared to prior year levels and determined that the carrying value of its goodwill exceeded its fair value. As a result, the Company recorded a non-cash, impairment charge to write down goodwill by \$7.8 million.

Depreciation and Amortization

The \$0.7 million increase in depreciation and amortization for the year ended December 31, 2024, compared to December 31, 2023, was primarily driven by the increase in amortization due to the newly released products and software.

Other Income and Expense

Twelve Months Ended December 31. 2024 2023 \$ Change % Change \$ 160,664 \$ 221,871 (61,207)(28)%Other (expense) income (1,483,732)246,138 (1,729,870)(703)%Total Other (Expense) Income..... (1,323,068) \$ 468,009 (1,791,077)(383)%

During the fiscal year ended 2024, the Company recorded \$0.2 million of interest income generated from its cash balances, the receipt of a \$39.6 thousand refund from the Internal Revenue Service in connection with its application of an employee retention credit for businesses and \$1.5 million of other expenses due to the fair value assessment of the Series H Preferred Stock that was issued to Series B Holders.

During the fiscal year ended 2023, the Company recorded \$0.2 million of interest income generated from its cash balances and the receipt of a \$0.2 million refund from the Internal Revenue Service in connection with its application of an employee retention credit for businesses.

Provision (Benefit) for Income Taxes

For the year ended December 31, 2024, the Company recorded a tax provision of \$9.9 thousand, or (0.12)% of the loss before income taxes. For the year ended December 31, 2023, the Company recorded a tax benefit of \$0.3 million, or 2.09% of the loss before income taxes, which differed from the tax benefit at the 21% statutory rate primarily due to changes in the valuation allowance.

Liquidity and Capital Resources

Sources of Liquidity

The Company generated an operating loss of \$7.7 million and a net loss of \$9.0 million for the year ended December 31, 2024. As of December 31, 2024, the Company had cash and cash equivalents of \$3.8 million. At December 31, 2024, the Company had working capital of \$3.3 million, compared to working capital as of December 31, 2023 of \$6.0 million. During the year ended December 31, 2024, the Company received gross proceeds of \$4.6 million from the issuance of Common Stock, warrants, as well as from the exercise of Common Stock purchase warrants.

Given our cash position as of December 31, 2024 and the completion of our February Offering which resulted in \$14.4 million in gross proceeds, we believe we will have sufficient capital to sustain operations for the next year. We may raise funds in the future through equity or debt offerings to accelerate the execution of our long-term strategic plan to develop and commercialize our new products.

Cash Flows

Cash Used in Operating Activities

During the year ended December 31, 2024, net cash used in operating activities was \$4.3 million. During the year ended December 31, 2023, net cash used in operating activities was \$4.3 million. Our primary ongoing uses of operating cash relate to payments to vendors, salaries and related expenses for our employees and consulting and professional fees. Our vendors and consultants generally provide us with normal trade payment terms (net 30).

Cash Used in Investing Activities

During the year ended December 31, 2024, we invested \$25.6 thousand in equipment and website development and invested \$1.4 million in product and software development. During the year ended December 31, 2023, we purchased \$53.4 thousand in equipment and website development and invested \$1.3 million in product and software development.

Cash Provided by Financing Activities

	Twelve Months Ended December 31,				
Cash flows from Financing Activities		2024		2023	
Proceeds from sale of common stock and exercise of warrants	\$	4,492,198	\$	5,211,428	
Fees paid in connection with equity offerings		(1,210,540)		(1,026,607)	
Common stock withheld to pay taxes		(4,235)			
Warrants exercised for common stock		146,654		1,165,156	
Series C redeemable preferred stock dividends		(300,000)		(300,000)	
Net Cash Provided by Financing Activities	\$	3,124,077	\$	5,049,977	

During each of the fiscal years ended 2024 and 2023, we paid \$0.3 million of dividends on our Series C Preferred Stock. During the fiscal year ended 2024, we completed a registered public offering of Common Stock and warrants, whereby we received gross proceeds of \$4.5 million and paid fees of \$1.2 million. In addition, we received proceeds of \$0.1 million from the exercise of certain holders' warrants for shares of Common Stock.

During the fiscal year ended 2023, we completed a registered public offering of Common Stock and warrants, whereby we received gross proceeds of \$5.2 million and paid fees of \$0.8 million. In addition, we received gross proceeds of \$1.2 million and paid fees of \$0.2 million for an inducement transaction whereby holders exercised their warrants for shares of Common Stock.

Business Outlook

Our future financial performance depends, in large part, on conditions in the markets that we serve and on conditions in the U.S. in general. During the year ended December 31, 2023, we began to build a durable business model, a recurring revenue base to generate significant cash flow, to invest in efficient growth and to develop innovative software and services solutions to expand into the broader Care Economy. We invested in a number of new verticals in the consumer, pro-care/healthcare and corporate benefits lines of business and expanded further into our established government line of business. Although we have made strides in expanding, the Company did face a drop in revenue mainly due to the sunsetting of the 3G PERS units to a 4G replacement unit in 2022 that did not occur in 2023 or 2024. During the year ended December 31, 2024, we continued to invest in innovative software and services solutions and continued to invest in the expansion of consumer, pro-care/healthcare and government lines of our business.

We believe that our business has been modestly impacted by inflationary trends during the past three fiscal years. However, continued domestic inflation may increase our cost of fulfilment in fiscal year 2025 through higher labor and shipping costs, as well as our operating and overhead expenses. Should inflation become a continuing factor in the worldwide economy, it may increase the cost of purchasing products from our contract manufacturers in Asia, as well as the cost of certain raw materials, component parts and labor used in the production of our products. We have been able to maintain our profit margins through higher productivity, better supply chain management, efficiency improvements, a move of our contract manufacturing from China and Hong Kong to Taiwan, and cost reduction programs.

Off Balance Sheet Arrangements

We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not have any undisclosed borrowings or debt, and we have not entered into any synthetic leases. We are, therefore, not materially exposed to any financing, liquidity, market, or credit risk that could arise if we had engaged in such relationships.

Critical Accounting Estimates

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results may differ from these estimates. Items subject to such estimates and assumptions could include: the carrying amount and estimated useful lives of long-lived assets; assumptions used in the preparation of the goodwill impairment test; the fair value of financial instruments; income tax recoverability of deferred tax assets, and provisions, among others.

Valuation and Goodwill Impairment

Goodwill represents the excess of consideration paid over the net assets acquired. The Company conducts an annual impairment test of goodwill in the fourth quarter, and more often if required, and evaluates if events or circumstances indicate whether fair value may be less than its carrying value. If an initial assessment indicates it is more likely than not goodwill may be impaired, it is evaluated by comparing estimated fair value to carrying value. An impairment charge would be recorded for the amount by which the carrying value exceeds estimated fair value. Estimated fair values are developed primarily under an income approach that discounts estimated future cash flows using risk-adjusted interest rates, as well as earnings multiples or other techniques as warranted. Estimating short-term revenue growth and the discount rates used to determine the fair value requires management judgement and estimation of uncertainties.

Critical Accounting Policies

The following discussion and analysis of financial condition and results of operations is based upon our financial statements, which have been prepared in conformity with accounting principles generally accepted in the U.S. Certain accounting policies and estimates are particularly important to the understanding of our financial position and results of operations and require the application of significant judgment by our management or can be materially affected by changes from period to period in economic factors or conditions that are outside of our control. As a result, they are subject to an inherent degree of uncertainty. In applying these policies, our management uses their judgment to determine the appropriate assumptions to be used in the determination of certain estimates. Those estimates are based on our historical operations, our future business plans and projected financial results, our observance of trends in the industry and information available from other outside sources, as appropriate. Please see Note 4 to our financial statements for a more complete description of our significant accounting policies.

Revenue Recognition

We enter into contracts with customers that may include combinations of product and subscription services, resulting in arrangements containing multiple performance obligations. The Company's revenues primarily consist of product sales to either end customers or to resellers. The Company's revenues are derived from contracts with customers, which are in most cases customer purchase orders. For each contract, the promise to transfer the control of the products, each of which is individually distinct, is considered to be the identified performance obligation. As part of the consideration promised in each contract, the Company evaluates the customer's credit risk. Our contracts do not have any financing components, as payment terms are generally due upfront. The Company's products are almost always sold at fixed prices. In determining the transaction price, we evaluate whether the price is subject to any refunds, due to product returns or adjustments due to volume discounts, rebates, or price concessions to determine the net consideration we expect to be entitled to. The Company's sales are recognized at a point-in-time under the core principle of recognizing revenue when control transfers to the customer, which generally occurs when the Company ships or delivers the product from its fulfilment center to our customers, when our customer accepts and has legal title of the goods, and the Company has a present right to payment for such goods. Based on the respective contract terms, most of our contract revenues are recognized either (i) upon shipment based on free on board ("FOB") shipping point, or (ii) when the product arrives at its destination.

In cases where the Company enters into contracts with customers that contain multiple performance obligations, product and subscription services, we allocate the transaction price for the contract among the performance obligations on a relative standalone selling price ("SSP") basis, which is generally not directly observable and requires the Company to estimate SSP based on management judgment by considering available data such as internal margin objectives, pricing strategies, as well as other observable inputs. Subscription services revenue in these cases are recognized over time.

During the years ended December 31, 2023 and December 31, 2024, the Company released new offerings which include leasing product coupled with monthly subscription services. We account for the revenue from its lease contracts by utilizing the single component accounting policy. This policy requires the Company to account for, by class of underlying asset, the lease component and non-lease component(s) associated with each lease as a single component if two criteria are met: (1) the timing and pattern of the lease component and the non-lease component are the same and (2) the lease component would be classified as an operating lease, if accounted for separately. The Company has determined that the leased product meets the criteria to be an operating lease and has the same timing and pattern of transfer as the monthly subscription services. The Company has elected the lessor practical expedient within ASC 842, *Leases* ("ASC 842") and recognizes, measures, presents, and discloses the revenue for the new offering based upon the predominant component, either the lease or non-lease component. The Company recognizes revenue under ASC 606, *Revenue Recognition from Contracts with Customers* ("ASC 606") for its leased product for which it has estimated that the non-lease components of the new offering is the predominant component of the contract.

Inventory

The Company performs regular reviews of inventory quantities on hand through periodic cycle counts and a comprehensive year-end inventory count and evaluates the realizable value of its inventories. The Company will adjust the carrying value of the inventory as necessary with the write-down for excess, obsolete, and slow-moving inventory by comparing the individual inventory parts to forecasted product demand or production requirements. The inventory is valued at the lower of cost or net realizable value with cost determined using the first-in, first-out method.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk.

We are not required to provide the information required by this Item 7A as we are a smaller reporting company.

Item 8. Financial Statements and Supplementary Data.

The Company's financial statements, notes to the financial statements, and the report of the Company's independent registered public accounting firm required to be filed in response to this Item 8 begin on page F-1 of this Report.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we are required to perform an evaluation of our disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Exchange Act, as of December 31, 2024.

Management has concluded that our disclosure controls and procedures were effective as of December 31, 2024 to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures.

Management's Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we are required to conduct an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2024, based on the criteria set forth in the report entitled Internal Control-Integrated Framework published by COSO. Management has completed an evaluation under the criteria set forth in Internal Control-Integrated Framework, and as such our management concluded that our internal control over financial reporting was effective as of December 31, 2024.

This Report does not include an attestation report of the Company's registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's registered public accounting firm, as we are neither an accelerated filer nor a large accelerated filer and are not required to provide such a report.

Limitations of the Effectiveness of Internal Control

Our management, including our CEO and CFO, does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations

include, but are not limited to, the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple errors. Additionally, controls can be circumvented by the individual acts of a person, by collusion of two or more people, or by management override of the control. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Changes in Internal Control over Financial Reporting

There were no changes in the Company's internal control over financial reporting in the Company's fourth quarter of the fiscal year ended December 31, 2024, covered by this Report that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Item 9B. Other Information

None.

Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections

Not applicable.

PART III

Item 10. Directors, Executive Officers, and Corporate Governance

Our executive officers and directors and their ages and positions are as follows:

Name	Age	Position	Date First Elected or Appointed
Chia-Lin Simmons	51	Chief Executive Officer and Director	June 14, 2021
Mark Archer	68	Chief Financial Officer	July 15, 2021
Robert Curtis	70	Director	July 25, 2018
John Pettitt	62	Chairman of the Board and Director	March 15, 2022
Barbara Gutierrez	62	Director	May 17, 2022
Carine Schneider	61	Director	October 27, 2023

Chia-Lin Simmons, Chief Executive Officer, and Director

Chia-Lin Simmons has served as the President and Chief Executive Officer ("CEO") and a director of the Company since June 14, 2021. From 2016 to June 2021, Ms. Simmons served as the CEO and co-founder of LookyLoo, Inc., an artificial intelligence social commerce company. Ms. Simmons served as a member of the Board of Directors for Servco Pacific Inc., a global automotive and consumer goods company with businesses in mobility, automotive distribution and sales, and entertainment from 2017 to 2022 and currently serves as a member of its investment board. She is also a member of the Board of Directors of New Energy Nexus, an international organization that supports clean energy entrepreneurs with funds, accelerators and networks and since March 2023, has served as a member of the Board of Directors for Chromocell, a biotech company developing treatments for chronic pain. From 2014 to 2016, Ms. Simmons served as Head of Global Partner Marketing at Google Play, prior to which, between 2010 and 2014, she served as VP of Marketing & Content for Harman International. She has served as a senior executive or VP at a number of companies, including VP of Strategic Alliances at Audible/Amazon as well as Director of Business Development at AOL/Time Warner. Ms. Simmons received her B.A. in Communications, Magna cum Laude and Phi Beta Kappa, from the University of California, San Diego in 1995. She also received her M.B.A. from Cornell University in 2002, where she was a Park Leadership Fellow, and her J.D. from George Mason University in 2005, and is currently a licensed attorney in the State of New York. The Company believes that Ms. Simmons' broad technology industry expertise, her experience in product development and launch, and her role as CEO give her the qualifications and skills to serve as a member of the Board.

Mark Archer, Chief Financial Officer

Mark Archer has served as the permanent Chief Financial Officer ("CFO") of the Company since February 15, 2022, and previously served as our Interim CFO from July 15, 2021, to February 15, 2022. Mr. Archer also serves as a partner at FLG Partners, a Silicon Valley CFO and board advisory consultancy firm. Mr. Archer has over 40 years of financial and operational experience, including assignments in high growth technology and consumer products companies. Prior to joining FLG Partners in 2021, from 2017 to 2020, Mr. Archer served as Executive Vice President and Chief Financial Officer of Saxco International LLC, a private equity owned middle market distributor of glass and other rigid packaging solutions to the wine, beer and spirits industries. From 2016 to 2018, Mr. Archer served as President and Chief Executive Officer of Swarm Technology LLC, a growth stage technology company selling product and subscription services based on IoT architecture. He has served as either Chief Financial Officer or Chief Executive Officer at a number of other public and privately held companies. Mr. Archer received both his B.S. degree in Business Administration and an M.B.A. in Finance, from the University of Southern California, where he was a Presidential Scholar.

Robert Curtis, Director

Robert Curtis has served as a director of the Company since July 25, 2018. Dr. Curtis is a 36-year veteran in the biosciences industry. Since 2012, Dr. Curtis has served as a consultant to emerging technology companies in his role at Curtis Consulting & Communications, LLC. From 2014 to 2016, he served as the Executive Chairman and Director of the Trudeau Institute in Saranac Lake, New York and prior to that position, he was Chief Executive Officer of the Regional Technology Development Corporation from 2007 to 2012, a non-profit organization in Woods Hole,

Massachusetts, where he was responsible for identifying and commercializing technology from the Marine Biological Laboratory and the Woods Hole Oceanographic Institute. Prior to such roles, Dr. Curtis has been a founder and the CEO of several companies, including HistoRx, Inc., a tissue proteomics company, Cape Aquaculture Technologies, Inc., which developed enhanced non-genetically modified fish, and Lion Pharmaceuticals/Phoenix Drug Discovery LLC, which developed and commercialized university-based technology from some of the leading biomedical institutions in the world. He assisted in the founding of Environmental Operating Solutions, Inc., which applied denitrification technology to wastewater, and which was sold in 2017. He was a co-founder of and CEO of CombiChem, Inc., which was sold to Dupont Pharmaceuticals, and served as founding President and CEO of MetaMorphix, Inc., a joint venture between Genetics Institute, Inc. and The Johns Hopkins School of Medicine. Prior to these entrepreneurial endeavors, Dr. Curtis held senior management positions at Pharmacopeia, Inc., Cambridge Neuroscience, Inc., and Pfizer, Inc. He also served as Assistant Professor of Pharmacy Practice at the University of Illinois Medical Center in Chicago. He currently serves on the Board or as an advisor to a number of private entrepreneurial companies and has served as judge for the annual MIT \$100K Business Plan Entrepreneurial Award. He is currently President of the Falmouth Commodores baseball team and serves on the Executive Committee of the Cape Cod Baseball League. Dr. Curtis holds a BS in Pharmacy from the Massachusetts College of Pharmacy, a Pharm.D. from the University of Missouri, and an MBA from Columbia University.

Dr. Curtis' significant experience in the biosciences, healthcare, and technology sector as well as his operational background gives him the qualifications and skills necessary to serve as a director of our Company.

John Pettitt, Chairman of the Board

John Pettitt has served as a director of the Company since March 15, 2022 and as Chairman of the Board since June 3, 2022. Since October 2017, Mr. Pettitt has served as Senior Staff Software Engineer at Google LLC ("Google"), focusing on software development and software engineering management. Prior to his role at Google, Mr. Pettitt served as chief technology officer at Relay Media Inc., a mobile content optimization company, where he focused on software development for digital media, from 2015 until it was acquired by Google in October 2017. Mr. Pettitt has 39 years of experience in communication and e-commerce. An internet pioneer since 1983, Mr. Pettitt has been a founder and chief technology officer of multiple successful companies, including: Specialix PLC, a manufacturer of communications and networking product, which was acquired by Pearl Systems; software.net, the first internet app store and an e-commerce pioneer, currently known as Beyond.com, which became a publicly traded company and was later acquired by Digital River; CyberSource, a world-leading payments and fraud detection company, which became a publicly traded company and was later acquired by Visa; and Relay Media Inc. In addition, Mr. Pettitt has been awarded multiple foundational patents relating to e-commerce, fraud detection and content distribution and management. We believe that Mr. Pettitt brings a deep technical understanding of product and software, combined with a strong entrepreneurial track record, which background gives him the qualifications and skills necessary to serve as a director.

Barbara Gutierrez, Director

Barbara Gutierrez has served as a director of the Company since May 17, 2022. Ms. Gutierrez began her career in public accounting and has directed and improved the financial operations of public, private equity, and privately held companies, with extensive experience with capital transactions including initial public offerings, debt and equity capital raises, and merger and acquisition transactions. She currently serves as the Chief Financial Officer of Modivcare, Inc (Nasdaq: MODV) and previously served as CFO of InnovAge Holding Corp. (Nasdaq: INNV) from 2017 to 2023. She has served as Chief Financial Officer and Chief People Services Officer for Hero Practice Services and in senior leadership roles at Strad Energy Services, Jones Knowledge Group, PhyCor, and HCA HealthOne. She has also served as a board member of Jones International University, Camp Fire Girls of Colorado (where she served as treasurer of the Board), and corporate secretary for Strad Energy Services, formerly a TSX-traded company. Ms. Gutierrez is a graduate, magna cum laude, of the University of Denver, and is a certified public accountant and chartered global management accountant. Ms. Gutierrez is qualified to serve on the Board because she is an accomplished leader with more than 30 years of experience in executive and financial leadership roles with high growth, entrepreneurial companies in a range of industries.

Carine Schneider, Director

Carine Schneider has served as director of the Company since October 27, 2023. She is an experienced and well-connected leader and author in the private market and global compensation industry with deep experience working in consulting, technology & financial services. Since June 2023, Ms. Schneider has served as co-founder of Compass Strategic Advisors, a strategic advisory firm, based in Menlo Park, California. She was named one of the 100 Influential Women in Silicon Valley by the Silicon Valley Business Journal (2017), one of "17 Women to Watch" in 2017 by Brown Brothers Harriman Center on Women and Wealth and received the 2019 ProShare Award for Services to Employee Share Ownership. In March 2022 she was named one of the 20 Most Inspiring Women Leaders by Women Leaders Magazine. In 2021, she published her first book, "The Democratization of the Private Market". Ms. Schneider was formerly the President, Nasdaq Private Market (NPM), CEO of Certent (now Insight Software), founder and CEO of Global Shares, Partner at PwC, Director of Strategic Planning with Morgan Stanley, served as President of AST Private Company Solutions, Inc. from January 2019 to June 2023, and was the Leader of the Global Stock Plan Services at Towers Watson. Ms. Schneider served on the Board of Directors of Certent, Global Shares and The Professional Business Women of California (PBWC). In 1992, Ms. Schneider was the founding Executive Director of the National Association of Stock Plan Professionals (NASPP). In 1999, Ms. Schneider founded the Global Equity Organization (GEO). Ms. Schneider has served as Chair Emeritus in for GEO since July 2017. Ms. Schneider was also a founding Board Member of the Santa Clara University CEP Program, having served as its Chair twice. Ms. Schneider started her career and worked as a Manager of Shareholder Relations at Oracle Corporation, where she assisted in the initial public offering and managed all aspects of the company's various stock plans. Ms. Schneider speaks Dutch and English. She received her degree in Psychology & Sociology from the University of California, Santa Cruz. She is a frequent speaker at conferences around the world, including President Obama's 2016 Global Entrepreneurial Summit. She was invited to join the inaugural class of Fellow Global Equity (FGE) in 2019. We believe that Ms. Schneider is qualified to serve on the Board because she has significant financial expertise, consulting, global compensation, entrepreneurial, and technological expertise.

Board Committees

Our Board has an audit committee ("Audit Committee"), a compensation committee ("Compensation Committee") and a corporate governance and nomination committee ("Corporate Governance and Nomination Committee"). Each committee has a charter, which is available on our website at *www.logicmark.com*. Information contained on our website is not incorporated herein by reference. Each of the Board committees has the composition and responsibilities described below. As of March 27, 2025, the members of such committees are:

Audit Committee — Barbara Gutierrez*(1), Robert Curtis and John Pettitt
Compensation Committee — Carine Schneider*, Robert Curtis and John Pettitt
Corporate Governance and Nomination Committee — Robert Curtis*, Barbara Gutierrez, and Carine Schneider

- * Indicates Committee Chair
- (1) Indicates Audit Committee Financial Expert

Audit Committee

We have an Audit Committee established in accordance with Section 3(a)(58)(A) of the Exchange Act. The members of our Audit Committee are Barbara Gutierrez, Robert Curtis, and John Pettitt. Mr. Pettitt, Dr. Curtis, and Ms. Gutierrez are each "independent" within the meaning of Rule 10A-3 under the Exchange Act and the Listing Rules of The Nasdaq Stock Market LLC (the "Nasdaq Rules"). Our Board has determined that Ms. Gutierrez shall serve as the "audit committee financial expert", as such term is defined in Item 407(d)(5) of Regulation S-K. In addition, Ms. Gutierrez serves as Chairperson of the Audit Committee.

The Audit Committee oversees our corporate accounting and financial reporting process and oversees the audit of our financial statements and the effectiveness of our internal control over financial reporting. The responsibilities of the Audit Committee include, among other matters:

- Selecting and recommending to our Board the appointment of an independent registered public accounting firm and overseeing the engagement of such firm;
- Approving the fees to be paid to the independent registered public accounting firm;

- Helping to ensure the independence of our independent registered public accounting firm;
- Overseeing the integrity of our financial statements;
- Preparing an audit committee report as required by the SEC to be included in our annual proxy statement;
- Reviewing major changes to our auditing and accounting principles and practices as suggested by our Company's independent registered public accounting firm, internal auditors (if any) or management;
- Reviewing and approving all related party transactions;
- Reviewing our significant risks or exposures, including the policies to govern the process by which
 risk assessment and risk management is implemented including, without limitation, policies relating to
 cybersecurity; and
- Overseeing our compliance with legal and regulatory requirements.

In 2024, the Audit Committee held four (4) electronic or virtual meetings, at which all of the members of the then current Audit Committee were present.

The Audit Committee operates under a written charter adopted by our Board that satisfies the applicable standards of Nasdaq.

Compensation Committee

The members of our Compensation Committee are Robert Curtis, John Pettitt and Carine Schneider. Mr. Pettitt, Dr. Curtis, and Ms. Schneider are each "independent" within the meaning of the Nasdaq Rules. In addition, each member of the Compensation Committee qualifies as a "non-employee director" under Rule 16b-3 of the Exchange Act. The Compensation Committee assists the Board in the discharge of its responsibilities relating to the compensation of the members of the Board and our executive officers. Ms. Schneider serves as Chairperson of the Compensation Committee.

The Compensation Committee's compensation-related responsibilities include:

- Assisting our Board in developing and evaluating potential candidates for executive positions and overseeing the development of executive succession plans;
- Reviewing and approving on an annual basis the corporate goals and objectives with respect to compensation for our CEO;
- Reviewing, approving, and recommending to our Board on an annual basis the evaluation process and compensation structure for our other executive officers;
- Providing oversight of management's decisions concerning the performance and compensation of other Company officers, employees, consultants, and advisors;
- Reviewing our incentive compensation and other stock-based plans and recommending changes in such plans to our Board as needed, and exercising all the authority of our Board with respect to the administration of such plans;
- Reviewing and recommending to our Board the compensation of independent directors, including incentive and equity-based compensation; and
- Selecting, retaining, and terminating such compensation consultants, outside counsel and other advisors as it deems necessary or appropriate.

In 2024, the Compensation Committee held one (1) electronic or virtual meeting, at which all of the members of the then current Compensation Committee were present.

The Compensation Committee operates under a written charter adopted by our Board that satisfies the applicable standards of Nasdaq.

The members of the Corporate Governance and Nomination Committee are Robert Curtis, Barbara Gutierrez, and Carine Schneider. Dr. Curtis, and Mses. Gutierrez and Schneider are each "independent" within the meaning of the Nasdaq Rules. In addition, each member of the Corporate Governance and Nomination Committee qualifies as a "non-employee director" under Rule 16b-3 of the Exchange Act. One of the main purposes of the Corporate Governance and Nomination Committee is to recommend to the Board nominees for election as directors and persons to be elected to fill any vacancies on the Board, develop and recommend a set of corporate governance principles and oversee the performance of the Board. Dr. Curtis serves as Chairman of the Corporate Governance and Nomination Committee.

The Corporate Governance and Nomination Committee is responsible for, among other objectives, making recommendations to the Board regarding candidates for directorships; overseeing the evaluation of the Board; reviewing developments in corporate governance practices; developing a set of corporate governance guidelines; and reviewing and recommending changes to the charters of other Board committees. In addition, the Corporate Governance and Nomination Committee is responsible for overseeing our corporate governance guidelines and reporting and making recommendations to the Board concerning corporate governance matters. The Corporate Governance and Nomination Committee operates under a written charter adopted by our Board that satisfies the applicable standards of Nasdaq.

In 2024, the Corporate Governance and Nomination Committee did not hold a meeting.

Involvement in Certain Legal Proceedings

To the best of our knowledge, none of our current directors or executive officers has, during the past ten years:

- been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
- had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation, or business association of which he or she was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time;
- been subject to any order, judgment, or decree, not subsequently reversed, suspended, or vacated, of any
 court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring,
 suspending or otherwise limiting his involvement in any type of business, securities, futures, commodities,
 investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged
 in any such activity;
- been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures
 Trading Commission to have violated a federal or state securities or commodities law, and the judgment
 has not been reversed, suspended, or vacated;
- been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or
- been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

Except as may be set forth in our discussion below in Item 13 "Certain Relationships and Related Transactions, and Director Independence" none of our directors or executive officers has been involved in any transactions with us or any of our directors, executive officers, affiliates, or associates which are required to be disclosed pursuant to the rules and regulations of the SEC.

Family Relationships

There are no relationships between any of the officers or directors of the Company.

Director Nomination Procedures

There have been no material changes to the procedures by which security holders may recommend nominees to our Board.

Code of Ethics

The Board has adopted a Code of Business Ethics and Conduct (the "Code of Conduct") which constitutes a "code of ethics," as defined by applicable SEC rules and a "code of conduct," as defined by applicable rules of Nasdaq. We require all employees, directors, and officers, including our principal executive officer and principal financial officer to adhere to the Code of Conduct in addressing legal and ethical issues encountered in conducting their work. The Code of Conduct requires that these individuals avoid conflicts of interest, comply with all laws and other legal requirements, conduct business in an honest and ethical manner and otherwise act with integrity and in our best interest. The Code of Conduct contains additional provisions that apply specifically to our CEO, CFO, and other finance department personnel with respect to full and accurate reporting. The Code of Conduct is available on our website at www.logicmark.com. The Company will post any amendments to the Code of Conduct, as well as any waivers that are required to be disclosed by the rules of the SEC on such website. Information contained on or that may be obtained from our website is not and shall not be deemed to be a part of this Report.

Delinquent Section 16(a) Reports

Under the securities laws of the United States, our directors, executive (and certain other) officers, and any persons holding ten percent or more of our Common Stock must report on their ownership of the Common Stock and any changes in that ownership to the SEC. Specific due dates for these reports have been established. Based solely upon a review of these reports filed electronically with the SEC and certain written representations provided to us by such persons, we believe that all reports required to be filed by our directors, executive officers and holders of more than 10% of our Common Stock pursuant to Section 16(a) of the Exchange Act during the fiscal year ended December 31, 2024 were filed on a timely basis, except for (i) two late Form 4s for Robert Curtis for two transactions not reported on a timely basis, (ii) one late Form 4 for each of Thomas Wiley Wilkinson, John Pettit, Carine Schneider and Barbara Gutierrez, in each case with respect to one transaction not reported on a timely basis.

Insider Trading Arrangements and Policies

We have a written insider trading policy that applies to our directors, officers, employees and contractors, including our principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions. We intend to disclose future amendments to such policy, or any waivers of its requirements, applicable to any principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions or our directors on our website identified above or in a current report on Form 8-K that we would file with the SEC.

Our directors and executive officers may adopt written plans, known as Rule 10b5-1 plans, in which they will contract with a broker to buy or sell shares of our Common Stock on a periodic basis. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the director or officer when entering into the plan, without further direction from them. The director or officer may amend a Rule 10b5-1 plan in some circumstances and may terminate a plan at any time. Our directors and executive officers also may buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of material non-public information subject to compliance with the terms of our insider trading policy.

Item 11. Executive Compensation.

All disclosure relating to the shares of Common Stock under this "Executive Compensation" section reflects the Common Stock Reverse Stock Split effected by the Company on November 18, 2024.

Summary Compensation Table for Fiscal Years 2024 and 2023

The following table sets forth all plan and non-plan compensation for the last two fiscal years paid to individuals who served as the Company's principal executive officers, as required by Item 402(m)(2) of Regulation S-K of the Securities Act. We refer to these individuals collectively as our "named executive officers."

Name and Principal Position	Year	Salary (\$)	Bonus (\$)	Stock Awards (\$) ⁽³⁾	Option Awards (\$)	Incentive Plan Compensation (\$)	Deferred Compensation Earnings (\$)	All Other Compensation (\$) ⁽⁴⁾	Total (\$)
Chia-Lin Simmons	2024	500,000	350,000	46,200	_	_	_	38,839	935,039
Chief Executive Officer ⁽¹⁾	2023	500,000	375,000	181,040	_		_	29,669	1,085,709
Mark Archer	2024	537,392	_	_	_	_	_	41,688	579,080
Chief Financial Officer ⁽²⁾	2023	572,617	_	64,240	_	_	_	28,979	665,836

- (1) Ms. Simmons was appointed the Company's CEO and member of the Board on June 14, 2021. Ms. Simmons has been granted (a) 2,480 shares of restricted Common Stock that vest over four years commencing July 3, 2023, and (b) 1,848 shares of restricted Common Stock that vest over four years commencing April 3, 2024, with a quarter of each such grant to vest on the anniversary of such grant, and thereafter in quarterly amounts until the entire award has vested, so long as Ms. Simmons remains in the service of the Company.
- (2) Mr. Archer was appointed the Company's Interim CFO on July 15, 2021, and was appointed the Company's permanent CFO on February 15, 2022. Salary reflects compensation received by FLG Partners, LLC ("FLG Partners") for Mr. Archer's services along with his salary from the Company. Additional details regarding Mr. Archer's compensation are summarized below under "Employment Agreements." Mr. Archer and FLG Partners were granted 836 and 44 shares of restricted Common Stock, respectively, that vest over three years commencing on July 3, 2023, with a quarter vested on July 3, 2024, with the remaining number of such shares to vest at the rate of 6.25% for each three-month period thereafter until the entire award has vested, provided, however, that if Mr. Archer or FLG Partners terminates or ceases to provide services during such three-month period, the portion of the shares that would otherwise vest at the end thereof will vest as of Mr. Archer's and FLG Partners' termination or cessation of services.
- (3) Amounts reported in this column reflect the grant date fair value of the restricted stock award granted during the fiscal years ended December 31, 2024, and 2023, as computed in accordance with Financial Accounting Standards Board ("FASB") ASC 718.
- (4) Other compensation includes primarily employer-paid health insurance.

Employment Agreements

Chia-Lin Simmons

On June 14, 2021, the Company entered into an employment agreement with Chia-Lin Simmons (the "Prior Agreement"), pursuant to which she was appointed our CEO and a member of the Board, effective June 14, 2021, in consideration for an annual cash salary of \$450,000. The Prior Agreement provided for incentive bonuses as determined by the Board, a one-time sign-on bonus of \$50,000, and employee benefits, including health and disability insurance, in accordance with the Company's policies, and remains in effect until her employment with the Company is terminated.

Additionally, pursuant to the Prior Agreement and as a material inducement to her acceptance of employment with the Company, the Company offered Ms. Simmons a stock award of 534 shares of restricted Common Stock. Such stock award was approved by the Board's compensation committee and the shares were issued in accordance with Nasdaq Listing Rule 5635(c)(4) outside of our 2013 Long-Term Stock Incentive Plan ("2013 LTIP") and our 2017 Stock Incentive Plan ("2017 SIP"), vesting over a four-year period commencing on October 15, 2021, with a quarter to vest on the anniversary of that date, and thereafter in quarterly amounts until such award has fully vested, so long as Ms. Simmons remains in the service of the Company.

On November 2, 2022, the Company executed an executive employment agreement (the "Simmons Agreement") with Ms. Simmons, effective as of June 14, 2022, and which supersedes the Prior Agreement. The term of the Simmons Agreement commenced on June 14, 2022, and continues through and until August 31, 2025 (the "Term"), unless

terminated on an earlier date pursuant to the terms set forth in the Simmons Agreement. In December 2024, the Board approved an extension to the Simmons Agreement for an additional year, and the Company and Ms. Simmons intend to formalize such extension during fiscal 2025. Pursuant to the Simmons Agreement, Ms. Simmons will receive an annual base salary of \$500,000 (the "Base Salary") and will be eligible to receive an annual bonus as of such effective date (the "Annual Bonus"). The Annual Bonus will have a maximum amount of 100% of Ms. Simmons' base salary and is contingent upon Ms. Simmons meeting certain annual goals (the "Annual Bonus Goals") as approved by the Board. Following the close of each fiscal year, the Board's compensation committee will determine the Annual Bonus within the guidance under the Annual Bonus Goals. The Simmons Agreement also provides that subject to the approval of the Board, Ms. Simmons will be granted restricted shares of Common Stock from time to time during the Term so that the aggregate number of such restricted shares of Common Stock held of record by Ms. Simmons at all times during the Term equals six percent (6%) of the Company's aggregate issued and outstanding stock as of the applicable date of grant. The Simmons Agreement also provides for certain employee benefits.

Pursuant to the Simmons Agreement, if the Board terminates Ms. Simmons' employment with Cause (as defined in the Simmons Agreement), or she resigns from the Company without Good Reason (as defined in the Simmons Agreement), then the Company shall pay the Base Salary prorated through the date of termination, at the rate in effect at the time notice of termination is given, together with accrued but unused vacation pay. In addition, Ms. Simmons will retain all of the restricted shares of Common Stock granted pursuant to the Simmons Agreement that have vested as of the date of termination. The Board also may terminate Ms. Simmons without Cause upon sixty (60) days' written notice. If Ms. Simmons terminates such employment with Good Reason, or such employment is terminated without Cause or due to Ms. Simmons's death or disability, Ms. Simmons would be entitled to receive the greater of (i) the balance of Base Salary and benefits still owed, and (ii) salary continuation and COBRA coverage for twelve (12) months, and would also be entitled to the target Bonus (irrespective of Annual Bonus Goals) prorated up until the date of termination and accrued but unused vacation pay, payment of both of which will be made at the time of termination, and all unvested restricted shares of Common Stock granted pursuant to the Simmons Agreement will vest in full as of such date of termination.

Mark Archer

Effective July 15, 2021, the Board appointed Mr. Archer as Interim CFO of the Company. In connection with the appointment, the Company entered into an agreement, effective July 15, 2021, with FLG Partners (the "FLG Agreement"), of which Mr. Archer is a partner, pursuant to which the Company agreed to pay FLG Partners \$500 per hour for its engagement of Mr. Archer's services as Interim CFO. The FLG Agreement also requires the Company to indemnify Mr. Archer and FLG Partners in connection with Mr. Archer's services to the Company. The FLG Agreement has an indefinite term and is terminable by the Company or FLG Partners upon 60 days' prior written notice.

Effective February 15, 2022, the Board appointed Mr. Archer as our permanent CFO. In connection with the appointment, the Company and FLG Partners entered into an amendment to the FLG Agreement, dated February 15, 2022 (the "Amendment"), pursuant to which the Company agreed to amend the fee payable to FLG Partners to \$10,000 per week, to permit Mr. Archer to separately invoice the Company for administrative charges of \$2,000 per month, payable to Mr. Archer only, and to the issuance of 6,470 restricted shares of Common Stock to Mr. Archer and 341 restricted shares of Common Stock to FLG Partners, a quarter of each such issuance vested on July 15, 2022, with subsequent vesting at 6.25% for each three-month period thereafter. Mr. Archer did not receive any securities of the Company in connection with the FLG Agreement or the Amendment during the fiscal year ended December 31, 2024.

A brief description of the 2013 LTIP and the 2017 SIP is contained in Note 9 of the Notes to the Financial Statements.

Other Compensation

We provide standard health insurance benefits to our executive officers, as we do with all other eligible employees. We believe these benefits are consistent with the broad-based employee benefits provided at the companies with whom we compete for talent and therefore are important to attracting and retaining qualified employees. Other than as described above, there were no post-employment compensation, pension or nonqualified deferred compensation benefits earned by our named executive officers during the years ended December 31, 2024, and 2023. We do not have any pension, or profit-sharing programs for the benefit of our directors, officers, or other employees. The Board may recommend adoption of one or more such programs in the future.

We do sponsor a retirement plan intended to qualify for favorable tax treatment under Section 401(a) of the Internal Revenue Code, containing a cash or deferred feature that is intended to meet the requirements of Section 401(k) of the Internal Revenue Code. Employees working 20 hours or more on a consistent weekly basis, and who are on our payroll and who have attained at least 18 years of age are generally eligible to participate in the plan on the first day of employment, contingent upon completion of certain onboarding tasks. Participants may make pre-tax contributions to the plan from their eligible earnings up to the statutorily prescribed annual limit on pre-tax contributions under the Internal Revenue Code. Pre-tax contributions by participants and the income earned on those contributions are generally not taxable to participants until withdrawn. Participant contributions are held in trust as required by law. No minimum benefit is provided under the plan. An employee's interest in his or her pre-tax deferrals is 100% vested when contributed. The plan provides for a discretionary employer matching contribution and a discretionary employer profit sharing contribution.

Outstanding Equity Awards at 2024 Fiscal Year End

The following table provides information relating to the vested and unvested option and stock awards held by our named executive officers as of December 31, 2024. Each award to each named executive officer is shown separately, with a footnote describing the award's vesting schedule.

	Option Awards						Stock Awards				
									Equity		
								Equity	Incentive		
								Incentive	Plan Awards:		
			Equity				Market	Plan Awards:	Market or		
			Incentive				Value of	Number of	Payout Value		
			Plan Awards:			Number of	Shares or	Unearned	of Unearned		
	Number of	Number of	Number of			Shares or	Units of	Shares,	Shares,		
	Securities	Securities	Securities			Units of	Stock	Units or	Units or		
	Underlying	Underlying	Underlying	Option		Stock	That	Other Rights	Other Rights		
	Unexercised	Unexercised	Unexercised	Exercise	Option	That	Have Not	That Have	That Have		
	Options	Options	Unearned	Price	Expiration	Have Not	Vested	Not Vested	Not Vested		
Name	(# Exercisable)	(# Unexercisable)	Options (#)	(\$)	Date	Vested (#)	(\$) ⁽⁷⁾	(#)	(\$)		
Chia-Lin											
$Simmons^{(1)(2)(3)(4)}$	_	_	_	_		4,395	656,760	_	_		
Mark Archer ⁽⁵⁾⁽⁶⁾	_	_	_	_	_	553	96,609	_	_		

- (1) Ms. Simmons was granted 534 shares of restricted Common Stock that vest over four years commencing on October 15, 2021, with a quarter to vest on the anniversary of the grant date, and thereafter in quarterly amounts until the entire award has vested, so long as Ms. Simmons remains in the service of the Company for such quarter.
- (2) Ms. Simmons was granted 409 shares of restricted Common Stock that vest over four years commencing on January 3, 2022, with a quarter to vest on the anniversary of the grant date, and thereafter in quarterly amounts until the entire award has vested, so long as Ms. Simmons remains in the service of the Company for such quarter.
- (3) Ms. Simmons was granted 2,480 shares of restricted Common Stock that vest over four years commencing on July 3, 2023, with a quarter to vest on the anniversary of the grant date, and thereafter in quarterly amounts until the entire award has vested, so long as Ms. Simmons remains in the service of the Company for such quarter.
- (4) Ms. Simmons was granted 1,848 shares of restricted Common Stock that vest over four years commencing on April 3, 2024, with a quarter to vest on the anniversary of the grant date, and thereafter in quarterly amounts until the entire award has vested, so long as Ms. Simmons remains in the service of the Company for such quarter.
- (5) Mr. Archer and FLG Partners were granted 259 and 14 shares of restricted Common Stock, respectively, that vest over three years commencing on February 15, 2022, with a quarter vested on July 15, 2022, with the remaining number of such shares to vest at the rate of 6.25% for each three-month period thereafter until the entire award has vested, provided, however, that if Mr. Archer or FLG Partners terminates or ceases to provide services during such three-month period, the portion of the shares that would otherwise vest at the end thereof will vest as of Mr. Archer's or FLG Partners' termination or cessation of services.
- (6) Mr. Archer and FLG Partners were granted 836 and 44 shares of restricted Common Stock, respectively, that vest over three years commencing on July 3, 2023, with a quarter vested on July 3, 2024, with the remaining number of such shares to vest at the rate of 6.25% for each three-month period thereafter until the entire award has vested, provided, however, that if Mr. Archer or FLG Partners terminates or ceases to provide services during such three-month period, the portion of the shares that would otherwise vest at the end thereof will vest as of Mr. Archer's or FLG Partners' termination or cessation of services.
- (7) Amounts reflect the grant date fair value of such award granted, as computed in accordance with FASB ASC 718. As required by SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions.

Director Compensation for Fiscal Year 2024

During the year ended December 31, 2024, each of our non-employee directors earned fees paid or to be paid in cash and stock options for serving on our Board. Such compensation was paid to each director in quarterly installments. The following table reflects all compensation awarded to and earned by the Company's directors for the fiscal year ended December 31, 2024.

					Nonqualified		
	ID	C4 1	Stock	Non-Equity	Deferred	All Odboo	
	Fees Earned	Stock Awards	Option Awards	Incentive Plan Compensation	Compensation Earnings	All Other Compensation	Total
Name	(\$)	(\$)	(\$) ⁽¹⁾	(\$)	(\$)	(\$) ⁽²⁾	(\$)
Barbara Gutierrez	65,000		49,726	_	_	3,206	117,932
Carine Schneider	63,000	_	37,345	_	_	3,128	103,473
John Pettitt	85,000		49,726				134,726
Robert Curtis	63,000	_	49,726			6,364	119,090

⁽¹⁾ Such board directors each received stock options, which were exercisable for shares of Common Stock at an average price of approximately \$11.66 per share.

Policies on the Timing of Option Grants in Relation to the Release of Material Non-public Information

We do not have any formal policy that requires the Company to grant, or avoid granting, equity-based compensation at certain times. We do not grant equity awards in anticipation of the release of material non-public information that is likely to result in changes to the price of our Common Stock, and do not time the public release of such information based on award grant dates. The timing of any equity grants to executive officers or directors in connection with new hires, promotions, or other non-routine grants is tied to the event giving rise to the award (such as an executive officer's commencement of employment or promotion effective date).

During the year ended December 31, 2024, there were no equity grants made to our executive officers during any period beginning four business days before the filing of a periodic report or current report disclosing material non-public information and ending one business day after the filing or furnishing of such report with the SEC.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth, as of March 27, 2025, information regarding beneficial ownership of our capital stock by:

- each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding voting securities;
- each of our named executive officers;
- each of our directors; and
- all of our named executive officers and directors as a group.

Beneficial ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power of that security, including securities that are convertible into or exercisable for shares of Common Stock, Series C Preferred Stock or Series F Preferred Stock within sixty (60) days of March 27, 2025. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the holders named in the table below have sole voting and investment power with respect to all shares of Common Stock, Series C Preferred Stock or Series F Preferred Stock shown that they beneficially own, subject to community property laws where applicable.

For purposes of computing the percentage of outstanding shares of our Common Stock, Series C Preferred Stock and Series F Preferred Stock held by each holder or group of holders named above, any shares of Common Stock, Series C Preferred Stock or Series F Preferred Stock that such holder or holders has the right to acquire within sixty (60) days of March 27, 2025 is deemed to be outstanding, but is not deemed to be outstanding for the purpose

⁽²⁾ The Company reimbursed such directors for travel-related expenses.

of computing the percentage ownership of any other holder. The presentation of the shares of Common Stock and Series C Preferred Stock on the following table reflects the Company's reverse stock splits of the outstanding shares of Common Stock and Series C Preferred Stock that were effected on November 18, 2024. The inclusion herein of any shares of Common Stock, Series C Preferred Stock or Series F Preferred Stock listed as beneficially owned does not constitute an admission of beneficial ownership. Unless otherwise identified, the address of each beneficial owner listed in the table below is c/o LogicMark, Inc., 2801 Diode Lane, Louisville, KY 40299.

	Shares Beneficially Owned							
	Common Stock		Series C Preferred Stock		Series F Preferred Stock		% Total Voting	
Name of Beneficial Owner	Shares	0 / 0 ⁽¹⁾	Shares	%	Shares	%	Power ⁽¹⁾⁽²⁾	
Non-Director or Officer 5% Stockholders:								
Alpha Capital Anstalt ⁽³⁾	7,751	*	_	_	106,333	100%	*	
Giesecke+Devrient Mobile Security America, Inc. (4)	_	_	1	100%	_	_	*	
Directors and Executive Officers:								
Chia-Lin Simmons ⁽⁵⁾ Chief Executive Officer and								
Director	213,483	*	_	_	_		*	
Mark Archer ⁽⁶⁾								
Chief Financial Officer	132,465	*	_	_	_	_	*	
Robert Curtis								
Director ⁽⁷⁾	102,635	*	_		_	_	*	
John Pettitt								
Director ⁽⁸⁾	102,580	*	_		_	_	*	
Barbara Gutierrez								
Director ⁽⁹⁾	102,570	*	_		_	_	*	
Carine Schneider								
Director ⁽¹⁰⁾	101,843	*					*	
Directors and Executive Officers as a Group (6 persons)	755,576	1.24%					1.24%	

^{*} Less than 1%

- (2) Percentage of total voting power represents voting power with respect to all shares of Common Stock, Series C Preferred Stock and Series F Preferred Stock. The holders of our Common Stock and Series C Preferred Stock are entitled to one vote per share. The holders of our Series F Preferred Stock vote on an as-converted to Common Stock basis.
- (3) Beneficial ownership includes an aggregate of 3,713 shares of Common Stock, an aggregate of 3,931 shares of Common Stock issuable upon exercise of all such holder's warrants and 107 shares of Common Stock issuable upon conversion of such holder's shares of Series F Preferred Stock. Konrad Ackermann has voting and investment control over the securities held by Capital Anstalt. The principal business address of Alpha Capital Anstalt is Altenbach 8-9490 Vaduz, Principality of Liechtenstein.

⁽¹⁾ The number of shares owned and the beneficial ownership percentages set forth in these columns are based on 60,588,224 shares of Common Stock, 1 share of Series C Preferred Stock, and 106,333 shares of Series F Preferred Stock convertible into an aggregate of 107 shares of Common Stock, issued and outstanding as of March 27, 2025. Shares of Common Stock issuable pursuant to options, preferred stock or warrants currently exercisable or exercisable within sixty (60) days are considered outstanding for purposes of computing the percentage beneficial ownership of the holder of such options, preferred stock, or warrants; they are not considered outstanding for purposes of computing the percentage of any other stockholder. Exercises of certain warrants and conversions of certain shares of preferred stock held by certain stockholders listed above are subject to certain beneficial ownership limitations, which provide that a holder of such securities will not have the right to exercise or convert any portion of such securities, as applicable, if such holder, together with such holder's affiliates, would beneficially own in excess of 4.99% or 9.99%, as applicable, of the number of shares of Common Stock outstanding immediately after giving effect to such exercise, provided that upon at least 61 days' prior notice to the Company, such holder may increase or decrease such limitation up to a maximum of 9.99% of the number of shares of Common Stock outstanding. As a result, the number of shares of Common Stock reflected in these columns as beneficially owned by the applicable stockholders includes (a) any outstanding shares of Common Stock held by such stockholder, and (b) if any, the securities convertible into or exercisable for shares of Common Stock that may be held by such stockholder, in each case which such stockholder has the right to acquire as of March 27, 2025 and without such holder or any of such holder's affiliates beneficially owning more than 4.99% or 9.99%, as applicable, of the number of outstanding shares of Common Stock as of March 27, 2025.

- (4) Giesecke & Devrient Mobile Security America, Inc. ("G&D") is the sole holder of our Series C Preferred Stock and thus has 100% of the voting power of our outstanding shares of Series C Preferred Stock, which have the same voting rights as our shares of Common Stock (one vote per share). The address for G&D is 45925 Horseshoe Drive, Dulles, VA 20166.
- (5) Represents (i) 534 shares of restricted stock granted outside the 2013 LTIP and the 2017 SIP, which vest over a period of 48 months, with one quarter on the anniversary of the grant and 1/16 each subsequent quarter until all shares have vested, so long as Ms. Simmons remains in the service of the Company, (ii) 409 shares of restricted stock granted under the 2013 LTIP, which shares vest over a period of three (3) years commencing on January 3, 2022, with 68 shares having vested on July 3, 2022, and thereafter, 34 shares to vest on the first day of each subsequent quarter until the entire award has vested, so long as Ms. Simmons remains in the service of the Company for each such quarter, (iii) 2,480 shares of restricted stock granted pursuant to the 2023 Plan, which shares vest over a period commencing on July 3, 2023, with 1/4 of such shares vested on July 3, 2024, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as Ms. Simmons remains in the service of the Company for each such quarter, (iv) 1,848 shares of restricted stock granted pursuant to the 2023 Plan, which shares vest over a period commencing on April 3, 2024, with 1/4 of such shares to vest on April 3, 2025, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as Ms. Simmons remains in the service of the Company for each such quarter, (v) 116,900 shares of restricted stock granted pursuant to the 2023 Plan, which shares vest over a period commencing on January 2, 2025, with 1/4 of such shares to vest on January 2, 2026, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as Ms. Simmons remains in the service of the Company for each such quarter, (vi) an aggregate of 90,452 shares of Common Stock issuable upon the exercise of Series A and Series B warrants at a weighted exercise price of \$0.22 per share issued in the Company's August 2024 Offering and (vii) 860 shares of Common Stock issued in the August 2024 Offering.
- Represents (i) 259 shares of restricted stock granted outside the 2013 LTIP and the 2017 SIP, which vest over a period of 48 months, with one quarter on the anniversary of the grant and 1/16 each subsequent quarter until all shares have vested, so long as Mr. Archer remains in the service of the Company, (ii) 836 shares of restricted stock granted pursuant to the 2023 Plan, which vest commencing on July 3, 2023, with 1/4 of such shares vested on July 3, 2024, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as Mr. Archer remains in the service of the Company for each such quarter, (iii) 38,000 shares of restricted stock granted pursuant to the 2023 Plan, which vest commencing on January 2, 2025, with 1/4 of such shares to vest on January 2, 2026, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as Mr. Archer remains in the service of the Company for each such quarter, (iv) 860 shares of Common Stock issued in the August 2024 Offering and (v) an aggregate of 90,452 shares of Common Stock issuable upon the exercise of Series A and Series B warrants at a weighted exercise price of \$0.22 per share issued in the August 2024 Offering. In addition, FLG Partners, of which Mr. Archer is a partner, was granted (i) 14 restricted shares of Common Stock outside the 2013 LTIP and the 2017 SIP, which vested one quarter on July 15, 2022, with subsequent vesting at 6.25% for each three-month period thereafter, (ii) 44 restricted shares of Common Stock, pursuant to the 2023 Plan, which vest commencing on July 3, 2023, with 1/4 of such shares vested on July 3, 2024, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, and (iii) 2,000 restricted shares of Common Stock, pursuant to the 2023 Plan, which vest commencing on January 2, 2025, with 1/4 of such shares to vest on January 2, 2026, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested. Mr. Archer disclaims beneficial ownership of such shares of Common Stock granted to FLG Partners.
- (7) Represents (i) 876 shares of Common Stock, (ii) stock options exercisable for an aggregate 11,307 shares of Common Stock at a weighted exercise price of \$19.82 per share, and (iii) an aggregate of 90,452 shares of Common Stock issuable upon the exercise of Series A and Series B Warrants at a weighted exercise price of \$0.22 per share issued in the August 2024 Offering.
- (8) Represents (i) 860 shares of Common Stock, (ii) stock options exercisable for an aggregate 11,268 shares of Common Stock at a weighted exercise price of \$10.96 per share, and (iii) an aggregate of 90,452 shares of Common Stock issuable upon the exercise of Series A and Series B Warrants at a weighted exercise price of \$0.22 per share issued in the August 2024 Offering
- (9) Represents (i) 860 shares of Common Stock, (ii) stock options exercisable for an aggregate 11,258 shares of Common Stock at a weighted exercise price of \$10.00 per share, and (iii) an aggregate of 90,452 shares of Common Stock issuable upon the exercise of Series A and Series B Warrants at a weighted exercise price of \$0.22 per share issued in the August 2024 Offering.
- (10) Represents (i) 880 shares of Common Stock, (ii) stock options exercisable for an aggregate 10,511 shares of Common Stock at a weighted exercise price of \$4.57 per share, and (iii) an aggregate of 90,452 shares of Common Stock issuable upon the exercise of Series A and Series B Warrants at a weighted exercise price of \$0.22 per share issued in the August 2024 Offering.

Securities Authorized for Issuance under Equity Compensation Plans

	Number of Securities to Be Issued upon Exercise of Outstanding	Weighted Average Exercise Price of Outstanding	Number of Securities Remaining Available for Future Issuance under the Plan (excluding
	Options,	Options,	securities
Plan Category	Warrants and Rights	Warrants and Rights	reflected in column (a)) ⁽²⁾
Tian Category	(a)	(b)	(c)
Equity compensation plans approved by security $holders^{(1)} \dots$	—		71,181
Equity compensation plans not approved by security holders	_	_	_
Total			71,181

⁽¹⁾ Represents the shares of Common Stock authorized for issuance under the 2023 Plan, which was approved by the Company's stockholders on March 7, 2023. The maximum aggregate number of shares of Common Stock that may be issued under the 2023 Plan, including stock options, stock awards, such as stock issued to our Board of directors for serving on our Board of directors, and stock appreciation rights, is limited to 15% of the shares of Common Stock outstanding on the first business day of each fiscal quarter, or 71,181 shares of Common Stock for the fiscal year ended December 31, 2024.

Item 13. Certain Relationships and Related Transactions, and Director Independence

Transactions with Related Parties

Other than as described below, except for compensation arrangements, since the past two fiscal years, there have been no transactions, whether directly or indirectly, between us and any of the Company's officers, directors, beneficial owners of more than 5% of outstanding shares of Common Stock or outstanding shares of a class of voting preferred stock, or their family members, that exceeded the lesser of (i) \$120,000 or (ii) one percent (1%) of the average of the Company's total assets at year-end for the last two fiscal years.

On November 21, 2023, the Company entered into each of the inducement agreements with certain of its warrant holders (the "Inducement Agreements"), including each of Anson Investments Master Fund LP ("Anson") and Alpha Capital Anstalt ("Alpha"), pursuant to which the Company induced such warrant holders to exercise for cash their warrants to purchase up to approximately 36,362 shares of Common Stock, at a lower exercise price of (x) \$50.00 per share (for the common stock purchase warrants issued pursuant to a firm commitment public offering by the Company that closed on September 15, 2021 (the "Existing September 2021 Warrants")) and (y) \$50.00 per one and one-half share (for the common stock purchase warrants issued pursuant to a firm commitment public offering by the Company that closed on January 25, 2023 (the "Existing January 2023 Warrants" and together with the Existing September 2021 Warrants, the "Existing Warrants")), during the period from the date of the Inducement Agreements until December 20, 2023. In consideration therefore and upon exercise by such holders of their respective Existing Warrants, the Company agreed to issue such holders new common stock purchase warrants as follows: (A) Series A Warrants to purchase up to a number of shares of Common Stock equal to 200% of the number of shares of Common Stock issued upon exercise of the Existing September 2021 Warrants (up to 3,229 shares), at an exercise price of \$50.00 per Series A Warrant Share; and (B) Series B Warrants to purchase up to a number of shares of Common Stock equal to 200% of the number of shares of Common Stock issued upon exercise of the Existing January 2023 Warrants (up to 55,282 shares), at an exercise price of \$50.00 per one and one-half Series B Warrant Share. Of the Series A Warrants issued, 50% consisted of Series A-1 Warrants, which are immediately exercisable and expire on the Termination Date (as defined in the Existing September 2021 Warrants) and 50% consisted of Series A-2 Warrants, which will be exercisable at any time on or after the Stockholder Approval Date (as defined in the Inducement Agreements) and have a term of exercise of five and a half years from the date of the initial closing of the Inducement Agreement transactions. Of the Series B Warrants issued until December 20, 2023, 50% consisted of Series B-1 Warrants, which are immediately exercisable and expire on the Termination Date (as defined in the Existing January 2023 Warrants) and 50% consist of Series B-2 Warrants, which will be exercisable at any time on or after the Stockholder Approval Date and have a term of exercise

⁽²⁾ As of December 31, 2024.

of five and a half years from the date of the Initial Closing. Anson exercised an aggregate of 2,000 Existing Warrants pursuant to the Inducement Agreements and received an aggregate of 3,000 Series B-1 Warrants and 3,000 Series B-2 Warrants, and Alpha signed the Inducement Agreements, but did not exercise any Existing Warrants.

On January 25, 2023, the Company closed a firm commitment registered public offering (the "January Offering") pursuant to which the Company issued (i) 21,170 shares of Common Stock and 423,400 common stock purchase warrants (exercisable for 44,520 shares of Common Stock at a purchase price of \$53.19 per share), subject to certain adjustments and (ii) 137,600 pre-funded common stock purchase warrants that were exercised for 6,880 shares of Common Stock at a purchase price of \$0.50 per share, subject to certain adjustments and 137,600 warrants to purchase up to an aggregate of 10,320 shares of Common Stock at a purchase price of \$63.00 per share and (iii) 32,607 additional warrants to purchase up to 2,445 shares of Common Stock at a purchase price of \$63.00 per share, which additional warrants were issued upon the partial exercise by the underwriters of their over-allotment option, pursuant to an underwriting agreement, dated as of January 23, 2023 between the Company and Maxim Group LLC, as representative of the underwriters. The January Offering resulted in gross proceeds to the Company of approximately \$5.2 million, before deducting underwriting discounts and commissions of 7% of the gross proceeds (3.5% of the gross proceeds in the case of certain identified investors) and estimated January Offering expenses. The investors in the January Offering included, among others, Anson and Alpha, which had interests in such offering equal to approximately 17% and 18%, respectively.

Director Independence

As the Company's Common Stock is listed on Nasdaq, the Company's determination of independence of its directors is made using the definition of "independent director" contained in Rule 5605(a)(2) of the Nasdaq Rules. The Board determines whether directors have a direct or indirect material relationship with us. In making independence determinations for the Company's directors, the Board observes criteria set forth by the Nasdaq Rules and reviews whether a director has a relationship with the Company that would impair such director's independence. Based on this review, our Board has determined that Dr. Curtis, Mr. Pettitt, Ms. Gutierrez, and Ms. Schneider currently qualify as independent directors under the Nasdaq Rules. Our Board has concluded that none of these directors possessed or currently possesses any relationship that could impair his, her or their judgment in connection with his, her or their duties and responsibilities as a director or that could otherwise be a direct or indirect material relationship under applicable Nasdaq Rules.

Item 14. Principal Accountant Fees and Services.

Audit Fees

The Company has engaged BPM LLP as the Company's independent registered public accounting firm for the years ended December 31, 2024 and 2023. The aggregate audit fees billed by BPM LLP for professional services rendered for the review of our financial statements for the three quarters and the audit for the year ended December 31, 2024 were approximately \$267 thousand. The aggregate audit fees billed by BPM LLP for professional services rendered for the review of our financial statements for the three quarters and the audit for the year ended December 31, 2023 were approximately \$286 thousand.

Audit Related Fees

The Company incurred additional audit related fees of \$71.9 thousand rendered by BPM LLP, for the Company's Registration Statements on Form S-3 and Form S-1 filed by the Company for the year ended December 31, 2024. The Company incurred additional audit related fees of \$25.2 thousand rendered by BPM LLP for the Company's Registration Statements on Form S-3 and Form S-1 filed by the Company for the year ended December 31, 2023.

Tax Fees

For the Company's fiscal years ended December 31, 2024 and 2023, BPM LLP did not provide any professional services for tax compliance, tax advice, and tax planning.

All Other Fees

The Company did not incur any other fees related to services rendered by BPM LLP for the fiscal years ended December 31, 2024 and 2023.

Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors

Our Audit Committee pre-approves all audit and non-audit services provided by the independent auditors prior to the engagement of the independent auditors with respect to such services. The chairperson of our Audit Committee has been delegated the authority by such committee to pre-approve interim services by the independent auditors other than the annual audit. The chairperson of our Audit Committee must report all such pre-approvals to the entire Audit Committee at the next committee meeting.

PART IV

Item 15. Exhibits and Financial Statement Schedules.

- (a) The following documents are filed as part of this Report:
 - (1) Financial Statements:

The audited balance sheets of the Company as of December 31, 2024 and 2023, the related statements of operations, changes in stockholders' equity and cash flows for the years then ended, the footnotes thereto, and the report of BPM LLP, the Company's independent registered public accounting firm, are filed herewith.

(2) Financial Schedules:

None. Financial statement schedules have been omitted because they are either not applicable or the required information is included in the financial statements or notes thereto.

(3) Exhibits:

The exhibits listed in the accompanying index to exhibits are filed with this Report or incorporated by reference into this Item 15(a)(3) as part of this Report.

(b) The following are exhibits to this Report and, if incorporated by reference, we have indicated the document previously filed with the SEC in which the exhibit was included.

Certain of the agreements filed as exhibits to this Report contain representations and warranties by the parties to the agreements that have been made solely for the benefit of such parties. These representations and warranties:

- May have been qualified by disclosures that were made to the other parties in connection with the negotiation of the agreements, which disclosures are not necessarily reflected in the agreements;
- May apply standards of materiality that differ from those of a reasonable investor; and
- Were made only as of specified dates contained in the agreements and are subject to subsequent developments and changed circumstances.

Accordingly, these representations and warranties may not describe the actual state of affairs as of the date that these representations and warranties were made or at any other time. Investors should not rely on them as statements of fact.

Exhibit No.	Description of Exhibit
2.1	Agreement and Plan of Merger, dated as of May 19, 2017, by and among the Company, Fit Merger Sub, Inc., Fit Pay, Inc. and Michael Orlando ⁽³⁾
2.2	Agreement and Plan of Merger, dated as of June 1, 2023, by and between the Company and LogicMark, Inc., a Delaware corporation. (22)
3.1(i)(a)	Certificate of Incorporation, as amended ⁽¹⁾
3.1(i)(b)	Certificate of Amendment to Certificate of Incorporation ⁽²⁾
3.1(i)(c)	Certificate of Amendment to Certificate of Incorporation ⁽¹⁶⁾
3.1(i)(d)	Certificate of Amendment to Certificate of Incorporation ⁽¹⁷⁾
3.1(i)(e)	Certificate of Designations for Series C Non-Convertible Preferred Stock(3)
3.1(i)(f)	Certificate of Amendment to the Certificate of Designations of Series C Non-Convertible Voting Preferred Stock ⁽¹⁶⁾
3.1(i)(g)	Form of Certificate of Designations, Preferences and Rights of Series F Convertible Preferred Stock ⁽¹⁴⁾
3.1(i)(h)	Certificate of Amendment to Certificate of Incorporation of LogicMark, Inc. (21)
3.1(i)(i)	Series C Certificate of Amendment to the Series C Certificate of Designations of LogicMark, Inc. (21)
3.1(i)(j)	Articles of Incorporation, filed with the Secretary of State of the State of Nevada on June 1, 2023 ⁽²²⁾

Exhibit No.	Description of Exhibit
3.1(i)(k)	Certificate of Designations, Preferences and Rights of Series C Non-Convertible Voting Preferred Stock, filed with the Secretary of State of the State of Nevada on June 1, 2023 ⁽²²⁾
3.1(i)(l)	Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock, filed with the Secretary of State of the State of Nevada on June 1, 2023 ⁽²²⁾
3.1(i)(m)	Certificate of Designation, Preferences and Rights of Series G Non-Convertible Voting Preferred Stock, filed with the Secretary of State of the State of Nevada on November 1, 2024 ⁽²³⁾
3.1(i)(n)	Certificate of Designation, Preferences, Rights and Limitations of Series H Convertible Non-Voting Preferred Stock, filed with the Secretary of State of the State of Nevada on November 13, 2024 ⁽²⁴⁾
3.1(i)(o)	Certificate of Designation, Preferences, Rights and Limitations of Series I Non-Convertible Voting Preferred Stock, filed with the Secretary of State of the State of Nevada on November 13, 2024 ⁽²⁴⁾
3.1(i)(p)	Series C Certificate of Amendment to the Series C Certificate of Designations of LogicMark, Inc. (25)
3.1(i)(q)	Certificate of Change to Articles of Incorporation of LogicMark, Inc. (25)
3.1(i)(r)	Certificate of Amendment to the Articles of Incorporation of LogicMark, Inc., filed with the Secretary of State of the State of Nevada on March 27, 2025 ⁽³⁴⁾
3.1(ii)	Bylaws ⁽²²⁾
4.1*	Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
4.2	Form of Pre-Funded Warrant for July 2020 Private Placement ⁽⁵⁾
4.3	Form of Registered Warrant for July 2020 Private Placement ⁽⁵⁾
4.4	Form of Unregistered Warrant for July 2020 Private Placement ⁽⁵⁾
4.5	Form of Registered Warrant for December 2020 Private Placement ⁽⁶⁾
4.6	Form of Unregistered Warrant for December 2020 Private Placement ⁽⁶⁾
4.7	Form of New Warrant ⁽⁷⁾
4.8	Form of Series F Convertible Preferred Stock Certificate ⁽¹⁸⁾
4.9	Form of Registered Warrant for February 2021 Private Placement ⁽⁹⁾
4.10	Form of Unregistered Warrant for February 2021 Private Placement ⁽⁹⁾
4.11	Form of Unregistered Warrant for August 2021 Private Placement ⁽¹⁴⁾
4.12	Form of Warrant for September 2021 Public Offering ⁽¹⁵⁾
4.13	Form of Warrant for January 2023 Public Offering ⁽²⁰⁾
4.14	Form of Pre-Funded Warrant for January 2023 Public Offering ⁽²⁰⁾
4.15	Form of Series A-1 Warrant ⁽²⁷⁾
4.16	Form of Series A-2 Warrant ⁽²⁷⁾
4.17	Form of Series B-1 Warrant ⁽²⁷⁾
4.18	Form of Series B-2 Warrant ⁽²⁷⁾
4.19	Form of Series A Warrant ⁽²⁸⁾
4.20	Form of Series B Warrant ⁽²⁸⁾
4.21	Form of Pre-Funded Warrant ⁽²⁸⁾
4.22	Rights Agreement, dated as of November 1, 2024, between the Company and Nevada Agency and Transfer Company ⁽²³⁾
4.23	Form of Series C Warrant ⁽³¹⁾
4.24	Form of Series D Warrant ⁽³¹⁾
4.25	Form of Pre-Funded Warrant ⁽³¹⁾
10.1†	2013 Long Term Incentive Plan ⁽¹⁾
10.2†	Forms of Agreement under 2013 Long Term Incentive Plan ⁽¹⁾
10.3†	2017 Stock Incentive Plan ⁽⁴⁾
10.4	Form of Securities Purchase Agreement for July 2020 Offering ⁽⁵⁾
10.5	Form of Securities Purchase Agreement for December 2020 Offering ⁽⁶⁾
10.6	Form of Warrant Amendment and Exercise Agreement, dated January 8, 2021 ⁽⁷⁾
10.7	Form of Securities Purchase Agreement for February 2021 Offering ⁽⁹⁾
10.8	Form of Securities Purchase Agreement for August 2021 Private Placement ⁽¹⁴⁾

Exhibit No.	Description of Exhibit
10.9	Form of Voting Agreement by and between the Company and certain investors in the September 2021 Public Offering ⁽¹⁵⁾
10.10	Lease Agreement, dated June 2, 2020, by and between LogicMark LLC and Moorman Properties, $LLC^{(10)}$
10.11	Settlement Agreement, dated August 11, 2021, by and between the Company and Giesecke+Devrient Mobile Security America, Inc. (12)
10.12†	Employment Agreement, entered into on January 8, 2021, by and between the Company and Vincent S. Miceli ⁽⁸⁾
10.13†	Letter Agreement, effective as of August 1, 2021, by and between the Company and Vincent S. Miceli ⁽¹³⁾
10.14†	Employment Agreement, dated as of June 8, 2021, by and between the Company and Chia-Lin Simmons ⁽¹¹⁾
10.15†	Executive Employment Agreement, dated as of November 2, 2022, by and between the Company and Chia-Lin Simmons ⁽¹⁹⁾
10.16†	Agreement, dated as of July 15, 2021, by and between the Company and FLG Partners, LLC(13)
10.17†	First Amendment to Agreement, dated as of February 15, 2022, by and between the Company and FLG Partners, LLC ⁽¹⁸⁾
10.18	Form of Voting Agreement, dated January 25, 2023, by and between the Company and certain investors in the January 2023 Public Offering ⁽²⁰⁾
10.19	Form of Warrant Agency Agreement, dated January 25, 2023, by and between the Company and Nevada Agency and Transfer Company ⁽²⁰⁾
10.20†	Form of Indemnification Agreement ⁽²²⁾
10.21†	LogicMark, Inc. 2023 Stock Incentive Plan ⁽²⁶⁾
10.22†	Form of Restricted Stock Award Agreement for LogicMark, Inc. 2023 Stock Incentive Plan ⁽²⁶⁾
10.23†	Form of Stock Option Agreement for LogicMark, Inc. 2023 Stock Incentive Plan ⁽²⁶⁾
10.24	Form of 2021 Inducement Agreement by and between the Company and each holder ⁽²⁹⁾
10.25	Form of 2023 Inducement Agreement by and between the Company and each holder ⁽²⁹⁾
10.26	Form of Securities Purchase Agreement for August 2024 Offering ⁽²⁸⁾
10.27	Form of Warrant Agency Agreement for August 2024 Offering ⁽²⁸⁾
10.28	Form of Placement Agency Agreement, for August 2024 Offering ⁽²⁸⁾
10.29	Form of Settlement Agreement and Release, by and among the Company and the signatories thereto ⁽³⁰⁾
10.30	Form of Registration Rights Agreement, by and among the Company and the signatories thereto ⁽³⁰⁾
10.31	Form of Securities Purchase Agreement, between the Company and each purchaser, dated February 18, 2025 ⁽³¹⁾
10.32	Warrant Agency Agreement, between the Company and Nevada Agency and Transfer Company, dated February 18, 2025 ⁽³¹⁾
10.33	Placement Agency Agreement between the Company and Roth Capital Partners, LLC, as lead placement agent, dated February 18, 2025 ⁽³¹⁾
14.1	Code of Business Conduct and Ethics ⁽³²⁾
19.1	Insider Trading Policy ⁽³³⁾
23.1*	Consent of BPM LLP, Independent Registered Public Accounting Firm
31.1*	Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
97.1	Clawback Policy ⁽³³⁾

Exhibit No.	Description of Exhibit
101.INS	Inline XBRL Instance Document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document.
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to be furnished with this Report and will not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.

- * Filed or furnished herewith, as applicable.
- † Management contract or compensatory plan or arrangement.
- Filed as an Exhibit to the Company's Registration Statement on Form S-1 (File No. 333-186331) with the SEC on January 31, 2013.
- (2) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on September 12, 2016.
- (3) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on May 30, 2017.
- (4) Filed as an Exhibit to the Company's Registration Statement on Form S-1 (File No. 333-226116) with the SEC on July 10, 2018.
- (5) Filed as an Exhibit to the Company's Current Report on Form 8-K/A with the SEC on July 13, 2020.
- (6) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on December 18, 2020.
- (7) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on January 8, 2021.
- (8) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on January 14, 2021.
- (9) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on February 1, 2021.
- (10) Filed as an Exhibit to the Company's Annual Report on Form 10-K with the SEC on April 15, 2021.
- (11) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on June 17, 2021.
- (12) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on August 13, 2021.
- (13) Filed as an Exhibit to the Company's Quarterly Report on Form 10-Q with the SEC on August 16, 2021.
- (14) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on August 17, 2021.
- (15) Filed as an Exhibit to the Company's Registration Statement on Form S-1/A (File No. 333-259105) with the SEC on September 14, 2021.
- (16) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on October 15, 2021.
- (17) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on March 2, 2022.
- (18) Filed as an Exhibit to the Company's Annual Report on Form 10-K with the SEC on April 15, 2022.
- (19) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on November 4, 2022.
- (20) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on January 26, 2023.
- (21) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on April 27, 2023.
- (22) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on June 2, 2023.
- (23) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on November 1, 2024.
- (24) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on November 14, 2024
- (25) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on November 18, 2024.
- (26) Filed as an Exhibit to the Company's Quarterly Report on Form 10-Q with the SEC on August 11, 2023.
- (27) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on November 21, 2023.
- (28) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on August 5, 2024.
- (29) Filed as an Exhibit to the Company's Current Report on Form 8-K/A with the SEC on November 21, 2023.
- (30) Filed as an Exhibit to the Company's Quarterly Report on Form 10-Q with the SEC on November 14, 2024.
- (31) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on February 18, 2025.
- (32) Filed as an Exhibit to the Company's Annual Report on Form 10-K with the SEC on March 30, 2023.
- (33) Filed as an Exhibit to the Company's Annual Report on Form 10-K with the SEC on April 16, 2024.
- (34) Filed as an Exhibit to the Company's Current Report on Form 8-K with the SEC on March 27, 2025.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

LogicMark, Inc.

Date: March 28, 2025 By: /s/ Chia-Lin Simmons

Chia-Lin Simmons Chief Executive Officer (Principal Executive Officer)

Date: March 28, 2025 By: /s/ Mark Archer

Mark Archer

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Date: March 28, 2025 By: /s/ Chia-Lin Simmons

Chia-Lin Simmons

Director

Date: March 28, 2025 By: /s/ Robert Curtis

Robert Curtis Director

Date: March 28, 2025 By: /s/ Carine Schneider

Carine Schneider

Director

Date: March 28, 2025 By: /s/ John Pettitt

John Pettitt Director

Date: March 28, 2025 By: /s/ Barbara Gutierrez

Barbara Gutierrez

Director

LogicMark, Inc.

CONTENTS

	Page
Report of Independent Registered Public Accounting Firm (PCAOB ID #207)	F-2
Financial Statements	
Balance Sheets	F-3
Statements of Operations	F-4
Statements of Changes in Stockholders' Equity	F-5 - F-6
Statements of Cash Flows	F-7
Notes to Financial Statements	F-8 – F-25

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of LogicMark, Inc.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of LogicMark, Inc. (the "Company") as of December 31, 2024 and 2023, and the related statements of operations, changes in stockholders' equity, and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

/s/ BPM LLP

We have served as the Company's auditor since 2022.

Walnut Creek, California

March 28, 2025

LogicMark, Inc. BALANCE SHEETS AS OF DECEMBER 31, 2024 AND 2023

	As of December 31, 2024	As of December 31, 2023
Assets		
Current Assets Cash and cash equivalents. Accounts receivable, net Inventory. Prepaid expenses and other current assets Total Current Assets	\$ 3,806,915 4,355 1,048,963 476,672 5,336,905	13,647 1,177,456 460,177
Property and equipment, net	112,605 48,641 1,384,172	203,333 113,761 1,269,021
\$23,354, respectively	2,019,090 3,143,662 2,176,262 \$ 14,221,337	3,143,662 2,938,058
Liabilities, Series C Redeemable Preferred Stock and Stockholders' Equity		
Current Liabilities Accounts payable Accrued expenses Deferred revenue Total Current Liabilities Other long-term liabilities Total Liabilities	\$ 750,336 1,053,301 225,195 2,028,832 2,028,832	1,151,198
Commitments and Contingencies (Note 11)		
Series C Redeemable Preferred Stock Series C redeemable preferred stock, par value \$0.0001 per share: 2,000 shares designated; 1 share issued and outstanding as of December 31, 2024 and December 31, 2023, respectively	1,807,300	1,807,300
Stockholders' Equity Preferred stock, par value \$0.0001 per share: 10,000,000 shares authorized Series F preferred stock, par value \$0.0001 per share: 1,333,333 shares designated; 106,333 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively, aggregate liquidation preference of \$319,000 as of December 31,	210,000	210.000
2024 and December 31, 2023, respectively	319,000 472,245	319,000
Series I preferred stock, par value \$0.0001 per share: 1,000 shares designated; 1,000 shares issued and 310 shares outstanding as of December 31, 2024	_	_
respectively Additional paid-in capital Accumulated deficit Total Stockholders' Equity Total Liabilities, Series C Redeemable Preferred Stock and Stockholders' Equity	240 118,758,356 (109,164,636 10,385,205 \$ 14,221,337	112,947,099 (100,160,891) 13,105,216

The accompanying notes are an integral part of these financial statements.

LogicMark, Inc. STATEMENTS OF OPERATIONS FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

	For the Years Ended December 31,			
		2024		2023
Revenues	\$	9,901,987	\$	9,929,629
Costs of goods sold		3,285,994		3,269,967
Gross Profit		6,615,993		6,659,662
Operating Expenses				
Direct operating cost		1,338,758		1,142,596
Advertising cost		557,783		270,709
Selling and marketing		2,277,698		2,206,091
Research and development		558,621		982,684
General and administrative		7,626,124		8,478,947
Other expense		317,313		147,506
Goodwill impairment		_		7,815,000
Depreciation and amortization		1,610,427		944,596
Total Operating Expenses.		14,286,724		21,988,129
Operating Loss		(7,670,731)		(15,328,467)
Other Income				
Interest income		160,664		221,871
Other (expense) income		(1,483,732)		246,138
Total Other (Expense) Income		(1,323,068)	_	468,009
Loss before Income Taxes		(8,993,799)		(14,860,458)
Income tax expense (benefit)		9,946		(309,849)
Net Loss	\$	(9,003,745)	\$	(14,550,609)
Preferred stock dividends		(300,000)		(300,000)
Deemed dividend				(930,122)
Net Loss Attributable to Common and Participating Preferred Stockholders	\$	(9,303,745)	\$	(15,780,731)
Net Loss Attributable to Common and Participating Preferred Stockholders Per Share – Basic and Diluted	\$	(14.65)	\$	(291.52)
Weighted Average Number of Common Shares Outstanding – Basic and				
Diluted		634,970		54,133

The accompanying notes are an integral part of these financial statements.

LogicMark, Inc. STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

	Preferre	ed Stock	Common	Stock	Additional Paid-in	Accumulated	
	Shares	Amount	Shares	Amount	Capital	Deficit	Total
Balance – January 1, 2024	106,333	\$ 319,000	86,017	\$ 8	\$ 112,947,099	\$ (100,160,891)	\$ 13,105,216
Stock based compensation							
expense		_	_	_	1,627,624	_	1,627,624
Shares issued as stock based			1.040		0.662		0.662
compensation			1,848	_	8,663	_	8,663
Common stock withheld to pay			(1.2.1)		(1.22.5)		(1.225)
taxes	_	_	(121)	_	(4,235)	_	(4,235)
Cancellation of common stock	_	_	(40)	_	_	_	_
Sale of common stock, warrants and pre-funded warrants pursuant to a registration							
statement on Form S-1	_	_	57,997	6	4,492,192	_	4,492,198
Fees incurred in connection with equity offerings	_	_	_	_	(1,210,540)	_	(1,210,540)
Warrants exercised for common stock	_	_	363,564	37	146,617	_	146,654
Warrants exercised for common stock on a cashless basis	_	_	1,526,573	153	(153)	_	_
Fractional shares issued in the 1-for-25 stock split	_	_	175	_	_	_	_
Issuance of Series H preferred stock	1,000	1,523,370	_	_	_	_	1,523,370
Issuance of Series I preferred							
stock	1,000	_	_			_	_
Conversion of Series H preferred stock for common stock	(690)	(1,051,125)	361,781	36	1,051,089	_	_
Redemption of Series I preferred stock	(690)	_	_	_	_	_	_
Series C Preferred stock dividends	_	_	_	_	(300,000)	_	(300,000)
Net loss						(9,003,745)	(9,003,745)
Balance – December 31, 2024	106,953	<u>\$ 791,245</u>	2,397,794	<u>\$ 240</u>	<u>\$ 118,758,356</u>	<u>\$ (109,164,636)</u>	<u>\$ 10,385,205</u>

LogicMark, Inc. STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY — (Continued) FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

	Preferre	ed Stock	Common	Stock	Additional Paid-in	Accumulated	
	Shares	Amount	Shares	Amount	Capital	Deficit	Total
Balance – January 1, 2023	173,333	\$ 520,000	19,218	\$ 2	\$ 106,070,299	\$ (85,610,282)	\$ 20,980,019
Stock based compensation expense	_	_	_	_	1,563,558	_	1,563,558
Shares issued as stock based compensation	_	_	3,960	_	13,882	_	13,882
Sale of common stock and warrants pursuant to a registration statement on Form S-1	_	_	28,050	3	5,211,425	_	5,211,428
Fees incurred in connection with equity offerings	_	_	_	_	(1,026,607)	_	(1,026,607)
Fractional shares issued in the 1-for-20 stock split	_	_	1,609	_	_	_	_
Warrants exercised for common stock	_	_	31,835	3	1,165,153	_	1,165,156
Series F preferred stock converted to common stock	(67,000)	(201,000)	1,084	_	201,000	_	_
Common stock issued to settle Series F preferred stock dividends	_	_	261	_	48,389	_	48,389
Series C preferred stock dividends	_	_	_	_	(300,000)	_	(300,000)
Net loss						(14,550,609)	(14,550,609)
Balance – December 31, 2023	106,333	\$ 319,000	86,017	<u>\$</u>	<u>\$ 112,947,099</u>	<u>\$ (100,160,891)</u>	<u>\$ 13,105,216</u>

The accompanying notes are an integral part of these financial statements.

LogicMark, Inc. STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

		For the Years Ended December 31,		
		2024		2023
Cash Flows from Operating Activities				
Net loss	\$	(9,003,745)	\$	(14,550,609)
Adjustments to reconcile net loss to net cash used in operating activities:				
Depreciation		114,643		105,674
Stock based compensation		1,636,287		1,577,440
Amortization of intangible assets		761,796		761,796
Amortization of product development costs		328,539		53,771
Amortization of software development costs		405,449		23,354
Loss on disposal of fixed assets		1,654		
Goodwill impairment		_		7,815,000
Deferred tax expense		_		(320,102)
Fair value of Series H preferred stock issued to Series B holders		1,523,370		
Changes in operating assets and liabilities:				
Accounts receivable		9,292		388,948
Inventory		128,493		567,755
Prepaid expenses and other current assets		(16,495)		(111,080)
Accounts payable		(276,625)		22,193
Accrued expenses		(92,619)		(649,620)
Deferred revenue		225,195		
Net Cash Used in Operating Activities		(4,254,765)		(4,315,480)
Cash flows from Investing Activities				
Purchase of equipment and website development		(25,568)		(53,429)
Product development costs		(435,285)		(562,610)
Software development costs		(999,708)		(757,396)
Net Cash Used in Investing Activities	_	(1,460,561)	_	(1,373,435)
The Cash Osea in Investing Activities		(1,400,301)		(1,373,433)
Cash flows from Financing Activities				
Proceeds from sale of common stock and warrants		4,492,198		5,211,428
Fees paid in connection with equity offerings		(1,210,540)		(1,026,607)
Common stock withheld to pay taxes		(4,235)		
Warrants exercised for common stock		146,654		1,165,156
Series C redeemable preferred stock dividends		(300,000)		(300,000)
Net Cash Provided by Financing Activities		3,124,077		5,049,977
Net Decrease in Cash and Cash Equivalents		(2,591,249)		(638,938)
Cash and Cash Equivalents – Beginning of Year		6,398,164		7,037,102
Cash and Cash Equivalents – End of Year	\$	3,806,915	\$	6,398,164
Supplemental Disclosures of Cash Flow Information:				
Cash paid during the years for:				
Taxes	\$	20,579	\$	3,152
Non-cash investing and financing activities:	Ψ	20,517	Ψ	5,152
Conversion of Series F preferred stock to common stock	\$	_	\$	201,000
Common stock issued for to settle Series F preferred stock dividend	Ψ		Ψ	48,389
Product development costs included in accounts payable and accrued expenses		8,405		113,538
Software development costs included in accounts payable and accrued expenses.		124,931		201,841
Series H preferred stock conversion to common stock		1,051,125		201,071
Solies II prototice stock conversion to common stock		1,001,120		

The accompanying notes are an integral part of these financial statements.

NOTE 1 — ORGANIZATION AND PRINCIPAL BUSINESS ACTIVITIES

LogicMark, Inc. ("LogicMark" or the "Company") was incorporated in the State of Delaware on February 8, 2012 and was reincorporated in the State of Nevada on June 1, 2023. LogicMark operates its business in one segment and provides personal emergency response systems ("PERS"), health communications devices, and Internet of Things technology that creates a connected care platform. The Company's devices give people the ability to receive care at home and confidence to age independently. LogicMark revolutionized the PERS industry by incorporating two-way voice communication technology directly in the medical alert pendant and providing life-saving technology at a price point everyday consumers could afford. The PERS technologies are sold direct-to-consumer through the Company's eCommerce platform, to retailers and resellers, and to the United States Veterans Health Administration ("VHA").

NOTE 2 — LIQUIDITY AND MANAGEMENT PLANS

The Company generated an operating loss of \$7.7 million and a net loss of \$9.0 million for the year ended December 31, 2024. As of December 31, 2024, the Company had cash and cash equivalents of \$3.8 million. As of December 31, 2024, the Company had working capital of \$3.3 million compared to working capital as of December 31, 2023, of \$6.0 million.

Given the Company's cash position as of December 31, 2024, its projected cash flow from operations, and the completion of a public offering on Form S-1 in February 2025 (refer to Note 13), the Company believes that it will have sufficient capital to sustain operations for a period of one year following the date of this filing. The Company may also raise funds through equity or debt offerings to accelerate the execution of its long-term strategic plan to develop and commercialize its core products and to fulfill its product development efforts.

NOTE 3 — BASIS OF PRESENTATION

The financial statements are prepared in conformity with generally accepted accounting principles in the United States ("U.S. GAAP").

Net loss per share and all share data for the year ended December 31, 2023 have been retroactively adjusted to reflect the 1-for-25 reverse stock split that occurred on November 18, 2024. See Note 8.

NOTE 4 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

USE OF ESTIMATES IN THE FINANCIAL STATEMENTS

U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company's management evaluates these significant estimates and assumptions, including those related to the fair value of acquired assets and liabilities, stock-based compensation, income taxes, allowance for doubtful accounts, long-lived assets, and inventories, and other matters that affect the financial statements and disclosures. Actual results could differ from those estimates.

CASH AND CASH EQUIVALENTS

The Company considers all highly liquid securities with an original maturity date of three months or less when purchased to be cash equivalents. Due to their short-term nature, cash equivalents are carried at cost, which approximates fair value. As of December 31, 2024 and 2023, the Company had cash equivalents of \$2.7 million and \$4.7 million in cash equivalents, respectively.

CONCENTRATIONS OF CREDIT RISK

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains its cash and cash equivalents balances in large well-established financial institutions located in the United States. At times, the Company's cash balances may be uninsured or in deposit accounts that exceed the Federal Deposit Insurance Corporation ("FDIC") insurance limits.

NOTE 4 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

REVENUE RECOGNITION

We enter into contracts with customers that may include combinations of product and subscription services, resulting in arrangements containing multiple performance obligations. The Company's revenues consist of product sales to either end customers, to resellers or direct bulk sales to the VHA. The Company's revenues are derived from contracts with customers, which are in most cases customer purchase orders. For each contract, the promise to transfer the title of the product, each of which is individually distinct, is considered to be the identified performance obligation. As part of the consideration promised in each contract, the Company evaluates the customer's credit risk. Our contracts do not have any financing components, as payments are mostly prepaid, or in limited cases, due Net 30 days after the invoice date. The majority of prepaid contracts are with the VHA, which consists of the majority of the Company's revenues. The Company's product are almost always sold at fixed prices. In determining the transaction price, we evaluate whether the price is subject to any refunds, due to product returns or adjustments due to volume discounts, rebates, or price concessions to determine the net consideration we expect to be entitled to. The Company's sales are recognized at a point-in-time under the core principle of recognizing revenue when title transfers to the customer, which generally occurs when the Company ships or delivers the product from its fulfillment center to our customers, when our customer accepts and has legal title of the goods, and the Company has a present right to payment for such goods. Based on the respective contract terms, most of our contract revenues are recognized either (i) upon shipment based on free on board ("FOB") shipping point, or (ii) when the product arrives at its destination.

In cases, where the Company enters into contracts with customers that contain multiple performance obligations, product and subscription services, we allocate the transaction price for the contract among the performance obligations on a relative standalone selling price ("SSP") basis, which is generally not directly observable and requires the Company to estimate SSP based on management judgment by considering available data such as internal margin objectives, pricing strategies, as well as other observable inputs. Subscription services revenue in these cases are recognized over time.

During the year ended December 31, 2023, the Company released new offerings by leasing product coupled with monthly subscription services. We account for the revenue from its lease contracts by utilizing the single component accounting policy. This policy requires the Company to account for, by class of underlying asset, the lease component and non-lease component(s) associated with each lease as a single component if two criteria are met: (1) the timing and pattern of the lease component and the non-lease component are the same and (2) the lease component would be classified as an operating lease, if accounted for separately. The Company has determined that its leased product meets the criteria to be operating leases and has the same timing and pattern of transfer as its monthly subscription services. The Company has elected the lessor practical expedient within ASC 842, *Leases* ("ASC 842") and recognizes, measures, presents, and discloses the revenue for the new offering based upon the predominant component, either the lease or non-lease component. The Company recognizes revenue under ASC 606, *Revenue Recognition from Contracts with Customers* ("ASC 606") for its leased product for which it has estimated that the non-lease components of the new offering is the predominant component of the contract.

For the year ended December 31, 2024, the Company's sales recognized over time were \$80 thousand. For the year ended December 31, 2023, the Company's sales recognized over time were immaterial.

SALES TO DEALERS AND RESELLERS

The Company maintains a reserve for unprocessed and estimated future price adjustments claims and returns as a refund liability. The reserve is recorded as a reduction to revenue in the same period that the related revenue is recorded and is calculated based on an analysis of historical claims and returns over a period of time to appropriately account for current pricing and business trends. Similarly, sales returns and allowances are recorded based on historical return rates, as a reduction to revenue with a corresponding reduction to cost of goods sold for the estimated cost of inventory that is expected to be returned. These reserves were not material as of December 31, 2024, and 2023.

NOTE 4 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

SHIPPING AND HANDLING

Amounts billed to customers for shipping and handling are included in revenues. The related freight charges incurred by the Company are included in cost of goods sold and were \$0.3 million and \$0.3 million for the years ended December 31, 2024, and 2023, respectively.

ACCOUNTS RECEIVABLE — NET

For the years ended December 31, 2024, and 2023, the Company's revenues were primarily the result of shipments to VHA hospitals and clinics, which are made in most cases on a prepaid basis. The Company also sells its products to dealer and resellers, typically providing customers with modest trade credit terms. Sales made to dealer and resellers are done with limited rights of return and are subject to the normal warranties offered to the ultimate consumer for product defects.

Accounts receivable is stated at net realizable value. The Company regularly reviews accounts receivable balances and adjusts the accounts receivable allowance for credit losses, as necessary whenever events or circumstances indicate the carrying value may not be recoverable. As of December 31, 2024, and 2023, the allowance for credit losses was immaterial.

DEFERRED REVENUE

Deferred revenue is recorded when amounts invoiced to customers are in excess of revenue that can be recognized because performance obligations have not been satisfied and control of the promised product or subscription services has not transferred to the customer. Deferred revenue largely represents amounts invoiced in advance for subscription services, where revenue cannot be recognized yet.

INVENTORY

The Company measures inventory at the lower of cost or net realizable value, defined as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Cost is determined using the first-in, first-out method.

The Company performs regular reviews of inventory quantities on hand and evaluates the realizable value of its inventories. The Company adjusts the carrying value of the inventory as necessary for excess, obsolete, and slow-moving inventory by comparing the individual inventory parts to forecasted product demand or production requirements. As of December 31, 2024, inventory was comprised of \$0.9 million in finished goods on hand and \$0.1 million in inventory in-transit from vendor, respectively. As of December 31, 2023, inventory consisted of \$1.2 million finished goods on hand.

The Company is required to partially prepay for inventory with certain vendors. As of December 31, 2024, and 2023, \$0.2 million and \$0.3 million, respectively, of prepayments made for inventory are included in prepaid expenses and other current assets on the balance sheet.

LONG-LIVED ASSETS

Long-lived assets, such as property and equipment, and other intangible assets are evaluated for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. When indicators exist, the Company tests for the impairment of the definite-lived assets based on the undiscounted future cash flow the assets are expected to generate over their remaining useful lives, compared to the carrying value of the assets. If the carrying amount of the assets is determined not to be recoverable, a write-down to fair value is recorded. Management estimates future cash flows using assumptions about expected future operating performance. Management's estimates of future cash flows may differ from actual cash flow due to, among other things, technological changes, economic conditions, or changes to the Company's business operations.

NOTE 4 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

PROPERTY AND EQUIPMENT

Property and equipment consisting of equipment, furniture, fixtures, website and tooling is stated at cost. The costs of additions and improvements are generally capitalized and expenditures for repairs and maintenance are expensed in the period incurred. When items of property and equipment are sold or retired, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is included in income. Depreciation of property and equipment is provided utilizing the straight-line method over the estimated useful life of the respective asset as follows:

Equipment 5 years
Furniture and fixtures 3 to 5 years
Website and other 3 years

GOODWILL

Goodwill is reviewed annually in the fourth quarter, or when circumstances indicate that an impairment may have occurred. The Company first performs a qualitative assessment of goodwill impairment, which considers factors such as market conditions, performance compared to forecast, business outlook and unusual events. If the qualitative assessment indicates a possible goodwill impairment, goodwill is then quantitatively tested for impairment. The Company may elect to bypass the qualitative assessment and proceed directly to the quantitative test. If a quantitative goodwill impairment test is required, the fair value is determined using a variety of assumptions including estimated future cash flows using applicable discount rates (income approach), comparisons to other similar companies (market approach), and an adjusted balance sheet approach.

As part of the annual evaluation of goodwill in 2023, the Company determined that it is more likely than not that the carrying value of goodwill exceeded its fair value, and therefore an impairment write-down was required. During the year ended December 31, 2023, the Company wrote down the carrying value of goodwill by \$7.8 million. See Note 5.

OTHER INTANGIBLE ASSETS

The Company's intangible assets are related to the acquisition of LogicMark, LLC in 2016, the former subsidiary that was merged with and into the Company and are included in other intangible assets in the Company's balance sheet as of December 31, 2024, and 2023.

As of December 31, 2024, the other intangible assets, net of accumulated amortization, are comprised of patents of \$0.9 million; trademarks of \$0.7 million; and customer relationships of \$0.5 million. As of December 31, 2023, the other intangible assets are comprised of patents of \$1.3 million; trademarks of \$0.8 million; and customer relationships of \$0.8 million. The Company amortizes these intangible assets using the straight-line method over their estimated useful lives which for the patents, trademarks and customer relationships are 11 years, 20 years, and 10 years, respectively. During the years ended December 31, 2024, and 2023, the Company had amortization expense of \$0.8 million for both years.

Amortization expense is estimated to be approximately \$0.8 million for fiscal year 2025, \$0.6 million for fiscal year 2026, \$0.3 million for fiscal year 2027, \$63 thousand for fiscal year 2028 and approximately \$0.5 million thereafter.

INCOME TAXES

The Company uses the asset and liability method of accounting for income taxes. Income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity's financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

NOTE 4 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

ASC Topic 740-10-30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company will classify as income tax expense any interest and penalties. The Company has no material uncertain tax positions for any of the reporting periods presented. Generally, the tax authorities may examine tax returns for three years from the date of filing. The Company has filed all its tax returns for all prior periods through December 31, 2023.

STOCK BASED COMPENSATION

The Company accounts for stock based awards exchanged for employee services at the estimated grant date fair value of the award. The Company accounts for equity instruments issued to non-employees at their fair value on the measurement date. The measurement of stock based compensation is subject to periodic adjustment as the underlying equity instrument vests or becomes non-forfeitable. Stock based compensation charges are amortized over the vesting period or as earned. Stock based compensation is recorded in the same component of operating expenses as if it were paid in cash.

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER SHARE

Basic net loss attributable to common stockholders per share ("Basic net loss per share") was computed using the weighted average number of common shares outstanding. Diluted net loss applicable to common stockholders per share ("Diluted net loss per share") includes the effect of diluted common stock equivalents. Potentially dilutive securities from the exercise of stock options to purchase 19,010 shares of common stock and warrants to purchase 2,599,276 shares of common stock as of December 31, 2024, were excluded from the computation of diluted net loss per share because the effect of their inclusion would have been anti-dilutive. Potentially dilutive securities from the exercise of stock options to purchase 2,370 shares of common stock and warrants to purchase 74,832 shares of common stock as of December 31, 2023, were excluded from the computation of diluted net loss per share because the effect of their inclusion would have been anti-dilutive. Net loss attributable to common stockholders per share as of December 31, 2024 was impacted by the payment of dividends for Series C Redeemable Preferred Stock of \$0.3 million. Net loss attributable to common stockholders per share as of December 31, 2023, was impacted by the payment of dividends for Series C Redeemable Preferred Stock of \$0.3 million and a deemed dividend of \$0.9 million resulting from the modification of certain warrant terms. Refer to Note 8.

The components of basic and diluted net loss per share were as follows for the period ending December 31, 2024:

Basic and Diluted Net Loss Per Share:

Net loss attributable to common stockholders	\$ (8,320,945)
Net loss attributable to common stockholders per share – basic and diluted	\$ (14.65)
Weighted average number of common shares outstanding – basic and diluted	567,895
Net loss attributable to participating preferred stockholders	\$ (982,800)
Net loss attributable to participating preferred stockholders per share – basic and diluted	\$ (14.65)
Weighted average number of common shares equivalent of participating preferred	67.075
outstanding – basic and diluted	 0/,0/5

NOTE 4 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

RESEARCH AND DEVELOPMENT AND PRODUCT AND SOFTWARE DEVELOPMENT COSTS

Research and development costs are expenditures on new market development and related engineering costs. In addition to internal resources, the Company utilizes functional consulting resources, third-party software, and product development firms. The Company expenses all research and development costs as incurred until technological feasibility has been established for the product. Once technological feasibility is established, development costs including software and product design are capitalized until the product is available for general release to customers. Judgment is required in determining when technological feasibility of a product is established. For the year ended December 31, 2024, the Company capitalized \$0.4 million of such product development costs and \$1.1 million of such software development costs. For the year ended December 31, 2023, the Company capitalized \$0.7 million and \$1.1 million of such product and software development costs, respectively. Amortization of these costs is on a straight-line basis over three years and amounted to approximately \$0.3 million and \$0.4 million for product development and software development, respectively, for the year ended December 31, 2024. Amortization for the year ended December 31, 2023 was \$53.8 thousand and \$23.4 thousand for product development and software development, respectively. Cumulatively, as of December 31, 2023, approximately \$1.0 million of capitalized product and software development costs arose from expenditures to a company considered to be a related party since it is controlled by the Company's Vice-President of Engineering. As of December 31, 2023, a total of \$0.3 million of expenditures to the Company considered to be a related party were included in accounts payable and accrued expenses.

RECENT ACCOUNTING PRONOUNCEMENTS

Recently Issued Accounting Pronouncements — Not Yet Adopted

In December 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"), which requires disclosure of incremental income tax information within the rate reconciliation and expanded disclosures of income taxes paid, among other disclosure requirements. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company's management does not believe the adoption of ASU 2023-09 will have a material impact on its financial statements and disclosures.

Recently Adopted Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). ASU 2023-07 requires public entities to (i) disclose significant segment expenses under the "significant expense principle", (ii) disclose other segment items which represents the difference between segment revenue and segment expenses under the significant expense principle, (iii) report the annual segment's profit or loss and assets, (iv) clarify the measures used by the chief operating decision maker to assess segment performance and decide how to allocate resources, and (v) disclose the title and position of the chief operating decision maker and explaining how measures are being used.. The new standard also requires that public companies that have a single reportable segment provide all the required disclosures noted previously. ASU 2023-07 was effective for SEC filers, for fiscal years beginning after December 15, 2023. Effective January 1, 2024, the Company adopted ASU 2023-07, and has reflected the respective disclosures in Note 12.

NOTE 5 — GOODWILL IMPAIRMENT

The Company's goodwill relates entirely to the acquisition of LogicMark, LLC in 2016, the former subsidiary that was merged with and into the Company. As of December 31, 2024, the Company determined that there were no indicators present to suggest that it was more likely than not that the fair value of goodwill was less than the carrying amount.

As of December 31, 2023, the Company completed an impairment test of goodwill. The fair value was determined by using a market-based approach (weighted 70%), an income approach (weighted 20%) and adjusted book value method (weighted 10%), as this combination was deemed to be the most indicative of the Company's fair value. The Company also included the current market value of the Company's equity in the overall analysis. Under the

NOTE 5 — GOODWILL IMPAIRMENT (cont.)

market-based approach, the Company utilized information regarding the Company, the Company's industry as well as publicly available industry information to determine earnings multiples and sales multiples that are used to value the Company. Under the income approach, the Company determined fair value based on estimated future cash flows of the Company, discounted by an estimated weighted-average cost of capital, which reflects the overall level of inherent risk and the rate of return an outside investor would expect to earn, which are unobservable Level 3 inputs. The discounted estimates of future cash flows include significant management assumptions such as revenue growth rates, operating margins, weighted average cost of capital, and future economic and market conditions. The Company further compared the estimated fair value to the Company's market capitalization. As of December 31, 2023, the Company concluded that the carrying value of its goodwill was partially impaired and recorded an impairment charge of \$7.8 million.

NOTE 6 — ACCRUED EXPENSES

Accrued expenses consist of the following:

	De	ecember 31, 2024	Do	ecember 31, 2023
Salaries, payroll taxes and vacation	\$	201,691	\$	167,930
Merchant card fees		15,728		14,983
Professional fees		140,150		83,532
Management incentives		420,000		503,800
Lease liability		51,841		68,321
Development costs		8,000		109,000
Other		215,891		203,632
Totals	\$	1,053,301	\$	1,151,198

NOTE 7 — FAIR VALUE MEASUREMENTS

The fair value of financial instruments is defined as an exit price, which is the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants. The degree of judgment used in measuring the fair value of assets and liabilities generally correlates to the level of pricing observability. Financial assets and liabilities with readily available, actively quoted prices or for which fair value can be measured from quoted prices in active markets generally have more pricing observability and require less judgment in measuring fair value. Conversely, financial assets and liabilities that are rarely traded or not quoted have less price observability and are generally measured at fair value using valuation models that require more judgment. These valuation techniques involve some level of management estimation and judgment, the degree to which depends on the price transparency of the asset, liability or market and the nature of the asset or liability. The Company has categorized its financial assets and liabilities measured at fair value into a three-level hierarchy.

Valuation Hierarchy

ASC 820, *Fair Value Measurements and Disclosures*, establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.
- Level 3 inputs are unobservable inputs based on the Company's own assumptions used to measure assets and liabilities at fair value.

NOTE 7 — **FAIR VALUE MEASUREMENTS** (cont.)

The classification of a financial asset or liability within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

Cash and accounts payable approximate their fair values due to their short maturities. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.

The Company's cash equivalents as of December 31, 2024 and 2023 were held in money market funds and are measured utilizing Level 1 valuation inputs.

NOTE 8 — STOCKHOLDERS' EQUITY

November 2024 Reverse stock split

On November 18, 2024, the Company effected a 1-for-25 reverse split of its outstanding common stock and Series C Redeemable Preferred Stock. As a result of the reverse splits, each 25 pre-split shares of common stock outstanding and each 25 pre-split shares of Series C Redeemable Preferred Stock outstanding were automatically exchanged for one new share of each without any action on the part of the holders. The number of outstanding shares of common stock was reduced from approximately 11,863,537 shares to approximately 474,541 shares, and the number of outstanding shares of Series C Redeemable Preferred Stock was reduced from 10 shares to 1 share. 175 shares of Common Stock were issued as a result of the treatment of fractional shares in connection with this reverse stock split, which rounded up outstanding post-split shares to the nearest whole number. The reverse stock split did not affect the total number of shares of capital stock, including Series C Redeemable Preferred Stock, that the Company is authorized to issue.

Net loss per share and all share data as of and for the year ended December 31, 2023 have been retroactively adjusted to reflect the reverse stock splits in accordance with ASC 260-10-55-12, "Restatement of EPS Data".

Settlement Agreements and Issuance of New Preferred Stock

On November 13, 2024, the Company entered into settlement and release agreements (the "Settlement Agreements") with the current and former holders (the "Series B Holders") of the Company's Series B Warrants to purchase common stock (the "August Series B Warrants"), issued in the Offering (as defined below), pursuant which on such date all remaining August Series B Warrants were exercised and the Series B Holders waived and released the Company from certain claims in connection with the exercise thereof and in exchange the Company agreed to issue the New Preferred Stock (as defined below).

In connection with the Settlement Agreements, on November 13, 2024, the Company filed with the Secretary of State of the State of Nevada (the "Nevada Secretary of State"): (i) a Certificate of Designation of Preferences, Rights and Limitations of Series H Convertible Non-Voting Preferred Stock (the "Series H Certificate of Designation") to designate 1,000 shares of the Company's authorized and unissued preferred stock as Series H Convertible Non-Voting Preferred Stock, \$0.0001 par value per share (the "Series H Preferred Stock"); and (ii) a Certificate of Designation of Preferences, Rights and Limitations of Series I Non-Convertible Voting Preferred Stock (the "Series I Certificate of Designation," and together with the Series H Certificate of Designation, the "Certificates of Designation") to designate 1,000 shares of the Company's authorized and unissued preferred stock as Series I Non-Convertible Voting Preferred Stock, \$0.0001 par value per share (the "Series I Preferred Stock", and together with the Series H Preferred Stock, the "New Preferred Stock"). Each Certificate of Designation became effective upon its filing with the Nevada Secretary of State, and establishes the rights, preferences, privileges, qualifications, restrictions, and limitations relating to the applicable Preferred Stock.

NOTE 8 — STOCKHOLDERS' EQUITY (cont.)

Pursuant to the Settlement Agreements, on November 14, 2024, the Company issued to the Series B Holders (i) an aggregate of 1,000 shares of Series H Preferred Stock, which are convertible at the option of the Series B Holder into shares of Common Stock (the "Conversion Shares") at an initial conversion price of \$11.64, and (ii) an aggregate of 1,000 shares of Series I Preferred Stock, each share of which entitles the holder thereof to two (2) votes on all matters submitted to a vote of the stockholders of the Company. The Series I Preferred Stock will be automatically redeemed for no consideration upon the redemption, conversion or sale of shares of Series H Preferred Stock on a one for one basis. The shares of Series H Preferred Stock have a stated value of \$1,000 and are initially convertible into approximately 85,948 shares of Common Stock in the aggregate. The conversion price will reset on the fifth trading day following the effective date of the Company's next reverse stock split of its shares of Common Stock to the greater of (i) the lowest volume weighted average price of the Common Stock during the five trading days immediately preceding the reset date and (ii) the floor price of \$4.4625. The Company completed a fair value assessment of the Series H Preferred Stock and Series I Preferred Stock and Series I Preferred Stock based on the total equity value of the Company. Based on the fair value assessment, the Company determined that the Series H Preferred Stock had a fair value of \$1.5 million and was recorded as a non-operating expense in the statement of operations.

As of December 31, 2024, the conversion price of the Series H Preferred Stock was subject to an adjustment due to the November 18, 2024 reverse stock split, which resulted in a new conversion price of \$1.75 per share of Series H Preferred Stock. As of December 31, 2024, 1,000 shares of Series H Preferred Stock and Series I Preferred Stock were issued, 690 shares of Series H Preferred Stock were converted into 361,781 shares of Common Stock and 690 shares of Series I Preferred Stock were redeemed upon the conversion of such shares of Series H Preferred Stock.

Also pursuant to the Settlement Agreements, on the issuance date of the New Preferred Stock, the Company entered into registration rights agreements with the Series B Holders pursuant to which the Company agreed to register the resale of the Conversion Shares. The Company was required to prepare and file the resale registration statement with the SEC no later than the 30th calendar day following the date of the issuance of the New Preferred Stock and to use its best efforts to have such registration statement declared effective within 60 calendar days after such date, subject to certain exceptions.

Rights Agreement

On November 1, 2024, the Company entered into a rights agreement with Nevada Agency and Transfer Company, as rights agent (the "Rights Agreement"). Pursuant to the Rights Agreement, in the event that a person or entity or group thereof becomes the Beneficial Owner (as defined in the Rights Agreement) of at least fifteen percent (15%) of the outstanding shares of Common Stock (an "Acquiring Person"), each holder of Common Stock as of the close of business on November 1, 2024 will be entitled to receive on the Distribution Date (as defined below) a dividend of one right for each share of Common Stock owned by such holder (each, a "Right"), with each Right exercisable for one one-hundredth of a share of the Company's Series G Non-Convertible Voting Preferred Stock, \$0.0001 par value per share (the "Series G Preferred Stock"), at a price of \$1.25 per one-hundredth of a share, subject to adjustment as set forth in the Rights Agreement. The Rights are not exercisable until the earlier of: (1) the first date of public announcement by the Company or by an Acquiring Person of such acquisition of beneficial ownership of 15% or more of the outstanding Common Stock without the prior approval of the Board or such earlier date as a majority of the Board shall become aware of the existence of an Acquiring Person, or (2) the tenth business day (subject to extension by the Board) following the commencement of, or public announcement of an intention to commence, a tender or exchange offer which would result in the beneficial ownership of 15% or more of the outstanding Common Stock (the "Distribution Date"). The Rights will expire upon the earlier of (i) November 1, 2027, unless otherwise extended by the Company's stockholders or and (ii) redemption or exchange by the Company.

On November 1, 2024, in connection with the Rights Agreement, the Company filed a Certificate of Designation, Preferences, and Rights of Series G Non-Convertible Voting Preferred Stock (the "Certificate of Designation") with the Secretary of State of the State of Nevada. This Certificate of Designation authorized 1,000,000 shares of the Series G Preferred Stock. Each share of Series G Preferred Stock entitles the holder to cast 4 votes on all matters

NOTE 8 — STOCKHOLDERS' EQUITY (cont.)

submitted to stockholders to vote and the Series G Preferred Stockholders will vote together as one class with the holders of Common Stock on any such matters. The Series G Preferred Stock purchasable upon exercise of the Rights are non-convertible and non-redeemable (except as provided in the Certificate of Designation) and junior to any other series of preferred stock the Company has issued or may issue (unless otherwise provided in the terms of such other series). In the event of liquidation of the Company, the holders of Series G Preferred Stock will receive a preferred liquidation payment equal to the greater of \$125.00 per share or an amount per share equal to 100 times the aggregate payment to be distributed per share of Common Stock.

August 2024 Public Offering

On August 5, 2024 (the "August Closing Date"), the Company, in connection with a best efforts public offering (the "August Offering"), sold to certain purchasers an aggregate of (x) 57,997 units of the Company (the "August Units") at an offering price of \$11.64 per August Unit, consisting of (i) 57,997 shares of the Company's common stock, par value \$0.0001 per share ("Common Stock") (ii) 57,997 of the Company's Series A warrants to purchase Common Stock, exercisable for up to 57,997 shares of Common Stock at an exercise price of \$11.64 per share (the "August Series A Warrants"), and (iii) 57,997 of the Company's August Series B Warrants at an exercise price of \$11.64 per share, exercisable for up to 57,997 shares of Common Stock; and (y) 328,803 pre-funded units of the Company (the "August Pre-Funded Units") at an offering price \$11.61 per August Pre-Funded Unit, consisting of (i) 328,803 pre-funded common stock purchase warrants exercisable for up to 328,803 shares of Common Stock at \$0.001 per share, (the "August Pre-Funded Warrants"), (ii) 328,803 August Series A Warrants and (iii) 328,803 August Series B Warrants, pursuant to the Company's Form S-1 registration statement, as amended (File No. 333-279133), declared effective by the SEC on August 1, 2024 and securities purchase agreements, dated August 2, 2024, between the Company and each of the purchasers signatory thereto (the "Purchasers"). The August Series B Warrants can be exercised on an alternate cashless basis which would result in holders receiving four (4) times the number of common stock if such election is made. On the Closing Date, the Company received gross proceeds of approximately \$4.5 million, before deducting placement agent commissions and estimated Offering expenses. The Company has begun to use the net proceeds from the Offering for continued new product development, working capital and other general corporate purposes. Due to the Company effecting the reverse stock split on November 18, 2024, the exercise prices and shares issuable upon exercise of such warrants and pre-funded warrants have been retroactively reported in accordance with ASC 260-10-55-12, "Restatement of EPS Data", and to reflect the adjustment to the number of shares underlying such warrants and pre-funded warrants and the exercise price of such warrants in accordance with the terms thereof.

In addition, as of December 31, 2024, the Purchasers exercised their August Pre-Funded Warrants for an aggregate of 328,803 shares of Common Stock, certain Purchasers exercised their August Series B Warrants for an aggregate of 1,526,573 shares of Common Stock under the alternate cashless basis and certain Purchasers exercised their August Series A Warrants for an aggregate of 34,761 shares of Common Stock. As of December 31, 2024, the exercise price and warrant shares of the August Series A Warrants and August Series B Warrants were subject to an adjustment due to the November 18, 2024 reverse stock split, which resulted in a new exercise price of \$1.75 per warrant share and an aggregate of 2,525,115 in warrant shares of the August Series A Warrants and August Series B Warrants outstanding.

November 2023 Warrant Inducement Transactions

On November 21, 2023, the Company entered into each of the 2021 Inducement Agreements and the 2023 Inducement Agreements (together, the "Inducement Agreements") with certain of its warrant holders, pursuant to which the Company induced such warrant holders to exercise for cash their common stock purchase warrants issued pursuant to firm commitment public offerings by the Company that closed on September 15, 2021 (the "Existing September 2021 Warrants") and January 25, 2023 (the "Existing January 2023 Warrants" and together with the Existing September 2021 Warrants, the "Existing Warrants") to purchase up to approximately 36,362 shares of Common Stock, at a lower exercise price of (x) \$50.00 per share for the Existing September 2021 Warrants and (y) \$50.00 per one and one-half share for the Existing January 2023 Warrants, during the period from the date of the Inducement Agreements until December 20, 2023 (the "Inducement Deadline"). In consideration for the warrant holders' agreement to exercise the Existing Warrants in accordance with the Inducement Agreements, the Company agreed to issue such warrant holders

NOTE 8 — STOCKHOLDERS' EQUITY (cont.)

certain warrants as follows: (A) Series A Common Stock purchase warrants (the "Series A Warrants") to purchase up to a number of shares of Common Stock equal to 200% of the number of shares of Common Stock issued upon exercise of the Existing September 2021 Warrants (up to 3,229 shares) (the "Series A Warrant Shares"), at an exercise price of \$50.00 per Series A Warrant Share; and (B) Series B Common Stock purchase warrants (the "Series B Warrants") to purchase up to a number of shares of Common Stock equal to 200% of the number of shares of Common Stock issued upon exercise of the Existing January 2023 Warrants (up to 55,282 shares) (the "Series B Warrant Shares"), at an exercise price of \$50.00 per one and one-half Series B Warrant Share. Of the Series A Warrants, 50% are immediately exercisable and expire on the Termination Date (as defined in the Existing September 2021 Warrants) and 50% are exercisable at any time on or after the Stockholder Approval Date (as defined in the Inducement Agreements), and have a term of exercise of five and a half years from the date of the initial closing of the transactions contemplated by the Inducement Agreements. Of the Series B Warrants) and 50% are exercisable at any time on or after the Stockholder Approval Date, and have a term of exercise of five years and a half years from the date of the initial closing of the transactions contemplated by the Inducement Agreements. The Company used the proceeds from the exercise of the Existing Warrants for working capital purposes and other general corporate purposes.

During the year ended December 31, 2023, the Company determined that the decrease in exercise price of the Existing Warrants discussed above resulted in a deemed dividend. The Company determined the deemed dividend was the difference between the fair value of the Existing Warrants immediately prior to the modification of terms and the fair value of the new Series A Warrants and Series B Warrants at the time of the modification. The difference between the fair value of the warrants immediately prior to modification of terms and immediately after the modification was calculated as \$0.9 million, using a Black Scholes model. This deemed dividend has been added to the net loss to arrive at net loss attributable to common stockholders on the statements of operations.

Due to the Company effecting the reverse stock split on November 18, 2024, the exercise prices and shares issuable upon exercise of such warrants have been retroactively reported in accordance with ASC 260-10-55-12, "Restatement of EPS Data", and to reflect the adjustment to the number of shares underlying such warrants and the exercise price of such warrants in accordance with the terms thereof.

January 2023 Offering

On January 25, 2023, the Company closed a firm commitment registered public offering (the "January Offering") pursuant to which the Company issued (i) 211,170 shares of Common Stock and 423,400 common stock purchase warrants (exercisable for 31,755 shares of Common Stock at a purchase price of \$2.13 per share), subject to certain adjustments and (ii) 137,600 pre-funded common stock purchase warrants that were exercised for 6,880 shares of Common Stock at a purchase price of \$0.50 per share, subject to certain adjustments and 6,880 warrants to purchase up to an aggregate of 10,320 shares of Common Stock at a purchase price of \$2.13 per share and (iii) 32,608 additional warrants to purchase up to 2,446 shares of Common Stock at a purchase price of \$2.13 per share, which additional warrants were issued upon the partial exercise by the underwriters of their over-allotment option, pursuant to an underwriting agreement, dated as of January 23, 2023 between the Company and Maxim Group LLC, as representative of the underwriters. The January Offering resulted in gross proceeds to the Company of approximately \$5.2 million, before deducting underwriting discounts and commissions of 7% of the gross proceeds (3.5% of the gross proceeds in the case of certain identified investors) and estimated January Offering expenses. Due to the Company effecting the reverse stock split on November 18, 2024, the exercise prices and shares issuable upon exercise of such warrants and pre-funded warrants have been retroactively reported in accordance with ASC 260-10-55-12, "Restatement of EPS Data", and to reflect the adjustment to the number of shares underlying such warrants and pre-funded warrants and the exercise price of such warrants in accordance with the terms thereof.

As of December 31, 2024, the exercise price for warrants were subject to an adjustment due to the November 18, 2024 reverse stock split, which resulted in a new exercise price of \$2.13 per warrant share.

NOTE 8 — STOCKHOLDERS' EQUITY (cont.)

Series C Redeemable Preferred Stock

In May 2017, the Company authorized Series C Redeemable Preferred Stock. Holders of Series C Preferred Stock are entitled to receive dividends of 15% per year, payable in cash. For each of the years ended December 31, 2024 and 2023, the Company recorded Series C Redeemable Preferred Stock dividends of \$0.3 million.

The Series C Redeemable Preferred Stock may be redeemed by the Company at the Company's option in cash at any time, in whole or in part, upon payment of the stated value of the Series C Redeemable Preferred Stock and unpaid dividends. If a "fundamental change" occurs, the Series C Redeemable Preferred Stock shall be immediately redeemed in cash equal to the stated value of the Series C Redeemable Preferred Stock, and unpaid dividends. A fundamental change includes but is not limited to any change in the ownership of at least fifty percent of the voting stock; liquidation or dissolution; or the common stock ceases to be listed on the market upon which it currently trades.

The holders of the Series C Redeemable Preferred Stock are entitled to vote on any matter submitted to the stockholders of the Company for a vote. One share of Series C Redeemable Preferred Stock carries the same voting rights as one share of common stock.

A redeemable equity security is to be classified as temporary equity if it is conditionally redeemable upon the occurrence of an event that is not solely within the control of the issuer. Upon the determination that such events are probable, the equity security would be classified as a liability. Given the Series C Redeemable Preferred Stock contains a fundamental change provision, the security is considered conditionally redeemable. Therefore, the Company has classified the Series C Redeemable Preferred Stock as temporary equity in the balance sheets as of December 31, 2024 and 2023 until such time that events occur that indicate otherwise.

Warrants

The following table summarizes the Company's warrants outstanding and exercisable as of December 31, 2024 and 2023:

Number of Warrants		Weighted Average Exercise Price	Weighted Average Remaining Life In Years		Aggregate Intrinsic Value
74,832	\$	986.00	3.72	\$	_
74,832	\$	986.00	3.72	\$	_
5,139,810		1.75	3.75		
328,803					
(328,803)					
(2,614,695)		1.75	_		_
(672)		6,130.24	_		
2,599,276	\$	8.46	4.53	\$	_
	74,832 74,832 5,139,810 328,803 (328,803) (2,614,695) (672)	74,832 \$ 74,832 \$ 5,139,810 328,803 (328,803) (2,614,695) (672)	Number of Warrants Average Exercise Price 74,832 \$ 986.00 5,139,810 1.75 328,803 — (2,614,695) 1.75 (672) 6,130.24	Number of Warrants Weighted Average Exercise Price Average Remaining Life In Years 74,832 \$ 986.00 3.72 74,832 \$ 986.00 3.72 5,139,810 1.75 3.75 328,803 — — (328,803) — — (2,614,695) 1.75 — (672) 6,130.24 —	Number of Warrants Weighted Average Exercise Price Average Remaining Life In Years 74,832 \$ 986.00 3.72 \$ 74,832 \$ 986.00 3.72 \$ 5,139,810 1.75 3.75 328,803 — — (328,803) — — — — (2,614,695) 1.75 — — (672) 6,130.24 — —

NOTE 9 — STOCK INCENTIVE PLANS

2023 Stock Incentive Plan

On March 7, 2023, the Company's stockholders approved the 2023 Stock Incentive Plan ("2023 Plan"). The aggregate maximum number of shares of common stock that may be issued under the 2023 Plan is 2,749 shares for fiscal 2023; thereafter, the maximum number is limited to 15% of the outstanding shares of common stock, calculated on the first business day of each fiscal quarter. As of December 31, 2024, the maximum number of shares of common stock that

NOTE 9 — STOCK INCENTIVE PLANS (cont.)

may be issued under the 2023 Plan is 71,181. Under the 2023 Plan, options which are forfeited or terminated, settled in cash in lieu of shares of common stock, or settled in a manner such that shares are not issued, will again immediately become available to be issued. If shares of common stock are withheld from payment of an award to satisfy tax obligations with respect to the award, those shares of common stock will be treated as shares that have been issued under the 2023 Plan and will not again be available for issuance.

During the year ended December 31, 2024, the Company issued an aggregate of 25 stock options vesting over a period of four years to employees at an average exercise price of \$25.00 per share. In addition, an aggregate of 16,626 fully vested stock options were granted under the 2023 Plan to non-employee directors at an average exercise price of \$11.66 per share, in each case in consideration for services provided to the Company. The aggregate fair value of the shares issued to the directors was \$0.2 million. As of December 31, 2024, the unrecognized compensation cost related to non-vested stock options was \$21.7 thousand.

During the year ended December 31, 2023, the Company issued 80 stock options vesting over a period of four years to employees with an exercise price of \$75.75 per share and 125 stock options vesting over a period of four years to employees with an exercise price of \$73.00 per share. In addition, 396 fully vested stock options were granted to three non-employee Board directors at an exercise price of \$75.75 per share and 411 fully vested stock options were granted to three non-employee Board directors at an exercise price of \$73.00 per share. The aggregate fair value of the shares issued to the directors was \$46 thousand.

During the year ended December 31, 2024, 352 of the Company's stock options were forfeited by participants under the 2023 Plan. During the year ended December 31, 2023, 70 of the Company's stock options were forfeited by participants under the 2023 Plan.

2017 Stock Incentive Plan

On August 24, 2017, the Company's stockholders approved the 2017 Stock Incentive Plan ("2017 SIP"). The aggregate maximum number of shares of common stock that may be issued under the 2017 SIP is limited to 10% of the outstanding shares of common stock, calculated on the first business day of each fiscal year. Under the 2017 SIP, options which are forfeited or terminated, settled in cash in lieu of shares of common stock, or settled in a manner such that shares are not issued, will again immediately become available to be issued. If shares of common stock are withheld from payment of an award to satisfy tax obligations with respect to the award, those shares of common stock will be treated as shares that have been issued under the 2017 SIP and will not again be available for issuance. On March 7, 2023, the Company's 2017 SIP was terminated upon the approval of the 2023 Plan at the Company's special meeting of stockholders.

During the year ended December 31, 2024, the Company did not issue stock options under the 2017 SIP. During the year ended December 31, 2024, 55 of the Company's stock options were forfeited by participants under the 2017 SIP.

During the year ended December 31, 2023, the Company issued 125 stock options vesting over four years to employees with an exercise price of \$95.00 per share and a total aggregate fair value of \$11 thousand. In addition, 421 fully vested stock options were granted to four non-employee Board directors at an exercise price of \$95.00 per share. The aggregate fair value of the shares issued to the directors was \$35 thousand.

As of December 31, 2024, the unrecognized compensation cost related to non-vested stock options was \$12 thousand.

During the year ended December 31, 2023, 30 of the Company's stock options were forfeited by participants under the 2017 SIP.

2013 Long-Term Stock Incentive Plan

On January 4, 2013, the Company's stockholders approved the Company's Long-Term Stock Incentive Plan ("2013 LTIP"). The maximum number of shares of common stock that may be issued under the 2013 LTIP, including stock awards, stock issued to the Company's Board, and stock appreciation rights, is limited to 10% of the common shares outstanding on the first business day of any fiscal year. The Company's 2013 LTIP expired in accordance with its terms on January 3, 2023.

NOTE 9 — STOCK INCENTIVE PLANS (cont.)

During the year ended December 31, 2024, the Company did not issue stock options under the 2013 LTIP. During the year ended December 31, 2024, the Company had 10 stock options forfeited under the 2013 LTIP. As of December 31, 2024, the unrecognized compensation cost related to non-vested stock options was \$0.1 million.

During the year ended December 31, 2023, the Company did not issue stock options under the 2013 LTIP. During the year ended December 31, 2023, the Company had 50 stock options forfeited under the 2013 LTIP.

Stock-based Compensation Expense

Total stock-based compensation expense during 2024 and 2023 pertaining to awards under the 2023 Plan, 2017 SIP and 2013 LTIP amounted to \$1.6 million for both periods.

NOTE 10 — INCOME TAXES

For financial reporting purposes, income before income taxes includes the following components:

		Years Ended December 31				
		2024		2023		
Loss before income taxes: United States	\$	(8,993,799)	¢	(14,860,458)		
Foreign	. —		Ψ			
Loss before income taxes:	\$	(8,993,799)	\$	(14,860,458)		
The expense for income taxes consists of:						
		Year Ended	Dec	ember 31,		
		2024		2023		
Current income tax provision						
Federal	\$		\$	_		
State		9,946		10,253		
Foreign						
		9,946		10,253		
Deferred income tax						
Federal				(106,387)		
State				(213,715)		
Foreign				<u> </u>		
				(320,102)		
Total income tax provision (benefit)	\$	9,946	\$	(309,849)		

Reconciliation between the effective tax rate on income from continuing operations and the statutory tax rate is as follows:

	Year Ended Dec	ember 31,
_	2024	2023
Provision at Federal statutory rate	21.00%	21.00%
State income taxes.	(0.12)%	1.07%
Other permanent tax adjustments	(2.62)%	(1.05)%
Change in valuation allowance	14.87%	(18.93)%
Attribute expirations	(27.50)%	0.00%
Series H preferred stock fair value	(3.56)%	0.00%
Prior period adjustments	(2.19)%	0.00%
Provision for income taxes	(0.12)%	2.09%

NOTE 10 — INCOME TAXES (cont.)

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, Management believes that significant uncertainty exists with respect to future realization of all of the deferred tax assets and has therefore established a full valuation allowance. The valuation allowance decreased by \$1.2 million for the year ended December 31, 2024, compared to the increase of \$3.5 million for the year ended December 31, 2023.

The significant components of the Company's deferred tax assets and liabilities are as follows:

	Year Ended December 31,				
	2024		2023		
Deferred tax assets:					
Net operating loss carryforward	\$ 17,061,064	\$	15,302,761		
Tax credits	205,028		205,028		
Lease liabilities	14,404		33,397		
Accruals and reserves	148,784		168,603		
Capital loss carryforwards			2,678,907		
Capitalized research costs	438,127		383,233		
Taxable goodwill	871,350		1,140,134		
Intangible assets	556,997		523,899		
Stock compensation	275,637		397,275		
Fixed assets	24,461		17,451		
Other	4,943		849		
Total deferred tax assets before valuation allowance:	19,600,795		20,851,537		
Valuation allowance	(19,587,280)		(20,819,919)		
Deferred tax assets, net of valuation allowance	13,515		31,618		
Deferred tax liabilities:					
Right-of-use assets	(13,515)		(31,618)		
Total deferred tax liabilities	(13,515)		(31,618)		
Net deferred tax liability.	\$	\$			

As of December 31, 2024, the Company had US federal and state net operating loss ("NOLs") carryovers of \$65.6 million and \$74.0 million, respectively. Federal and state NOLs generated through December 31, 2017 are available to offset future taxable income, which expire beginning in 2032. Federal NOLs generated for years starting after December 31, 2017 are available to offset future taxable income indefinitely. State NOLs generated for years starting after December 31, 2017 that are available to offset future taxable income indefinitely vary by state. In addition, the Company had tax credit carryforwards of \$0.2 million at December 31, 2024 that will be available to reduce future tax liabilities. The tax credit carryforwards will begin to expire beginning in 2032.

In accordance with Section 382 of the Internal Revenue Code, deductibility of the Company's NOLs may be subject to an annual limitation in the event of a change of control. The Company has not determined whether a change of control has occurred as of December 31, 2024 with respect to the NOLs and therefore no limitation under Section 382 has been computed. Management will review for such limitations before any of the LogicMark NOLs are utilized against future taxable income.

NOTE 10 — INCOME TAXES (cont.)

The Company has no material uncertain tax positions for any of the reporting periods presented. No interest or penalty expense was recorded during the year or has been accrued as of December 31, 2024 or 2023. The Company does not expect any material changes to any uncertain tax positions in the next twelve months. The Company has filed all of its tax returns for all prior periods through December 31, 2023, and intends to timely file the income tax returns for the period ending December 31, 2024.

The Company is subject to taxation in the United States and various states. As of December 31, 2024, the Company is not under examination by any taxing authority, however, all of the Company's U.S. and state income tax returns remain open to examination.

NOTE 11 — COMMITMENTS AND CONTINGENCIES

LEGAL MATTERS

From time to time, the Company may be involved in various claims and legal actions arising in the ordinary course of our business. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of the Company or any of our subsidiaries, threatened against or affecting our company, or any of our subsidiaries in which an adverse decision could have a material adverse effect upon our business, operating results, or financial condition.

COMMITMENTS

The Company leases warehouse space and equipment, in the U.S., which is classified as operating leases expiring at various dates. The Company determines if an arrangement qualifies as a lease at the lease inception. Operating lease liabilities are recorded based on the present value of the future lease payments over the lease term, assessed as of the commencement date. The Company's real estate lease is for a fulfillment center, with a lease term of 5 years expiring in August 2025. The Company has elected to account for the lease and non-lease components (insurance and property taxes) as a single lease component for its real estate leases. Lease payments, which includes lease components and non-lease components, are included in the measurement of the Company's lease liabilities to the extent that such payments are either fixed amounts or variable amounts based on a rate or index (fixed in substance) as stipulated in the lease contract. Any actual costs in excess of such amounts are expensed as incurred as variable lease cost.

The Company's lease agreements generally do not specify an implicit borrowing rate, and as such, the Company uses its incremental borrowing rate to calculate the present value of the future lease payments. The discount rate represents a risk-adjusted rate on a secured basis and is the rate at which the Company would borrow funds to satisfy the scheduled lease liability payment streams. The Company entered into a new five-year lease agreement in June 2020 for new warehouse space located in Louisville, Kentucky. The Right of Use (ROU) asset value added as a result of this new lease agreement was \$0.3 million. The Company's ROU asset and lease liability accounts reflect the inclusion of this lease in the Company's balance sheet as of December 31, 2024. The current monthly rent of \$6.8 thousand increased from the amount of \$6.6 thousand in September 2024 in accordance with the 3% annual increase.

The Company's lease agreements include options for the Company to either renew or early terminate the lease. Renewal options are reviewed at lease commencement to determine if such options are reasonably certain of being exercised, which could impact the lease term. When determining if a renewal option is reasonably certain of being exercised, the Company considers several factors, including significance of leasehold improvements on the property, whether the asset is difficult to replace, or specific characteristics unique to the lease that would make it reasonably certain that the Company would exercise the option. In most cases, the Company has concluded that renewal and early termination options are not reasonably certain of being exercised by the Company and thus not included in the Company's ROU asset and lease liability.

NOTE 11 — COMMITMENTS AND CONTINGENCIES (cont.)

For the year ended December 31, 2024, total operating lease cost was \$78.7 thousand and is recorded in direct operating costs. Operating lease cost is recognized on a straight-line basis over the lease term. The following summarizes (i) the future minimum undiscounted lease payments under the non-cancelable lease for each of the next three years and thereafter, incorporating the practical expedient to account for lease and non-lease components as a single lease component for our existing real estate lease, (ii) a reconciliation of the undiscounted lease payments to the present value of the lease liabilities, and (iii) the lease-related account balances on the Company's balance sheet as of December 31, 2024:

Year Ending December 31,	
2025	54,400
Total future minimum lease payments	\$ 54,400
Less imputed interest	(2,559)
Total present value of future minimum lease payments	\$ 51,841
As of December 31, 2024	
Operating lease right-of-use assets	\$ 48,641
Other accrued expenses.	\$ 51,841
As of December 31, 2024	
Weighted Average Remaining Lease Term	0.67
Weighted Average Discount Rate	13.00%

NOTE 12 — SEGMENT REPORTING

The Company's operations are managed and reported to its Chief Executive Officer ("CEO"), Chia-Lin Simmons, the Company's chief operating decision maker ("CODM"), on a consolidated basis. The CODM assesses performance and allocates resources based on the Company's statements of operations, which assists the CODM to manage and evaluate the results of the business in a consolidated manner to drive efficiencies and develop uniform strategies. Accordingly, components and processes of the Company's operations are managed centrally, including contracting with the government, capitalizing and developing new products or software, including releases, customer service, marketing, and legal affairs. Segment asset information is not used by the CODM to allocate resources or manage the business. Under this reporting structure, the Company has one reportable segment. As a single reportable segment entity, the Company's segment performance measure is net loss attributable to common stockholders. Significant segment expenses are presented in the Company's statements of operations.

NOTE 13 — SUBSEQUENT EVENTS

February 2025 Public Offering

On February 18, 2025 (the "Closing Date"), the Company, in connection with a best efforts public offering (the "February Offering"), sold an aggregate of (x) 2,260,000 units of the Company (the "Units") at an offering price of \$0.59 per Unit, consisting of (i) 2,260,000 shares (the "Shares") of Common Stock, (ii) Series C warrants to purchase up to 2,260,000 shares of Common Stock (the "Series C Warrants"), and (iii) Series D warrants to purchase up to 2,260,000 shares of Common Stock (the "Series D Warrants" and, together with the Series C Warrants, the "Warrants"); and (y) 22,146,750 pre-funded units of the Company (the "Pre-Funded Units") at an offering price \$0.589 per Pre-Funded Unit, consisting of (i) pre-funded common stock purchase warrants exercisable for up to 22,146,750 shares of Common Stock at \$0.001 per share (the "Pre-Funded Warrants"), (ii) Series C Warrants exercisable for up to 22,146,750 shares of Common Stock and (iii) Series D Warrants exercisable for up to 22,146,750 shares of Common Stock, pursuant to the Company's registration statement on Form S-1, as amended (File No. 333-284135), filed by the Company with the SEC under the Securities Act, which the SEC declared effective on February 14, 2025, and (ii) the Registration Statement on Form S-1MEF (File No. 333-284997) filed by the Company with the SEC

NOTE 13 — SUBSEQUENT EVENTS (cont.)

on February 14, 2025 pursuant to Rule 462(b) of the Securities Act and securities purchase agreements, each dated February 18, 2025 (the "Purchase Agreements"), between the Company and each of the purchasers signatory thereto (the "February Purchasers"). Neither the Units nor the Pre-Funded Units have stand-alone rights, are certificated or were issued as stand-alone securities. The Shares and the Warrants included in the Units, and the Pre-Funded Warrants and the Warrants included in the Pre-Funded Units, were immediately separable from one another and were issued separately in the Offering. On the Closing Date, the Company received gross proceeds of approximately \$14.4 million, before deducting placement agent commissions and estimated Offering expenses. The Company has begun to use the net proceeds from the Offering for continued new product development, working capital and other general corporate purposes.

As of March 27, 2025, the February Purchasers exercised all of their February Pre-Funded Warrants for an aggregate of 22,146,750 shares of Common Stock. In addition, the exercise price for the Series C Warrants and Series D Warrants were subject to an adjustment due to the Company obtaining stockholder approval for the issuance of the underlying shares obtained on March 27, 2025, which resulted in a new exercise price of \$0.118 per warrant share and the number of shares of Common Stock issuable upon exercise of such Warrants correspondingly increased to 122,033,750 shares and 183,050,625 shares for the Series C Warrants and Series D Warrants, respectively.

On March 20, 2025, the Company received a written notification from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement") because the Company's closing bid price for the Common Stock was below \$1.00 per share for the prior thirty (30) consecutive business days. The Company has requested a hearing before a Nasdaq hearings panel to appeal such determination and to address compliance with the Minimum Bid Price Requirement, which hearing date has been set as April 29, 2025. While the appeal process is pending, the suspension of trading of the Common Stock will be stayed and the Common Stock will continue to trade on the Nasdaq Capital Market until the hearing process concludes and the Nasdaq hearings panel issues a written decision. If the Company does not regain compliance within any compliance period granted or is not successful in its appeal, the Common Stock may be subject to delisting.

On March 27, 2025, the Company held a special meeting of its stockholders, at which, among other actions, the Company's stockholders approved the issuance of all shares of Common Stock upon the exercise of the Warrants, as well as the filing of a certificate of amendment to its articles of incorporation, as amended (the "Charter Amendment"), whereupon the Company filed the Charter Amendment on the same day in order to increase the number of authorized shares of the Company's capital stock from 110,000,000 shares to 880,000,000 shares, of which 800,000,000 shares are classified as Common Stock and 80,000,000 shares are classified as "blank check" preferred stock, par value \$0.0001 per share. Upon the filing of the Charter Amendment, all of the Warrants became immediately exercisable, and as of March 27, 2025, holders of Series D Warrants have exercised a portion of such warrants for an aggregate of 33,435,000 shares of Common Stock.